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SUMMARY 
 
The 26S proteasome is a multicatalytic protease complex ATP-dependent which is responsible for 
intracellular protein turnover in prokaryotes and eukaryotes. It consists of a proteolytic core 
particle, the 20S proteasome, sandwiched between two 19S “cap” regulatory complexes. Since the 
proteasome hydrolyses various cell cycle regulators, transcription factors and antigenic proteins, it 
is a promising target for the development of drugs for the treatment of many different diseases, and 
in particular for cancer therapy. Various classes of proteasome inhibitors have been found.  
In the first part of the presented work, we designed (by the help of molecular modelling) and 
synthesized a new original series of proteasome inhibitors introducing fluorinated peptidomimetics. 
Fluorine atom is able to favour hydrogen bonds and to increase hydrophobicity and metabolic 
stability of the molecules. The biological evaluation of these compounds showed that four 
molecules have a micromolar IC50. 
The second topic of the project is the synthesis of new δ-amino acids towards new foldamers. The 
function of peptides and proteins in living systems is strictly related to their three-dimensional 
architecture. Therefore, the development of synthetic tools mimicking the structure and activity of 
biologically interesting peptide and protein targets has become of crucial importance in 
pharmaceutical and medicinal chemistry research. In the last decade, many efforts have been made 
to design oligomers, so-called foldamers, which are able to adopt predictable and well-defined 
conformations. We designed two new enantiomeric δ-amino acids. On one hand, these cyclic 
scaffolds can be described as δ-amino acids bearing a lactone ring at β and γ positions. On the other 
hand, they mimic a glycyl-glycyl dipeptide unit, in which the amide bond is replaced by a lactone 
ring. We have investigated the properties of these building blocks as homo-δ-oligomers as well as 
dipeptide surrogates in α-amino acid sequences to define the secondary structural features 
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DESIGN OF PEPTIDOMIMETICS TOWARDS NEW 
FOLDAMERS AND 26S PROTEASOME INHIBITORS 
 
GENERAL INTRODUCTION 
 
Over the last years peptidomimetics have attracted interest from both organic and medicinal 
chemists. In the biological, chemical, and pharmaceutical areas, they offer advantages over 
physiologically active peptides, which as active substances are crucial for the organism and may 
lead to severe side effects. There is much current interest in the preparation of peptides and 
peptidomimetics with a well-defined conformation. These conformationally constrained peptides 
are useful to probe protein folding and to mimic peptide structures.  
 
In the first chapter, we report a brief description of the proteins organization and the bases to 
develop mimics of peptide and protein structures. 
 
The second part of this PhD work has been focused on the synthesis of peptidomimetics as 
potential non covalent inhibitors of the 26S proteasome. The 26S proteasome is a multicatalytic 
protein complex implicated in the degradation of the majority of cellular proteins. Thus, 
proteasome inhibitors are new potential therapeutic agents for treating many disorders such as 
cancer, inflammation, immune diseases. As further “peptidomimetic tool”, we introduced in our 
molecules a fluorinated scaffold. In fact, fluorine atom is able to favour hydrogen bonds, to 
increase hydrophobicity and metabolic stability of the molecules. We described here the synthesis 
and the biological evaluation of these analogues. 
 
In the last chapter of the work we described the synthesis of peptidomimetics containing a new 
unnatural amino acid, a δ-amino acid, which is a glycylglycine mimic where the central amide 
group is replaced by a lactone ring. Using solid-phase synthesis we obtained several peptides 
containing our pentalactone scaffold. The following step was a conformational analysis using CD, 
NMR, FT-IR measurements and the molecular modelling in order to establish the secondary 
structure adopted by these molecules. 
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I   PEPTIDES AND PEPTIDOMIMETICS 
 
I.1   Structure of Proteins 
 
In nature, proteins constitute a class of biomacromolecules which virtually affect every feature 
that characterizes a living organism. Structural proteins such as collagen or elastin provide 
support in organisms. The rate of the chemical reactions in all organisms is increased, of many 
orders of magnitude, by the presence of enzymes, which are proteins. Defensive proteins such as 
antibodies provide protection. Proteins store and transport a variety of particles ranging from 
macromolecules to electrons and are the crucial components of muscles and other systems for 
converting chemical energy into mechanical energy. In spite of these diverse biological functions, 
proteins are all the linear polymers built on various combinations of 20 amino acids. They differ 
only for the sequence in which the amino acids are assembled into polymeric chains. The secret 
of their functional diversity lies in the diversity of the three-dimensional structures that these 
building blocks can form, simply by being linked in different sequences. In fact, the amino acid 
sequence itself contains all the instructions needed for proper folding (Figure 1). 
 
                         
                                                                                                                                                                                                          
                                                                          
   
Figure 1.  The folding of the polypeptide chain.1  
 
The complex structure of proteins can be characterized in four general levels of structural 
organization: primary, secondary, tertiary and quaternary structure (Figure 2). 
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• The primary structure represents the linear arrangement of the individual amino acids in 
the protein sequence. 
• The secondary structure describes the local architecture of linear segments of the 
polypeptide chain (i.e. α-helix, β-sheet), without regarding the conformation of the side 
chains. Another level of structural organization, which was introduced not before very 
recently, is the so-called supersecondary structure. It describes the association of 
secondary structural elements through side chain interactions. 
• The tertiary structure portrays the overall topology of the folded polypeptide chain. 
• The quaternary structure describes the arrangement of separate subunits or monomers into 
the functional protein. 
 
 
 
 
Figure 2. Hierarchy of protein structure. 
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A portion of the backbone of a polypeptide chain is shown in Figure 3. The main chain torsion 
angles in proteins are named φ, ψ, ω. Rotation about the N-Cα bond is described by the torsion 
angle φ, rotation about Cα-C bond by ψ, and rotation about the peptide bond C-N by ω. 
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Figure 3.  Torsion angles in a protein. 
 
The peptide bond is usually planar because of its partial double bond character and nearly always 
has the trans configuration (ω = 180°). The permitted values of φ and ψ were first analyzed and 
determined by Ramachandran and co-workers.2 Since φ and ψ constitute a virtually complete 
description of the backbone conformation, the 2D Ramachandran plot is an important and easy-
to-analyze test for the validity of 3D protein structure (Figure 4). 
 
 
 
 Figure 4. The Ramachandran plot. 
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Types of Secondary Structural Elements 
 
 
The α-Helix 
 
The right-handed α-helix is the best known and most easily recognized secondary structural 
element in protein.3,4 Polymers of α-amino acids are characterized by precise hydrogen bond 
patterns and torsional angles along their backbone. A repeated  hydrogen bond between the 
carbonyl function of residue i and the NH of residue i+4 leads to the α-helix.  
Variations of the classical α-helix in which the protein backbone is either more tightly or more 
loosely coiled (with hydrogen bonds to residues i+3 and i+5), are named 310-helix and π-helix, 
respectively (Figure 5). 
 
 
 
                                                                   2r ribbon         310 helix         α-helix         π helix 
 
Figure 5. Some possible hydrogen bonds patterns in α-peptides helices.5  
 
 
The β-Sheet 
 
The second most regular and recognizable secondary structural motif is the β-sheet,6,7 a periodic 
element like the α-helix. The β-sheets are formed from β-strands which develop when a linear 
extended conformation of a polypeptide backbone appears.7 The amide bonds are almost coplanar  
and side chains are alternate above and below the plane of the peptide backbone (Figure 6a). 
 6 
Since interactions between residues of the same strand are not possible, isolated β-strands are not 
common and are usually found hydrogen bonded in at least pairs, forming β-sheets structures. 
Adjacent β-strands can be arranged in either parallel or antiparallel fashion. In  parallel sheets the 
strands all run in the same direction forming 12-membered hydrogen-bonded rings (Figure 6b), 
whereas in antiparallel sheets they run in opposite directions forming alternate 10 and 14-
membered hydrogen-bonded rings (Figure 6c).  
                                a 
 b 
 
c 
 
Figure 6. Architecture of a) β-strand b) parallel and c) antiparallel β-sheets. 
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Turns 
The general function of turns is to reverse the direction of the polypeptide chain. Various 
different types of reverse turns have been observed in proteins and the most common are shown 
in Figure 7. A β-turns involve 4 amino acids with a i→ i+3 hydrogen bond. The repeating of the 
β-turn type III along the peptide chain leads to a 310-helix. A γ-turn involves 3 residues with a 
i→i+2 hydrogen bond. 
 
 
 
 
Figure 7. Torsional angles of β-turns and γ-turns. 
 
 
Peptides like drugs 
 
Several endogenous peptides are biologically active, for example Somatostatin, Met- and Leu-
enkephalin, Angiotensin II. However, the development of peptides as clinically useful drugs has 
to overcome their poor metabolic stability and to increase their low bioavailability, due in part to 
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their inability to cross biological membrane barriers. More, the peptide receptors can be widely 
distributed in organisms and their stimulation results in a variety of desired and undesired effects, 
especially, when the peptide is conformationally flexible and hence able to interact with 
alternative receptors.8 The aim of peptide medicinal chemistry is, therefore, to develop strategies 
to overcome these problems. 
 
 
I.2.   Peptidomimetics  
                                                          
In biological, chemical, and pharmaceutical areas modified peptides and mimetics offer 
interesting advantages over physiologically active peptides. Beside increasing efficiency and 
selectivity of natural peptides, this class of compounds known as peptidomimetics may decrease 
side effects, improving oral bioavailability and prolonging the pharmacological activity by 
hindering enzymatic degradation within the organism.9 The peptidomimetic research continues to 
inspire medicinal chemists for seeking either potential drugs or pharmacological tools to 
investigate how the secondary structure can affect activity.10 This knowledge can be useful to 
modulate the activity of the studied target proteins and peptides. 
Peptidomimetics can be prepared by approaches ranging from the slight modification of the 
initial structure of a peptide to the generation of a pure non-peptide. The very first steps in 
peptidomimetic design were based on simple N- or C- terminus modifications, methylation of 
amide nitrogen and Cα, replacement of L- with D-amino acids.11,12,13 The introduction of amide 
bond isosters completely prevents protease degradation of the amide bond and it may also 
significantly modify the biochemical properties of a peptide, particularly its conformation and its 
hydrophobicity. The isosteres are used to investigate the role and function of backbone peptide 
bonds and to modify the properties of the parent peptides (Figure 8).14  
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Figure 8. Examples of peptide bond isosters. 
 
The replacement of CONH with a CH2NH or CH2SH can help to investigate the possible 
functional role of the carbonyl group. The replacement with a CH=CH is the best replacement to 
maintain the planarity and rigidity of the amide bond. Enkephalin analogues with the CH=CH N-
terminus amide bond isoster were found to have similar activity to the original peptide, 
simultaneously providing protection from degradation.15 There are also some examples of 
replacement of CONH with the retro amide NHCO.16 
Chorev, Goodman, and co-workers synthesized the first highly bioactive, partially modified 
retro-inverso peptides, i.e. some enkephalin analogues that display higher activity than 
Metenkephalin and prolonged duration of action in vitro and in vivo.17 
Another strategy for producing modified peptides is to use dehydroamino acids, cyclic amino 
acids and other structurally rigid mimetics because of their ability to give turns or helices.10 
Cyclization reactions are very useful in the synthesis of peptidomimetic. The conformation of a 
peptide can be stabilized or blocked by the introduction of bridges of various lengths between 
different parts of the molecule. The bridging can either occur within a single amino acid residue, 
or involve several amino acid residues. Bridges can be introduced at various sites and involve 
various backbone regions. The bridge can be a link between two side chains, between two 
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backbone units, or between a side chain and backbone unit. In addition, the peptide bond can be 
completely or exclusively incorporated into a ring.  
There are also interesting examples of cyclic peptides and peptidomimetics having a sugar moiety. 
Sugar amino acids offer many possibilities in the preparation of peptidomimetics with predictable 
conformational characteristics.  
Few examples of the huge amount of available peptidomimetic compounds with structural motifs 
ranging from peptide chains to completely non-peptidic components are shown in Figure 9. 
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Figure 9. Structural motifs of some peptidomimetics.18 
 
A peptidomimetic approach, which has emerged in recent years with significant potential, is the 
use of non-proteinogenic amino acids, such as β-,19 γ-19 and δ-amino acids,20 in the construction 
of “foldamers”,21 conformationally ordered synthetic oligomers. The use of non-proteinogenic 
amino acids has became important because non-natural amino acid containing peptides form 
unique secondary structures,19 show novel biological activities,22 and can be used as rulers for the 
design of molecular devices and catalysts.23 Non-proteinogenic amino acids can have pronounced 
effects on the conformation of the peptide backbone. For example, α,α-Disubstituted amino acids, 
such as Aib (α-aminoisobutyric acid or Cα,α-dimethylglycine)  and α-ethylalanine,24 rigidify the 
peptide backbone through the formation of helixes and β-turns.25 
N-Substituted peptides may also exhibit enhanced hydrophobicity and improved stability to 
proteolytic enzymes, which can increase bioavailability and therapeutic potential.26  
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Facile synthesis is one of the most important attributes of a foldamer in the long run, as this will 
allow access to a wider variety of derivatized and ideally functional foldamers, but it is often 
underestimated that the coupling of these unusual residues is sometimes difficult, due to the 
amino acid structures that can complicate the amide bond formation by conventional synthetic 
methods. 
 
 
β-strand peptidomimetics  
 
As mentioned before, β-strands are usually found hydrogen bonded at least in pairs, forming β-
sheet structures in proteins. Isolated β-strands are not common.  
Many biological processes are connected with the creation of a β-sheet structure in peptide and 
proteins. Lack of control is often fatal. In fact, aggregation of some proteins to form insoluble β-
sheet structures is responsible for a number of neurological disorders. For example, β-amyloid 
deposition leads to Alzheimer’s disease,27, 28 and the conversion of α-helices to larger β-sheet 
aggregates causes Creutzfeld-Jakob disease, BSE, and other prion diseases.29-31  
Currently, despite their dramatic progression there is virtually no therapy for protein misfolding 
diseases. Therefore a better understanding of the mechanism of aggregation and the development 
of possible β-sheet ligands, which can slow down or prevent the pathological process, is of great 
interest from both a mechanistic and a therapeutic point of view. Historically mimicry of the β-
strand conformation in a compound has been pursued for fundamental purposes, and 
subsequently it has been stimulated by the pursuit of inhibitors of enzymes such as HIV-protease 
and caspases. In fact, the proteases, that are involved in the synthesis and turnover of all proteins, 
bind their inhibitors/substrates using the same extended β-strand peptide backbone conformation 
or equivalent non-peptide structure.32 The proteolytic enzymes are associated with most diseased 
states and their selective inhibition is a viable therapeutic strategy.  
In consequence, β-strand peptidomimetics are of great interest to study biological systems such as 
aggregation of β-sheet structure or enzyme-substrates interaction. β-strands peptidomimetics are 
also of great interest to obtain inhibitors of these biological systems. We report herein few 
examples of β-strands mimics with a potential biological interest. 
Martin and co-workers reported 1,2,3-trisubstituted cyclopropanes as peptide isosteres that mimic 
β-strand conformation to synthesize novel renin inhibitors.33 
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Strand mimetics have been developed by Hirschmann and co-workers using pyrrolinones34 within 
novel scaffolds that replace the hydrolysable backbone of bioactive peptides. These mimetics are 
stable to protease,35, 36 and have an extended conformation both in solution and solid states34 
(Figure 10). 
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Figure 10.  Mimetics pyrrolinone based inhibitor of HIV-1 protease. 
 
Schrader and co-workers introduced acylated 3-aminopyrazoles as effective β-sheet ligands, 
which are able to stabilize an extended conformation in N/C-protected small peptides through 
three simultaneous hydrogen bonds on one face of a peptide strand.37 Strands of larger size 2 
(Figure 11), have been obtained by oligomerization of aminopyrazole ligands.38 After, they 
developed a new class of peptide aminopyrazole hybrid compounds combining natural and 
unnatural amino acids, the latter derived from 3-aminopyrazole-5-carboxylic acid.39 
Recently, Schrader and co-workers described 3-aminopyrazole derivatives and their oligomers as 
rationally designed non peptidic β-sheet templates that block the amyloid β-peptide aggregation. 
Thus, these β-sheet ligands are very interesting in the prevention of Alzheimer’s disease 
associated with the amyloid deposition of the Aβ peptide.40 
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Figure 11.  Schematic representation of hydrogen bonding between 2, an aminopyrazole oligomer, and a peptide 
chain. Hydrogen bonds are indicated by dashed lines.  
 
Since 1992, Nowick and co-workers reported on the development of peptidomimetic templates, 
which were termed “molecular scaffolds”.41 These templates have an oligourea structure. In 1996, 
they introduced 5-amino-2-methoxybenzamide as a β-strand mimic 3 (Figure 12).42  
This aromatic system contains an intramolecular hydrogen bond between the oxygen atom of the 
methoxy group and the lone pair of the nitrogen atom of the amide bond making the receptor 
more rigid. To evaluate the ability of this derivative to be useful as β-strand mimic, Nowick 
synthesized an artificial antiparallel β-sheet 4 (Figure 12) in which the 5-amino-2-
methoxybenzamide unit 3 and a diurea molecular scaffold stabilize β-sheet structure in an 
attached peptide strand.42 With the goal of preparing larger artificial β-sheets, they required an 
extended β-strand mimic as in the case of 5 (Figure 12) a 5-hydrazino-2-methoxybenzoic acid β-
strand mimic, obtained by linking two or more of these units 3 end-to-end, by the nitrogen 
atoms.43 Thus, this extended β-strand mimic was applied to the creation of an artificial β-sheet.43 
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Figure 12.  Schematic representation of  β-strand mimics 3 and 5, and an artificial β-sheet 4. Hydrogen bonds are 
indicated by dashed lines.  
 
Several artificial β-sheets with β-strand mimics positioned in the upper or the lower edge of the 
two and three-stranded β-sheets was described from Nowick and co-workers in the last years.44-47  
Currently, only a relatively scarce number of β-strand mimics have been developed and there are 
only few examples of biological and therapeutic applications.48 It remains a lot of work in order 
to create new β-strand mimics with appropriate bioavailability characteristics and biological 
activities, and also to identify the importance of the β-strand structure in other examples of 
protein recognition. 
 
 
α-Helix peptidomimetics containing δ-amino acids 
 
As mentioned before, in the past years, the interest in a rational design of amino acid and peptide 
mimetics has extensively grown due to the pharmacological limitation of bioactive peptides. 
Numerous example of unnatural oligomeric sequences have been found that fold into well 
defined conformations in solution.49, 50 Although the oligomers of β- and γ-amino acids are more 
extensively studied, experimental hints were also obtained for the formation of ordered structures 
in oligomers of δ-amino acids. However detailed structure information is still missing. 
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Members of the δ-peptide family are isosteric replacements of dipeptide units. As such, this is the 
first member of the peptidomimetics lineage in which a single unit represents two or more α-
peptide repeats. Thus, δ-amino acid monomers are able to adopt the secondary structures of α-
peptide sequences, particularly helices and β-turns.  
In 2004, Hofmann and co-workers described on the basis of theoretical studies all possible helix 
types in oligomers of δ-amino acids (δ-peptides) and their stabilities.51 
Thus far, the chemical literature has mostly involved carbopeptoid backbones. In fact, 
carbohydrate research produced interesting examples of new δ-amino acids as building blocks for 
peptidomimetic design. Sugar amino acids can adopt robust secondary turn or helical structures 
and they can be used as substitutes for single amino acids or dipeptide isosters 6 (Figure 13). 
 
 
 
 
Figure 13.  Comparison between the α-peptide subunit and the furanose-based subunit as a dipeptide isoster 
 
Carbopeptoids,52 homooligomers of sugar amino acids, have been prepared from both furanose53 
and pyranose54 residues. 
Motivated by the fact that O-glycoside oligomers of sialic acid were helical in solution,55 Gervay 
and co-workers reported in 1998 that (1→5) amide-linked sialooligomers 7 longer than the trimer 
formed ordered secondary structures in water56 (Figure 14). The conformational features 
apparently varied with chain length. After circular dichroism (CD) studies57 and in combination 
with molecular medelling, the hypothesis was that for the shorter oligomers, 16-membered 
hydrogen-bonded rings stabilized a helix involving three residues per turn while for the octamer 
22-membered hydrogen-bonding stabilized a helix involving four residues per turn. More 
recently, Gervay synthesized also new neuraminic acid analogues.58  
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Figure 14.  Amide-linked β-O-methoxy neuraminic acid oligomer. 
 
In 2005, on the basis of their conformational investigations, Fleet and co-workers described an 
octameric chain of carbohydrate amino acids 8 that adopt in solution a left-handed helical 
secondary structure stabilized by 16-membered (i, i–3) interresidue hydrogen bonds (Figure 
15).20 
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Figure 15. Octameric chain of C-glycosyl α-D-furanose configured tetrahydrofuran amino acids 8. 
 
Huc and co-workers reported on the stable helical conformation adopted by oligomers of a new 
quinoline-derived δ-amino acid 9 (Figure 16).59, 60 This class of aromatics foldamers present the 
advantage that the quinoline amino acid monomers are easily accessible, functionalizable, and 
assembled into oligoamides. These oligomers adopt unusually stable helical conformations even 
in polar solvents at high temperature.  
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Figure 16. Structure of quinoline-derived oligoamide foldamers. 
 
 
Turn peptidomimetics containing δ-amino acids 
 
The β-turn is a common structural feature of proteins associated with the dipeptide fragment. 
Thus, much activity in the δ-peptide family has been aimed at creating β-turn mimics.  
As in the case of helices, Hofmann and co-workers envisaged also β-turns as folding possibility, 
using δ-amino acid constituents.51 In fact, since the first and the fourth amino acids of a β-turn are 
involved in periodic structures, the induction of the β-turn is controlled predominantly by the 
second and the third amino acid. So that, the replacement of this dipeptide unit by a δ-amino acid 
could be suitable for the induction of β-folded structures. 
A long approach has involved δ-amino acid in which the “missing” amide bond is replaced by a 
(E)-alkene isosteres.61-64  
Wipf and co-workers, reported in 1998, the synthesis and the evaluation of L-Ala-D-Ala 
dipeptide alkene isostere sequences that, for the first time, included the preparation of a 
(trifluoromethyl)alkene isostere.64 It was established by X-ray studies that methyl and 
trifluoromethyl-substituted alkenes provided highly preorganized peptide mimetics.  
The D–L methyl-(E)-alkene isostere sequence 10 preferred an intramolecularly hydrogen bonded 
type-II′ β-turn in the solid state, while the corresponding trifluoromethyl analogue 11 
representing a L–D sequence showed a preference for a type-II β-turn (Figure 17). 
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Figure 17. Structures of alkene peptide isosteres 10, 11. 
 
In 2000, Chakraborky and coworkers reported on the design and synthesis of peptidic turn 
mimics using the new furanoid sugar amino acids Gaa (6-amino-2,5-anhydro-6-deoxy-D-
gluconic acid) 12 and Iaa (6-amino-2,5-anhydro-6-deoxy-D-idonic acid) 13 (Figure 18).65 These 
amino acids were incorporated into Leu-enkephalin 14 replacing its glycine-glycine portion to 
give two analogues 15. Structural analysis of these molecules showed that they have folded 
conformations composed of an unusual nine-membered pseudo β-turn-like structure with a strong 
intramolecular H-bond between LeuNH→ sugarC3-OH. 
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Figure 18.  Furanoid sugar amino acids and their analogues. 
  
In the course of this year, Fleet and co-worker described oxetane amino acids and oligomers 16 
obtained from it (Figure 19).66 These δ-2,4-cis-oxetane amino acid oligomers adopt well-defined 
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secondary structure in solution in which the major conformation is dictated by internal 10-
membered H-bonded rings.67 This β-turn motif is repeated along both the tetramer and hexamer. 
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Figure 19.  Structures of homo-oligomers of  δ-2,4-cis-oxetane amino acid. 
 
In the field of peptidomimetics, we will present in the next two chapters our work concerning the 
design and the synthesis of peptidomimetics as 26S proteasome inhibitors and as cyclic δ-amino 
acid  to obtain new foldamers. 
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II   INHIBITORS OF THE 26S PROTEASOME 
 
II.1.   INTRODUCTION 
 
II.1.1.   Structure and Functions of the 26S Proteasome 
          
The amount of proteins in a living cell is a balance between the rate of synthesis and the rate of 
degradation. The cell has different strategies to eliminate abnormal proteins or to decrease the 
intracellular concentration of one kind of protein. Eukaryotic cells are degraded primarily by two 
distinct proteolytic mechanisms. Proteins that enter the cells from extracellular compartment are 
degraded by lysosomes. Lysosomal-mediated breakdown is mainly involved in the degradation of 
intracellular proteins under stressed conditions, membrane-associated proteins or extracellular 
proteins taken up by endocytosis. Another more selective proteolytic mechanism, the ubiquitin-
proteasome pathway (UPP), which is present in the cytosol and the nucleus, is responsible for the 
majority of non lysosomal proteolysis of intracellular proteins in stressed and non-stressed cellular 
environments. This pathway (Figure 20) which involves ATP and contains the 26S proteasome at 
its core, plays a primary role not only in the degradation of short-lived and long-lived proteins, 
which comprise the bulk of proteins in mammalian cells,1,2 but also in the selective removal of  
abnormal, misfolded or incorrectly assembled proteins. In this way, UPP produces most of the 
antigenic peptides presented to the immune system by MHC (Major Histocompatibility Complex) 
class I molecules. Another important function of the UPP is in the regulation of various cellular 
processes such as cell cycle progression, cell differentiation, signal transduction, inflammatory and 
stress responses and apoptosis.3 
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Figure 20. The simplified scheme of the ubiquitin-proteasome pathway. From Kisselev et al.3 
(Reproduction by courtesy of  Prof. Goldberg). 
 
 
The ubiquitin system 
 
The majority of substrates of this pathway are marked for degradation by covalent attachment of 
multiple molecules of ubiquitin (Ub). A minimum of four Ub molecules are required for efficient 
targeting and destruction of proteins, whereas attachment of mono-Ub has other regulatory effects, 
e.g., the internalization of cell-surface proteins.4 Ubiquitin is a small 76 amino acid protein (8,5 
kDa) found throughout eukaryotic cells and is highly conserved, with only three amino acid 
differences between yeast and human homologues. This remarkable conservation reflects the 
importance of Ub’s biological functions in eukaryotic cells. The conjugation of Ub to substrates is 
accomplished by three different enzymes:5,6 ubiquitin-activating enzyme (E1), ubiquitin-carrier 
enzyme (E2), ubiquitin- ligase enzyme (E3), (Figure 21). First, a thioester bond between the C-
terminal glycine of Ub and the active cysteine of E1 is formed in a ATP-dependent manner. Ub is 
then transferred to a cysteine of E2, again forming a thioester linkage. Finally, an E3 catalyzes the 
formation of an isopeptide bond between the C-terminal glycine of Ub and ε-amino group of lysine 
residue of a specific target protein. The E3 enzyme can recognize the protein target which is to be 
destroyed. In fact, it is the specificity of this enzyme that determines which proteins in the cell are 
to be marked for destruction in proteasome.  
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Figure 21. Enzymatic reactions in the ligation of ubiquitin to proteins. 
 
The resulting ubiquitinylated proteins are then recognized and degraded by a 2.4 MDa proteolytic 
complex, the 26S proteasome. 
 
 
The 26S proteasome: a multifunctional proteolytic machine 
 
The structure and function of the proteasome are highly conserved from archaebacteria to 
eukaryotes. This large ATP-dependent complex consists of a proteolytic core particle, the 20S 
proteasome, sandwiched between two 19S “cap” regulatory complexes, also termed PA700 (Figure 
22). These complexes associate together in an ATP-dependent manner. 
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Figure22. The 26S proteasomes and its components. From Kisselev et al.3  
(Reproduction by courtesy of  Prof. Goldberg). 
 
 
The 20S proteasome 
 
The 20 S proteasome, a 700 kDa particle, is a hollow cylindrical particle formed by four stacked 
rings. Each outer ring is composed of seven different α subunits, while each inner ring is composed 
of seven different β subunits.7 Each β-ring contains three proteolytic active sites which differ in 
their specificities: the β1 subunit contains a post-acidic (PA) active site, which cleaves peptide 
bonds preferentially after acidic residues; the β2 is associated with a trypsin-like (T-L) activity and 
splits peptide bonds after basic amino acids; the β5 subunit has a chymotrypsin-like (CT-L) active 
site and cut after hydrophobic residues (Figure 23).8 All the proteolytic sites utilize a N-terminal 
threonine residue of β-subunits as nucleophile in the hydrolysis reaction and classify the 
proteasome as member of the Ntn (N-terminal nucleophilic) hydrolases group.9 The β-subunits are 
genetically encoded as precursors and are processed during particle maturation by autolysis. In the 
eukaryotic proteasome, only β1, β2, and β5 of the seven different β-subunits can be activated by 
this autolytic process, with the release of the amino-terminal Thr1 functioning as the nucleophile.10 
In mammalian proteasomes, γ-interferon provokes the substitution of these three active β-subunits 
(β1, β2,and β5) for three new β-type subunits termed “induced β-type subunits, βi”: β1i, β2i, and 
β5i. The incorporation of the γ-interferon inducible subunits into the proteasome requires its de 
novo assembly and depends on the cell development state and the tissue type.11,12 In this alternative 
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proteasome form, known as the immunoproteasome, 19S particles are replaced by the protein 
complexes termed PA28 or 11S. The immunoproteasome is involved in processing of antigens for 
presentation by MHC class I molecules.13 In contrast to the majority of other proteases which have 
easily accessible active sites, proteasomes have active sites which are confined to the inner cavity of 
the 20S core, thereby preventing uncontrolled destruction of the bulk of cellular proteins. The X-ray 
crystal structure of the yeast proteasome complexed with TMC-95A14 43 (Figure 36, page 42) 
showed that in β1, β2, and β5 active sites  two hydrophobic pockets, known as S1 and S3, are of 
fundamental importance to accommodate the substrate/inhibitor. The formation of crucial hydrogen 
bonds to have a non covalent interaction is generally permitted by some common amino acidic 
residues in the three active sites, such as Ser 20, Thr 21, Gly 47 and Ala 49 (vide infra chapter II.2.2 
Molecular Modelling: tool for the conception, page 47, for details).  
Generally, the major responsible for the formation of the S1-specificity pocket is locate in the 
position 45. Additionally, adjacent subunits in the β-rings to the S1 pockets contribute to their 
selectivity. The β1 subunit presents in position 45 a charged arginine, for this reason electrostatic 
interactions have a fundamental role in the activity of this subunit. 
 In the subunit β2, a glycine residue is situated in position 45, consequently S1 pocket in this 
subunit is very spacious and suitable for very large residues.  
Finally, in the case of the β5 subunit we can see in the key position 45 a methionine residue, that 
minimize the space of the S1 pocket.  
The 19S regulatory complexes control the access of substrates into the proteolytic core. 
 
 
 
Figure23. Active sites of the 26S proteasomes. From Borissenko et al.15 
(Reproduction by courtesy of  Prof. Groll). 
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The PA700 or 19S Regulatory Complex 
 
The PA700 or 19S Regulatory Complex provides components necessary for selective degradation 
of ubiquitinated proteins. Each 19S cap consists of a base, which associates with the 20S particle, 
and a lid16 and plays  a role in the recognition of substrates that have been targeted for degradation 
by the addition of multiple molecules of the ubiquitin. The lid binds to the polyubiquitin chain with 
high affinity and cleaves it away from the substrate. The base consists of eight polypeptides 
including six homologous ATPases of the AAA family, a superfamily of proteins with one or two 
nucleotide-binding domains (‘AAA modules’), which often form ring-like oligomers and function 
as chaperones in diverse cellular processes. 
The six ATPases were suggested to assemble into a ring that forms the interface of the 19S complex 
with the 20S core particle.17 Several functions have been proposed for the ATPases. First, the 
hydrolysis of ATP by the 19S ATPases is supposed to promote the assembly of 26S proteasomes 
from 19S complexes and 20S proteasomes.18-21 Second, these ATPases, interacting  directly with α-
rings of the 20S core particle, have a role in the ATP-depended opening of the channel in the α-
rings, allowing polypeptide access into the proteolytic chamber of the 20S particle.22 Third, 
substrate proteins are likely bound23 and unfolded by the ATPases,24 which also catalyze their 
translocation into 20S proteasomes.25 In fact, the only way for substrates to reach this chamber is 
through the gated channels in the α-ring, which is too narrow to be traversed by tightly folded 
globular proteins. Deubiquitinating enzymes (DUBs or isopeptidades) in the 19S cap disassemble 
ubiquitin chains. Ubiquitin molecules  can then be reused in degradation of other substrates. The 
process of deubiquitination plays an essential role in cellular ubiquitin homeostasis because the 
ubiquitin recycled by this process is required to maintain cellular ubiquitin at normal levels.26,27 The 
mechanistic details of this recycling process, including the identity and relative roles of specific 
DUBs that catalyze substrate deubiquitination, have remain poorly defined.  
 
 
Products Generated by the Proteasome 
 
Target proteins are degraded in a processive manner by the 20S proteasome and the size distribution 
of released peptides is broad, ranging from 3 to 25 residues, with an average length of  8 to 9 amino 
acids.28 Until recently, the mechanism of peptide product length control was unclear. Some of these 
oligopeptides are presented by MHC class I molecules on the cell surface for generation of immune 
response. In fact, the immunoproteasome generates oligopeptides which have higher affinity to bind 
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to MHC class I receptors,29,30 but the majority of these oligopeptides are being further degraded to 
free amino acids by different cytosolic peptidases. 
 
 
Biological role and Potential therapeutic applications 
 
Given the fact that all mammalian cells have ubiquitin ligases and proteasomes, dysregulation of the 
ubiquitin-proteasome pathway (UPP) causes onset of many inherited and acquired diseases. In fact, 
the majority of cellular proteins are degraded by this ubiquitin- and proteasome-dependent 
proteolytic pathway. Among those proteins are various regulators of crucial processes, like the cell-
cycle progression, apoptosis, inflammatory responses, NF-kB activation, antigen presentation, and 
others.31-34 Therefore, the proteasome constitutes an interesting target for drug discovery. 
Particularly, the UPP pathway has been extensively studied in human cancers, which is known to 
play an important role in regulating cell proliferation and cell death.35,5 It has been well-established 
that through a tight regulation of cell growth inducers and growth inhibitors, an optimum balance of 
cell proliferation and cell death can be achieved. In cancer cells, however, an altered balance 
between cell growth inducers and inhibitors leads to disruption of the cell cycle, causing 
deregulated growth and inhibition of intrinsic apoptotic cell death pathways. Thus, proteasome 
inhibition is a desirable target for controlling the aberrant growth of tumor cells. Proteasome 
inhibitors are known to induce cell death rapidly and selectively in oncogene-transformed but not 
normal or untransformed cells. They are also able to trigger apoptosis in human cancer cells that are 
resistant to chemotherapy.36,37  
Various inhibitors of this multicatalytic enzyme complex are already available.3 Experiments on 
animal models of various diseases have shown, that they can be useful anticancer, anti-
inflammatory, anticachectic and antiparasital drugs. The inhibitors are usually short peptides linked 
to a reactive function, generally located at their C-terminus (epoxyketone, aldehyde, boronic acid, 
α-ketoaldehyde, and vinyl sulfone). The reactive function interacts with the Thr1 of the proteasome 
with the formation of reversible or irreversible covalent adduct, while the peptide portion 
specifically associates with the enzyme’s substrate binding pocket in the active site. Moreover, 
recently some non covalent inhibitors have been described. So, in this manuscript the 20S 
proteasome modulators covered are categorized in two broad groups: covalent and non covalent 
inhibitors. 
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II.1.2   Covalent inhibitors of the 20S proteasome 
 
An advantage of such covalent inhibitors is that they can be used both as tools to investigate 
regulation of the ubiquitin-proteasomal system in different tissues and cells and as lead structures 
for design of fine-tuned proteasome inhibitors with perspectives for possible drug development. On 
the other hand, the ultimate effect of proteasome inhibitors depends on several parameters, such as 
cell type and the proliferation status, nature and dose of the inhibitor, and the time of the exposure.38 
In fact, long-term exposure to these compounds is toxic to nearly all cells and causes death by 
apoptosis. The estimation of the overall biological effect of the inhibitor treatment should be made 
cautiously, since many of the inhibitors affect not only the proteasome but also other cytosolic 
proteases. For example, peptide aldehydes and vinyl sulfones are also able to inhibit the activity of 
proteases such as cathepsins and calpains. The treatment with Bortezomib (Velcade®) 26 (Figure 
28) the first 20S proteasome inhibitor approved for the clinical treatment of multiple myeloma and 
currently in use, results in severe side effects, such as peripheral neuropathy, cardiac and pulmonary 
disorders, gastrointestinal adverse events.  
 
 
Peptide aldehydes  
 
Peptide aldehydes were the first proteasome inhibitors to be developed.1 In earlier studies was used 
calpain inhibitor I, also termed ALLN (Ac-Leu-Leu-NLeu-al) 17 (Figure 24).39 The aldehyde forms 
a reversible covalent hemiacetal intermediate 21 with the hydroxyl group of the amino terminal 
threonine of all proteasomal β-subunits (Figure 25). Upon binding, the inhibitor adopts a β-
conformation and fills the gap between two strands by forming hydrogen bonds with residues 20, 
21, 47 and generating an antiparallel β-sheet structure. In eukaryotic proteasomes, ALLN 17 
inhibits the chymotrypsin-like peptidase with an IC50 of 2.1 µM, and only with IC50 values  > 100 
µM the post-acidic and tryptic-like peptidase. This compound as inhibitor is 25-fold more potent 
against cathepsin B and calpain than the proteasome.1 Generally, aldehyde inhibitors enter in cells 
rapidly and their effect is reversible. In fact, they have fast dissociation rates, they are rapidly 
oxidized in inactive carbonic acids, and they are transported out of cell by the multi-drug resistance 
(MDR) system carrier.40 Many peptide aldehydes have been designed and synthesized, and some of 
them are now used for proteasome inhibition experiments. For example, MG132 (Z-Leu-Leu-Leu-
al) 18 (Figure 24) has a leucine (instead of Nle in ALLN) that is more favourable for ligand 
stabilisation. This inhibitor is not only significantly more potent than ALLN to inhibit the 
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proteasome, but is also much more selective. A dipeptide aldehyde CEP1612, compound 19 (Figure 
24), appears at least as good as 18 in potency and selectivity41 and induces apoptosis in a panel of 
human tumor cell lines.  
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Figure 24.  Example of peptide aldehydes. 
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Figure 25.  Mechanism of proteasome inhibition by peptide aldehydes. 
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Design of new bi- or multivalent proteasome inhibitors is a strategy to increase inhibitor potency. 
These inhibitors contain polyethylene glycol (PEG) as a spacer that is appropriate for simultaneous 
binding at two active sites. The spacer links two monovalent binding head groups to each other, 
with the formation of homo- or heterobivalent compounds.42 Homobivalent compounds can 
neutralize the active subunits of the same type (β1-β1, β2-β2, β5-β5). In the case in which two 
different head groups are connected with PEG spacer, it is possible to obtain31-34 a simultaneous 
inactivation of two distinct proteolytically active subunits (Figure 26). This hypothesis was 
confirmed experimentally by designing a heterobivalent inhibitor containing as head groups the 
tripeptide aldehydes calpain inhibitor I and Arg-Val-Arg-al.  
These kinds of inhibitors are promising compounds for further investigations and applications in 
biomedical field. 
 
 
 
Figure 26.  Strategy of creation of monovalent, bivalent, and heterobivalent PEG-peptide aldehyde conjugates. 
 
 
Peptide boronates 
   
Peptide boronates are much more potent inhibitors of proteasome than aldehydes.43 The mechanism 
of inhibition for both compounds is the same, also boronates form a tetrahedral adduct 23 with the 
active site N-terminal threonine (Figure 27) but the boronate-proteasome adducts have much slower 
 34 
dissociation rates than proteasome-aldehyde adducts. Boronates are also more selective inhibitors 
than aldehydes. In fact, because of the weak interactions between sulphur and boron atoms, 
boronates are poor inhibitors of cysteine proteases. Finally, boronates, unlike aldehydes, are not 
inactivated by oxidation and are not rapidly secreted from cells by MDR (J. Adams, personal 
communication).  
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Figure 27.  Mechanism of proteasome inhibition by  peptide boronates. 
 
Two peptide boronates, dansyl-Phe-Leu-boronate (DFLB) 24 and morpholino-naphthylalanine-Leu-
boronate (PS-273, also termed MNLB or MG273)3 25 (Figure 28) were used as useful fluorescent 
probes to analyze proteasomal active sites in living cells.44 Another boronic acid dipeptide 
derivative, PS-341 (Bortezomib, Velcade®) 26 (Figure 28) has been the first 20S proteasome 
inhibitor approved by the US FDA for the clinical treatment of multiple myeloma in patients who 
have received at least two prior therapies and have demonstrated disease progression on the last 
therapy.45 Bortezomib is a covalent inhibitor of the proteasomal chymotrypsin-like activity (Ki = 
0.6 nM) binding to the proteasome with very high affinity and dissociates slowly, conferring stable 
but reversible proteasome inhibition.46 In the multiple myeloma the compound abrogated TNF-α 
induced NF-κB activation and IL-6 secretion, and decreased the binding of multiple myeloma cells 
to bone marrow stromal cells. The most clinically significant toxicity was cumulative dose-related 
peripheral sensory neuropathy. At this moment, ongoing clinical trials are evaluating bortezomib in 
a variety of cancers to provide critical data to confirm the activity and to clarify its potential adverse 
effect profile further. 
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 Figure 28.  Example of peptide boronates. 
 
 
Non-peptide inhibitors: Lactacystin, Salinosporamide A  
 
Lactacystin 27 (Figure 29) is a Streptomyces metabolite, which was discovered by Omura and 
coworkers as a  result of its ability to induce differentiation of cultured neuronal cells.47 Radioactive 
lactacystin was shown to bind mainly to the proteasomal subunit β5,48 effectively and irreversibly 
inhibiting the chymotrypsin-like activity. The trypsin-like and the post-acidic activities are also 
blocked, but to a lower extent.2 Subsequent studies, however, demonstrated that lactacystin itself is 
not active against proteasomes in vitro but undergoes in aqueous solutions at pH 8 a spontaneous 
conversion - lactonization - to the active proteasome inhibitor, clasto-lactacystin β-lactone,49 also 
termed ‘omuralide’50 28 (Figure 29). It is this β-lactone which reacts with the active site Thr1 Oγ  of 
the enzyme,49 resulting in the opening of the β-lactone ring and acylation of the N-terminal 
threonine β5 subunit of the 20S proteasome 30 (Figure 29). This acylation has been confirmed by 
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X-ray crystallography studies.7 Although the β-lactone is considered an irreversible inhibitor, the 
acyl ester intermediate is slowly (t ½  ≈ 20 h) hydrolyzed by the nucleophilic water molecule, 
releasing the peptide and restoring the proteolytic activity of the enzyme. The main reason for 
increased selectivity of omuralide for the chymotrypsin-like peptidase is the apolar nature of this 
site’s S1 specificity pocket. 
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Figure 29.  Mechanism of proteasome inhibition by lactacystin and its β-lactone. 
 
A structurally related analogue of clasto-lactacystin β-lactone is Salinosporamide A (compound 32, 
Figure 30) a small secondary metabolite of the marine actinomycete Salinospora tropica.51 This 
natural product is a potent and selective inhibitor of the proteasome that exhibits low nM IC50 
values against a broad panel of tumor cell lines and, for this reason, currently undergoing clinical 
studies as potential drug for cancer treatment.52 The presence in this compound of a cyclohexene 
ring and a chloroethyl group in place, respectively, of the isopropyl and methyl groups of the 
omuralide, collectively enhances its potency both in vitro and in vivo.53 
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Figure 30.  Structure of Salinosporamide A. 
 
 
Peptide vinyl sulfones 
 
Another class of proteasome inhibitors exemplified by NLVS (NIP-Leu3-vinyl sulfone) 33 (Figure 
31) possesses a vinyl sulfone moiety at the C-terminus.54  
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Figure 31.  Example of peptide vinyl sulfone. 
 
This group forms an irreversible covalent adduct with the hydroxyl group of the catalytic threonine 
residue, acting as Michael acceptor (Figure 32). The structure of the resulting covalent adduct 36 
has been determined by X-ray diffraction.55 Peptide vinyl sulfones do not inhibit serine proteases, 
but they were first described as inhibitors of cysteine proteases,56 which implies certain restrictions 
to their application in vivo. Therefore the selectivity of inhibition depends on the peptide portion of 
these inhibitors. Vinyl sulfones are easier to synthesize than other irreversible inhibitors of the 
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proteasome, and they can be used as sensitive probes to study substrate binding and specificity of 
the proteasome in different tissues and cells.57  
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Figure 32.  Mechanism of proteasome inhibition by peptide vinyl sulfone. Candidate residue for H-B are Thr1 amino 
terminus, a bound water molecule, and invariant Ser129 Oγ. 
 
 
Epoxyketones 
 
Representative examples of natural products that exert their biological effects by proteasome 
inhibition58,59 are α',β'-ketoepoxides: epoxomicin 37 and eponemycin 38 (Figure 33). Epoxomicin, 
isolated from the actinomycete strain Q996-17,60 was cocrystallized with the yeast S. cerevisiae 20S 
proteasome to show the specificity of this compound for the proteasome.61 The epoxomicin 37 
binds to the catalytic subunits completing an antiparallel β-sheet.7 This natural product reacts 
potently and irreversibly with the chymotrypsin-like site at low concentrations,58 while inhibits 
post-acidic and trypsin-like activity only at the higher concentration used to obtain the cocrystal. 
The less potent epoxyketone eponemycin 38 and its synthetic analogue dihydroeponemycin 39 
(Figure 33) react with the post-acidic-like and chymotrypsin-like sites at similar rates. 
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Figure 33.  Natural and synthetic α', β'-epoxyketone containing compounds. 
 
All these compounds act by an interesting and unique mechanism, in which they react with both the 
hydroxyl and amino groups of the catalytic N-terminal threonine of the proteasome with formation 
of a morpholino ring 41 (Figure 34).61 Epoxyketones, because of their unique mechanism, are the 
most selective inhibitors of the proteasome known. Epoxomicin causes cell morphology change and 
growth arrest, leading to apoptosis, and also exhibits anti-inflammatory activity in mice, 
presumably by inhibition of NF-kB activation.58 Biotinylated derivatives of epoxomicin62 38 and 
dihydroeponemycin63 39 (dihydroeponemycin retains the biological activity of eponemycin) are 
inhibitors which can be used as active site probes. 
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Figure 34.  Schematic representation of the proposed morpholino derivative adduct formation mechanism. 
 
 
II.1.3   Non Covalent inhibitors of the 20S proteasome 
 
Application of covalent inhibitors in vivo often induces apoptosis and causes cell death. Thus,  the 
covalent inhibitors of 20S proteasome by their mechanism of action if in one hand are operative, on 
the other hand they also can be toxic and show severe side effects.64-66 That is why their potential in 
possible disease treatment is strongly limited. Identification and development of inhibitors that do 
not covalently modify the protein should avoid the inherent drawbacks often associated with the 
reactive groups used for the establishment of the covalent interaction: lack of specificity, excessive 
reactivity and instability. So far, non covalent inhibitors have been investigated less extensively 
judging from the paucity of reports on this type of compounds. 
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TMC-95 and Its Derivatives 
 
The natural products from Apiospora Montagnei, TMC-95s (TMC-95A, B, C, D)  selectively and 
competitively inhibit the proteolytic activity of the proteasome in the low nanomolar range.67,68 
Particularly TMC-95A has a higher effect on chymotrypsin-like activity (IC50 = 5.4 nM) than on 
trypsin-like (IC50 = 200 nM) and post-acidic activity (IC50 = 60 nM). TMC-95B inhibits these 
activities to the same extent as TMC-95A, while the inhibitory activities of TMC-95C and D are 20 
to 150 times weaker than TMC-95A and B. All these compounds consist of a heterocyclic ring 
system made of modified amino acids 42 (Figure 35).  
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Figure 35.  Chemical structure of TMC-95s including diastereomers A to D. 
 
TMC-95A 43, crystallized in a complex with the yeast 20S proteasome,14 is linked non-covalently 
to all proteolytically active β-subunits, not modifying their N-terminal threonine residues, in 
contrast to all previously structurally analysed proteasome inhibitor-complexes. A tight array of 
hydrogen bonds connects this inhibitor with protein, stabilizing the compound in its bound status 
(Figure 36). The backbone of TMC-95A adopts a β-conformation and forms an antiparallel β-sheet 
structure in the active site. The n-propylene group of this inhibitor protrudes into the S1 pocket, 
making weak hydrophobic contacts with Lys33, while the side-chain of the asparagine residue is 
inserted deeply into the S3 pocket and has been ascribed a major role in the differing IC50 values 
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amongst the post- acidic, chymotrypsin- and trypsin-like activity. TMC-95s have been the first non-
covalent and reversible inhibitors of the proteasome to be discovered.  
 
 
43 
 
Figure 36.  Schematic overview of TMC-95A 43 (yellow) bound to the active site of subunit β2. Hydrogen bonds with 
their correlated distances in Å are shown as green dashed lines. Non-polar hydrogen interactions are drawn as green 
cycle segments. The amino acid which is in particular responsible for the character of the S3 pocket (aspartic acid in the 
case of the yeast subunit β2) is shown in grey. From Groll et al.14  
(Reproduction by courtesy of  Prof. Groll). 
 
 
Linear TMC-95 derivatives 
 
As already mentioned, the natural constrained cyclopeptide TMC-95A 43 was the first product 
discovered that inhibits the proteasome noncovalently.68 45 linear analogues of this compound69 
were designed and evaluated. The basic idea was that the structural elements of the natural product 
that are required for proteasome inhibition could be identified and used to design linear TMC-95A 
mimics that are less difficult to prepare than TMC-95A itself or its cyclic mimics. The objective 
was to determine how the catalytic activities of the 20S proteasome were influenced by elements 
derived from TMC-95A. Therefore, the tripeptide compounds 44 and 45 (Figure 37), were 
synthesized and depending on the structures of the R1, R2, R3, and R4 groups, gave inhibition on 
all three active sites, two active sites, or only one active site with Ki values of 0.32-84 µM. These 
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linear TMC-95 derivatives are significant inhibitors in vitro and in cell tumor lines and are 
metabolically stable. 
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Figure 37. Structures of linear TMC-95A-Based Proteasome Inhibitors. 
                                                                                                                                      
 
 2-Aminobenzylstatine Derivatives and Synthetic Analogues 
 
A series of 2-aminobenzylstatine derivatives (Figure 38) which were originally designed to target 
the HIV-1 protease, have shown to inhibit non-covalently the chymotrypsin-like activity of the 
human 20S proteasome.70 The SAR data generated during the optimization of this compound class 
has allowed to design an alternative inhibitor scaffold with reduced size and attenuated peptidic 
character71 48 (Figure 38). In this scaffold, the non-productive structural features have been 
removed and the critical interactions of the 2-aminobenzylstatine inhibitors have been incorporated 
or mimicked. The two crucial amide bonds flanking the valine residue and the C-terminal phenol 
group filling the S1 pocket are preserved whereas the statine moiety is replaced by a 3,4,5-
trimethoxy-L-phenylalanine residue. This nonproteinogenic amino acid is able to form exactly the 
same interactions with the S3 pocket as the entire 2-aminobenzylstatine moiety. The two other 
critical pharmacophore features, i.e., the tert-leucine side chain and the hydrophobic N-terminal 
group, are mimicked in the prototype compound by a single phenoxy substituted benzylic N-
terminal group. Molecular studies suggested that the two phenyl rings of this bulky N-terminal 
group present a spatial arrangement adequate to simultaneously fill the AS1 and AS2 accessory 
hydrophobic pockets. 
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This compound, potent and selective, blocks the chymotrypsin-like activity with IC50 = 15 nM. That 
is why, it is an interesting tool for investigations of proteasome function in many aspects of cellular 
regulation. In addition, the high antiproliferative activity obtained is encouraging to develop an 
anticancer drug based on the concept of proteasome inhibition. 
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Figure 38. 2-Aminobenzylstatine derivatives and their synthetic analogue 48. 
 
 
Lipopeptides 
 
The lipopeptides72 are a new class of non-covalent inhibitors. If was postulated that adding a large 
aliphatic blocking group to the N-terminus of a short peptide that is known to inhibit proteasome 
activities would make it a better inhibitor. The ability of these compounds to inhibit at micromolar 
concentrations chymotrypsin-like and post-acid activities depends on peptide length (3 or 6 amino 
acids), sequence (presence of a positively or negatively charged amino acid), and alkyl chain length 
(C6–C18). These structural features could be varied to selectively inhibit one or more of the three 
proteasome activities. The best result was obtained with compound 49 (Figure 39) that inhibited 
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rabbit 20S proteasome with an inhibitory effect increased (CT-L and PA with Ki = 18 and 15 nM, 
respectively) or decreased (T-L, Ki = 80 nM) by a factor of 2 compared to yeast 20S proteasome. 
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Figure 39. Lipotripeptide proteasome inhibitor. 
 
 
New potential drugs 
 
Clinical studies with Bortezomib 26 (Figure 28) have validated the proteasome as a therapeutic 
target for the treatment of multiple myeloma and non-Hodgkin's lymphoma. However, significant 
toxicities have restricted the intensity of bortezomib dosing. Therefore, clinical evaluation of 
additional proteasome inhibitor classes is warranted. Currently, three irreversible proteasome 
inhibitors are under development: (a) salinosporamide A (NPI-0052)52, 53 32 (Figure 30) a natural 
product related to lactacytsin, as mentioned before (b) PR-171 (Carfilzomib)73 50 (Figure 40) a 
modified peptide related to the natural product epoxomicin and (c) CEP-1877074 51 (Figure 40).  
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Figure 40. New inhibitors of the proteasome. 
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II.2.   Objectives and Design 
 
II.2.1.   Objectives 
 
Noncovalent inhibitors of the 20S proteasome have been investigated less extensively, although 
they should have weaker side effects in therapeutic applications, as already mentioned in chap II.1.3. 
The inherent drawbacks of the classical protease inhibitors (e.g., non-target specific, too reactive or 
unstable) prompted us to focus our efforts in developing new molecules that have no reactive group 
(“warhead”) that could react with the catalytic Oγ-Thr1 of the proteasome. Thus, the goal of our 
work was the design and the synthesis of new peptidomimetics able to bind the proteasome non-
covalently and to modulate its function, in particular to inhibit its activity.  
A peptidomimetic, as discussed above, is a compound containing non-peptidic structural elements 
that is capable of mimicking or blocking the biological action of a natural parent peptide.75 The 
advantages of these molecules in comparison with native peptides are a possible improvement of 
pharmacological properties and the increase of metabolic stability, oral availability and cell-
permeability. The requirements for the peptidomimetics are a few or no peptide bonds, a low 
molecular weight and a similar pharmacophore to have an analogous binding mode of the natural 
peptide.  
Regarding the non covalent inhibition of the active sites of the proteasome core particle, we could 
note, for example in the case of TMC-95A 43 that the inhibitor interacts with two peptidic chains of 
the proteasome active site by adopting a β-conformation and forming an antiparallel three strands β-
sheet (by filling a gap between strands including residues 20, 21 and 47, 49 in particular). We could 
also note that parts of the inhibitor fill two pockets S1 and S3 of the active site of the proteasome. 
These concepts will form the basis for the development of new synthetic non covalent proteasome 
inhibitors as promising drugs. 
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II.2.2.  Molecular Modelling: tool for the conception 
 
We have carried out computer simulations in the hope of understanding the properties of assemblies 
of molecules in terms of their structure and the microscopic interactions between them. This serves 
as a complement to conventional experiments, enabling us to learn something new. The use of 
theoretic methods to obtain models that allow predicting structures, properties and molecular 
interactions is known as “Molecular Modelling”. 
Molecular structures generated in silico have to be geometry optimized to find the individual energy 
minimum state by applying a molecular mechanics method. This is a method employed to calculate 
molecular geometries and energies. In the framework of the molecular mechanics method the atoms 
in molecules are treated as rubber balls of different sizes (atom types) joined together by springs of 
varying length (bonds). For calculating the potential energy of the atomic ensemble Hooke’s law is 
used. In the course of  a calculation the total energy is minimized with respect to atomic coordinates 
where: 
 
Etot = Estr + Ebend + Etors + Evdw + E elec 
 
where Etot is the total energy of the molecule, Estr is the bond-stretching energy term, Ebend is the 
angle-bending energy term, Etors is the torsional energy term, Evdw is the van der Waals energy term, 
and E elec is the electrostatic energy term. Molecular mechanics enables the calculation of the total 
steric energy of a molecule. The set of parameters consisting of equilibrium bond lengths, bond 
angles, partial charge values, force constants and van der Waals parameters is known as the force 
field. In our work was used the MMFF94 Force Field76 that was developed as a combined 
"organic/protein" force field, one which was equally applicable to small molecules as well as 
proteins and other systems of biological importance. 
The technique known as energy minimization is used by molecular mechanics only to find the local 
energy minimum but not implicitly the global energy minimum. Lower energy states are more 
stable and are commonly investigated because of their role in chemical and biological processes. 
Molecules can be modeled either in vacuum or in the presence of a solvent. Simulations of systems 
in vacuum are referred to as gas-phase simulations, while those that include the presence of solvent 
molecules are referred to as explicit solvent simulations. In another type of simulation, the effect of 
solvent is estimated using an empirical mathematical expression; these are known as implicit 
solvation simulations. In our work the molecular modelling was performed in vacuum.  
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In order to design new proteasome inhibitors, we first studied the known inhibitors and tried to 
establish which parts of these inhibitors were essential for the proteasome inhibitor activity, 
meaning that we had to point out some structure-activity-relationships. For this purpose we 
extracted from the PDB (Protein Data Bank) the known inhibitors crystallised in the active sites of 
the 20S proteasome from yeast. Three inhibitors were described in the PDB: TMC-95A14 (PDB 
code: 1JD2) 43 (Figure 36) morpholino adduct of epoxomicin 61 (PDB code: 1G65) 41 (Figure 34) 
and ALLN7 (PDB code: 1RYP) 17 (Figure 24). In the three cases the active site used to obtain the 
complex with the inhibitor was not always the same, but all the three inhibitors were able to bind 
and block all active subunits, also if with different activities. For this reason, we decided not to 
choose a specific active site in our study. 
Then, by using the Sybyl program (version 7.0) we studied the structure and the interactions of the 
two covalent inhibitors (morpholino adduct of epoxomicin 41 and ALLN 17) and the non covalent 
inhibitor (TMC-95A 43) into the proteasome. 
For all three inhibitors we found some constant interactions: hydrogen bonds between the CO and 
the NH of Thr21; the CO of Gly47 and the NH of Ala49 (Figure 41). In the case of TMC-95A 43 
hydrogen bonds with the NH of Gly23 and with the COOH of  the lateral chain of Asp114 are also 
observed. In the case of morpholino adduct of epoxomicin 41, hydrogen bond with Asp114 is also 
observed. We could note that for these three inhibitors there is an interaction with the proteasome 
mediated by hydrogen bonds implicating in particular residues 21, 47 and 49 with the formation of 
an antiparallel β-sheet between the inhibitor and the amino acid residues of the binding pockets.15 
We could also note that hydrophobic parts of the three inhibitors occupied the two pockets S1 and 
S3 of the active sites of the proteasome (Figure 41).  
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Figure 41. Overview of TMC-95A, morpholino adduct of epoxomicin and ALLN bound to the active site of the     
proteasome. 
 
In the second time we checked the ability of superposition of these inhibitors. Therefore, we tried to 
compare TMC95-A 43 and morpholino adduct of epoxomicin 41, by superposing points from 1 to 8 
(Figure 41). Both molecules were kept fixed in the conformation adopted in the proteasome binding 
site. 
It resulted in a good superposition of the eight atoms, in particular the ones that contract the 
hydrogen bonds with residue 21, 47 and 49. More, the superposition indicates that the S1 and S3 
pockets are occupied in a unique way by the corresponding residues of the inhibitors (Figure 42). 
The superposition has also been achieved between morpholino adduct of epoxomicin 41 and ALLN 
17 and resulted in a good superposition as well. 
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Figure 42. Result of the superposition in eight points between TMC-95A 43 (yellow) and morpholino adduct of 
epoxomicin 41 (green). Hydrogen atoms are omitted for clarity. 
 
The pharmaceutical company Novartis described the molecule 4871 (Figure 38) that inhibits the 20S 
proteasome in a non covalent mode and that is highly specific for the chymotrypsin-like activity. 
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Figure 43. Left: chemical structure of Novartis molecule 48 showing the correspondence between their respective 
chemical moieties in terms of interaction with the proteasome binding site. Right: model of designed Novartis molecule  
bound to the CT-L active site into the proteasome. Hydrogen bonds are shown in magenta. From Furet et al.71 
(Reproduction by courtesy of  Dr. Garcia-Echeverria). 
 
This molecule was not crystallized into the proteasome but it was studied by molecular modelling.77 
It was shown that it contracts similar hydrogen bonds with residues of the active site of proteasome 
than the three previous inhibitors. In fact, four β-sheet like hydrogen bonds are formed between the 
amide bonds flanking the valine residue of the inhibitor and the residues Thr 21, Gly 47, and Ala 49. 
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These hydrogen bonds place the inhibitor in the active site in such a way that its C-terminal phenol 
and 3,4,5-trimethoxy-L-phenylalanine moieties fill the S1 and S3 pockets, respectively. The N-
terminal group with its two phenyl rings also form favourable interactions with the active site by 
occupying small accessory hydrophobic pockets AS1 and AS2. By the help of molecular modelling 
we obtained 48 in our study by using the following steps: 
 
• Construction of the molecule 48. 
• Choice of the conformation that gives the best superposition with adduct of epoxomicin 41 
(points 1-8). 
• Minimisation. 
• Superposition between 48 and morpholino adduct of epoxomicin 41 (points 1-8). 
• Further minimisation. 
• Insertion of the resulting molecule 48 in the active site of the crystallised yeast 20S 
proteasome,61 after that morpholino adduct of epoxomicin 41 was removed, in order to check 
the presence of the all fundamental interactions (hydrogen bonds, filling of the pockets…). 
The superposition between 48 and morpholino adduct of epoxomicin 41 was satisfactory (Figure 
44). 
 
 
 
Figure 44. Result of the superposition in eight points between Novartis molecule 48 (white) and morpholino adduct of 
epoxomicin 41 (yellow). Hydrogen atoms are omitted for clarity. 
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We decided to use this molecule as our starting point for the design of new proteasome 
inhibitors.For the design of new inhibitors we will follow the same procedure described above, 
considering this time the molecule 48 as the molecule of reference for the superposition. 
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II.2.3.  Design 
 
As already mentioned, after the discovery of the natural compound TMC-95s 42 (Figure 35) as the 
first non covalent inhibitors, the pharmaceutical company Novartis developed the peptidomimetic 
compound 48 (Figure 38) a non covalent chymotrypsin-like activity inhibitor. Modulation of this 
enzymatic activity by β-subunit-specific inhibitors may convey an anti tumor effect by induction of 
cell cycle arrest and apoptosis in tumor cells.78,79  
As described before, the peptidomimetic 48 inhibits the proteasome in a non covalent manner by 
hydrogen bonds formation with residues 21, 47 and 49, and by hydrophobic interactions with S1 
and S3 pockets.  
Our goal was to obtain by a simple and reproducible synthesis molecules of small size which  met 
the following criteria:  
• To be peptidomimetic compounds. 
• To be able to contract essential hydrogen bonds in particular with Thr 21, Gly 47, and Ala 
49 in the active sites of the proteasome. 
• To be able to fill the S1 and S3 pockets and potentially the small accessory hydrophobic 
pockets AS1 and AS2. 
• To be able to interact in a β-sheet like manner by forming an antiparallel β-sheet in 
particular with residue 21 on a side and residues 47-49 on the other side. 
• To inhibit the proteasome without forming an adduct with the catalytic threonine residue. 
We used Novartis molecule 48 as our point of start and we tried to strengthen its ability to form a β 
arm. In particular, we decided to replace the valine residue and the C-terminal phenol group of 48 
by peptidomimetic fragment structure. 
The subject of this presented PhD work was completely new in our laboratory but we had 
experience in the design and the synthesis of molecular tongs containing amino acid mimetic 
fragments, inhibitors of HIV-1 protease dimerization.80 To be more precise, we incorporated in our 
molecular tongs a 5-amino-2-methoxybenzhydrazide group described by Nowick81 as a rigid 
peptidomimetic able to stabilise a β-sheet.80  
So we decided to incorporate this rigid peptidomimetic group in our molecules potentially 
proteasome inhibitors. To that purpose we replaced the valine residue and the C-terminal residue of 
Novartis molecule by a 5-amino-2-methoxybenzhydrazide derivative in molecule 52 (Figure 45). 
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Figure 45. Structure and potential interactions of compound 52. 
 
We reasoned that this peptidomimetic group could stabilise the β-sheet like structure and that the 
aromatic ring could fill the S1 pocket, while the 3,4-dimethoxyphenylalanine should fill the S3 pocket. 
3,4-dimethoxyphenylalanine was proposed in a first time because it is commercially available and a 
proteasome inhibitor was also described with it.71 While 3,4,5-trimethoxyphenylalanine gave better 
results71 but has to be synthesized. Essential hydrogen bonds with Thr 21 and Ala 49 should be 
contracted while no NH is available in molecule 52 to make a hydrogen bond with the CO of Gly47 
(Figure 45). Superposition between Novartis molecule 48 and 52 is shown in Figure 46. 
 
 
 
 
 
 
 
 
 
 
 
Figure 46. Result of the superposition in six points between Novartis molecule 48 (white) and molecule 52 (yellow). 
Hydrogen atoms are omitted for clarity. 
 
Unfortunately at 100 µM, no inhibition could be observed on the post-acidic, trypsin- and 
chymotrypsin-like activities of the 20S proteasome of rabbit. It is known that the active site of the 
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proteasome is narrow and not easily reachable. Maybe compound 52 was too rigid and too bulky to 
enter in the core particle (CP) of the proteasome.  
In parallel of this first objective and as part of ongoing investigations into the design of proteasome 
inhibitors and the development of new trifluoromethyl peptidomimetics,82-87 we have decided to 
design less rigid molecule and to incorporate fluorinated peptidomimetics. 
Fluorine has become a fundamental tool in the development of drugs.88,89 Trifluoromethylated 
compounds are particularly important, as shown by the number of CF3-containing drugs and drug-
candidates in clinical use or in development. The introduction of one or more fluorines into a 
molecule modifies its physicochemical and/or biological properties:  
 
• The C—F bond has a relatively important ionic character and a strong energy that increases 
metabolic stability of the fluorinated compound.  
• Replacing some of the hydrogen by fluorine atoms can enhance the hydrophobicity and then 
strengthen the interaction with a hydrophobic pocket of the enzyme. 
• Fluoroalkyl groups are strong electron-withdrawing substituents, and consequently, the 
acidity of neighbouring hydrogen atoms is greatly increased. The presence of fluorine atoms 
enhances the ability of its neighbouring function to donate a hydrogen bond (α2H) (acidity) 
and lowers its ability to accept hydrogen bond (β2H) (basicity). 
• The trifluoromethyl group can mimic several naturally occurring functional groups such as 
methyl, isopropyl and phenyl, and consequently can have an effect on the conformational 
equilibrium of a molecule. For this reason, a non negligible impact is possible on the affinity. 
• Fluorine is a poor acceptor of hydrogen bond. Most of the examples of H---F bonds reported 
in the literature concern intramolecular hydrogen bonds (fluoroalcohols, fluorophenols, and 
fluoroanilines).90,91 Hydrogen bonds between fluorinated substrates and biological 
macromolecules have been postulated in some enzyme-substrate complexes. However, it is 
rather difficult to determine if these hydrogen bonds really exist: other factors may stabilize 
the conformation corresponding to the short H---F interatomic distance (distance between 
2.0 and 2.3Å) considered as criterion to determine the existence of hydrogen bond with F. 
 
The possibility to modify or modulate the pharmacological profile of a molecule by inserting 
fluorine atoms clearly explains why the bioorganic and medicinal chemistry of fluorine has become 
so important. The incorporation of a trifluoromethyl group into peptidomimetics to produce potent 
inhibitors of various enzymes has been extensively studied.  
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One example are the trifluoromethyl (Tfm)-malic peptidomimetics that are micromolar inhibitor of 
some metalloproteinases,  proteolytic enzymes involved in the degradation of the extracellular 
matrix.92 Another example of the use of fluorine to improve drug properties is represented by the 
fluoroartemisinins, metabolically more stable antimalarial artemisinin derivatives.93 
We have developed new trifluoromethyl inhibitors based on the trifluoromethyl-β-hydrazino acid 
scaffold 53 (Figure 47). 
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Figure 47. New trifluoromethyl-β-hydrazino acid scaffold 53. 
 
To overcome some of the pharmaceutical limitations inherent in peptides, hydrazino-azapeptoids94 
and more recently retro hydrazino-azapeptoids95 were described as covalent proteasome inhibitors 
of the CT-L activity with IC50 ranging from 50 to 500 µM.  
β-hydrazino acids are peptidomimetic building blocks that have two nitrogen atoms. They can be 
considered to be analogues of β-amino acids in which the amine group has been replaced by a 
hydrazine. But while the β-amino acids are well documented,96-98 almost nothing is known about 
these peptidomimetics. Obviously, these structures can mimic the typical secondary structure of 
native α-peptides, making them useful tools with which to design new protease inhibitors. To our 
knowledge, the synthesis of CF3-β-hydrazino acid has not been reported. This scaffold was also 
chosen because it has a trifluoromethyl group, which can greatly improve the acidity of the 
neighbouring hydrazine functional group and thus increase its hydrogen bond donor ability.88 
Finally, the elongation of the backbone may introduce flexibility, thus facilitating the putative 
interaction of substituants R1 and R2 with the enzyme S1 and S3 pockets.  
Five compounds 54-58 (Figure 48) were designed and synthesized. 
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Figure 48. Designed trifluoromethyl-β-hydrazino compounds 54-58. 
 
The N-terminus of our starting molecule 54 was inspired by aminobenzylstatine derivatives,71 
which interact with the S3 pocket and, by the phenoxysubstituted benzylic N-terminal group, with 
the AS1 and AS2 accessory hydrophobic pockets. The smaller analogous 55 have been also 
designed. Replacing the 3,4-dimethoxyphenylalanine amino acid by the more hydrophilic lysine 
amino acid in molecule 56 could facilitate the interaction of the aspartic residues in the S3 pocket of 
the T-L active site with εNH2 group.99,69 It should also increase the solubility of the compound. 
The phenyl group of the C-terminal phenylalanine of molecules 54-56 was assumed to occupy the 
S1 pocket. In the case of molecules 57 and 58 we decided to combine the similar Novartis motif 
with our scaffold that this time is inverted (Figure 49) to study the eventual change on the inhibition 
effect. 
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Figure 49. New trifluoromethyl-β-hydrazino acid scaffold regular 53 and inverse 59. 
 
For synthetic reasons we added in these two molecules another hydrazine group as a link between 
the scaffold and the N-terminal part of the molecule. In this way it was also possible to form the 
hydrogen bonds with the residue Thr 21 in the active site of the proteasome. The hydrazino group of 
the scaffold was protected with Boc or Cbz groups, in molecule 57 and 58 respectively, to test the 
different filling of the S1 pocket.  
In both cases, either for molecules that contain regular scaffold or for those that contain inverse 
scaffold, it should be possible to make hydrogen bonds with all three residues 21, 47, 49. 
The main difference was that in the first case (regular scaffold) the hydrogen bond between the 
molecules and NH of Thr 21 could potentially involve a fluorine atom, having in mind as described 
above about the examples of H---F bonds. 
As explained in the previous chapter II.2.2., molecules 54 and 58 (Figure 48) were superposed with 
our Novartis molecule model 48. The two superposition were rather satisfactory. The results are 
shown for molecule 54 and 58 in Figure 50 and Figure 51, respectively. 
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Figure 50. Result of the superposition in eight points between Novartis molecule 48 (green) and molecule 54 (purple). 
Hydrogen atoms are omitted for clarity. 
 
 
 
 
 Figure 51. Result of the superposition in eight points between Novartis molecule 48 (green) and molecule 58 (orange). 
Hydrogen atoms are omitted for clarity. 
 
We show in Figure 52 that hydrogen-bonds with essential amino acids Thr 21, Gly 47 and Ala 49 
could be present. 
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Figure 52. Overview of molecule 54 bound to the active site of the proteasome. Hydrogen atoms are omitted for       
clarity. 
 
 
II.3.  Synthesis of non fluorinated molecule 52 
 
The synthesis of the molecule 52 is described in Scheme 1. This compound was synthesized in eight 
steps from commercially available 2-methoxy-benzoic acid 60, which was converted to 
intermediate 61 by nitration with NH4NO3, H2SO4 in good yield (80%), following the Nowick’s 
procedure.100 The coupling with tert-butyl-carbazate with a good yield (86%), following a 
procedure described in the laboratory, and successive reduction of the nitro group of 63 gave the 
Boc-protected 5-amino-2-methoxybenzhydrazide 64, described in literature by Nowick.101 After 
classical acylation of compound 64 with Ac2O in THF in quantitative yield, the resulting compound 
65 was Boc deprotected by treating it with TFA in dry CH2Cl2 to give 66. The compound 66, 
obtained in quantitative yield, was coupled to the non natural amino acid Fmoc-L-3,4-
dimethoxyphenylalanine, in presence of HBTU and HOBt as coupling agents, to afford the Fmoc-
protected compound 68 in 50% yield. The purification of 68 was not easy to do because this 
Thr 
Ala Gly 
 61 
product had the tendency to form a gel in aqueous phase and was not soluble in several organic 
solvents. After Fmoc deprotection with 10% of piperidine in DMF, the coupling of 69 with 3-
phenoxyphenylacetic acid 70 gave the desired product 52. This product 52 had the same tendency 
as 68 to form a gel in aqueous and organic solutions. However it was possible to purify it by 
chromatography on silica gel to obtain 52 with a good yield (75%). 
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Scheme 1. Synthesis of compound 52. Reagents: 
a) NH4NO3, H2SO4, 80%; b) EDC.HCl,  HOBt, CH2Cl2, DIPEA, 86%; c) H2, Pd/C 10%, MeOH, 96%; 
d) Ac2O, THF, 100%; e) TFA, CH2Cl2, 100%; f) HBTU, HOBt, DMF, 2,4,6 collidine, 50%; g) 10% piperidine/DMF, 100%;
h) HBTU, HOBt, DMF, 2,4,6 collidine, 75%.
 
Note: The gel obtained with compound 52 in EtOAc was observed under Microscope Eclipse E600 
Nikon (examination in white light) to check the presence or not of an organized structure. 
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The result was that we did not find any organization of this gel under form of the crystals or fibrils. 
The experience was done in collaboration with the Department of  “Physico Chemistry of the 
Polyphase systems”, UMR 8612 of the CNRS, University Paris-Sud 11.   
 
 
II.4.   Synthesis of fluorinated molecules 54-58 
 
The first target compound 54 was synthesized starting from the ethyl 4,4,4- trifluorocrotonate102 71 
as outlined in Scheme 2. Michael addition of tert-butyl-carbazate 62 on 71 in refluxing MeOH gave 
the N-protected trifluoromethyl-β-hydrazino ester 72 with a very good yield (95%). This product 72 
after saponification with sodium hydroxide was coupled to the L-phenylalanine methyl ester to 
afford 75 in 91% yield using HBTU and HOBt as coupling agents in presence of DIPEA in 
DMF/CH2Cl2. The cleavage of the Boc group of the hydrazine moiety with trifluoroacetic acid 
(TFA) in dry CH2Cl2 gave compound 76 which was coupled with Fmoc-L-3,4-
dimethoxyphenylalanine 67 using HBTU and HOBt in presence of 2,4,6-collidine in DMF. The 
resulting molecule 77 was really hard to purify and the yield dramatically fell (22%). In fact, during 
the washing with acidic and basic aqueous solutions we observed the formation of a gel very hard to 
disrupt. Addition of a solvent mixture H2O/EtOAc, and subsequent extraction allowed the isolation 
of a residue which could be purified by chromatography on silica gel. The cleavage of the Fmoc 
group of 77 with 10% of piperidine in DMF afforded the amine 78 (in 86% yield) which was 
coupled with 3-phenoxyphenylacetic acid to give the final compound 54 in moderate yield (47%). It 
is important to note that the coupling of the racemic acid 73 with L-phenylalanine methyl ester 74 
afforded 75 in a 1:1 diastereoisomeric mixture that could not be separated by flash chromatography 
or by crystallisation. Compounds 76-78 progressed then as 1:1 diastereoisomers mixtures. However 
compound 54 was obtained with a 2/3 ratio of diastereoisomers probably because of the loss of one 
diastereoisomer during the purification. 
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Scheme 2. Synthesis of compound 54. Reagents: 
a) MeOH, reflux, 94%; b) 2N aq. NaOH, THF/MeOH, 98%; c) HBTU, HOBt, DIPEA, CH2Cl2, DMF, 91%; d) TFA, CH2Cl2,
100%; e) HBTU, HOBt, 2,4,6-collidine, DMF, 22%; f) 10% piperidine/DMF, 86%; g) HBTU, HOBt,DIPEA, DMF, 41%.
 
As depicted in Scheme 3, the intermediate 76 was used to obtain the second target molecule 55 by a 
simple coupling with 3-phenoxyphenylacetic acid 70 with HBTU and HOBt as coupling agents. 
After purification by chromatography on silica gel a 1:1 mixture of diastereoisomers of 55 was 
obtained in 42% yield. 
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Scheme 3. Synthesis of compound 55. Reagents: 
 a) HBTU, HOBt, 2,4,6-collidine, DMF, 42%.
 
 
The synthetic pathway to obtain the third target compound 56 is presented in Scheme 4.  
The TFA salt 76 was converted to 80 by coupling with Nα-Boc-Nε-Z-L-Lysine, using HBTU and 
HOBt as coupling reagents, in 57% yield. The Nα-Boc protecting group was removed by treatment 
with TFA in dry CH2Cl2 and compound 81 was isolated in quantitative yield. The coupling reaction 
between 81 and 3-phenoxyphenylacetic acid 70 gave compound 82 with a good yield (71%). 82 was 
finally N-deprotected by hydrogenation over 20% Pd/C, and TFA was added to provide compound 
56 in quantitative yield and in a 1:1 mixture of diastereoisomers. 
In parallel, a part of product 80 was N-deprotected by hydrogenation over 20% Pd/C, and citric acid 
monohydrate was added to give 83 with a modest yield (51%) (Scheme 4). We decided to 
synthesize also compound 83, analogous to molecule 56, to test if was possible to have same 
inhibitor effect due to the different N-terminal groups.  
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Scheme 4. Synthesis of compounds 56 and 83. Reagents: 
a) HBTU, HOBt, DIPEA, DMF, 57%; b) H2, Pd/C 20%, MeOH, citric acid monohydrate, 51%; c) TFA, CH2Cl2, 100%;
d) HBTU, HOBt, DIPEA, DMF, 71%; e) H2, Pd/C 20%, MeOH,TFA,100%.
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The only difference between the last two targets 57 and 58 was the protecting group, Boc or Cbz 
respectively. The synthesis of compound 57 is outlined in Scheme 5. Reaction of 72 with hydrazine 
monohydrate afforded the hydrazide compound 85 in quantitative yield. Coupling of 85 with Fmoc-
L-3,4-dimethoxyphenylalanine, using HBTU, HOBt as coupling agents in presence of 2,4,6-
collidine in DMF, gave 86 in 68% yield. The following deprotection of the Fmoc group and the 
final coupling of the resulting compound 87 with 3-phenoxyphenylacetic acid 70 provided 
compound 57 in satisfactory yield and in a 1:1 mixture of diastereoisomers. 
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Scheme 5. Synthesis of compounds 57. Reagents: 
a) EtOH, 100%; b) HBTU, HOBt, DMF,2,4,6-collidine, 68%; c) 10% piperidine/DMF, 88%; d) HBTU, HOBt, DMF,2,4,6-collidine, 84%.
 
 
In a first approach we envisaged to synthesize the molecule 58 from the molecule 57, by a simple 
removing of the Boc group and a reprotection of the amino group at the C-terminal side of the 
expected compound 88 with Cl-Cbz. Unfortunately, we could not obtain the desired product 58 
using this way. Effectively, the reaction of the N-Boc removing by a solution of HCl/MeOH did not 
afforded the expected compound 88 but gave only compound 89 in a quantitative yield. We 
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supposed that the compound 89 is obtained by the nucleophilic attack of MeOH on the protonated 
carboxyl group of the hydrazide motif (Schema 6). 
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Scheme 6. Envisaged synthesis of compounds 58. Reagents: 
a) HCl/MeOH, MeOH b) Cbz-Cl, DIPEA, CH2Cl2.
 
 
Consequently, we decided to investigate a new route as illustrated in Scheme 7. 
We started from the protected trifluoromethyl-β-hydrazino ester 72. The first step was the N-Boc 
deprotection of 72 with TFA in dry CH2Cl2 in a quantitative yield followed by the N-protection of 
90 with Cbz group. The resulting compound 91, obtained in a good yield (81%), reacted with 
hydrazine monohydrate 84 to give compound 92 in quantitative yield. This compound was coupled 
with Fmoc-L-3,4-dimethoxyphenylalanine, using HBTU and HOBt as coupling agents in presence 
of 2,4,6-collidine in DMF to give 93. As in the case of products 86 and 57 previously reported in 
Scheme 5, also 93 precipitated directly pure in EtOAc in 67% yield. After treatment with 10% of 
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piperidine in DMF to remove the Fmoc group, the last coupling between 94 and 3-
phenoxyphenylacetic acid 70 using HBTU and HOBt in presence of DIPEA in DMF allowed to 
obtain the final product 58 in high yield (85%) and in 1:1 mixture of diadtereoisomers. 
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Scheme 7. Synthesis of compounds 58. Reagents: 
a) TFA, CH2Cl2, 100%; b) Cl-Cbz, CH2Cl2, DIPEA, 81%; c) EtOH, reflux, 100%; 
d) HBTU, HOBt, DMF, 2,4,6 collidine, 67%; e) 10% piperidine/DMF, 78%; f) HBTU, HOBt, DIPEA, DMF, 85%. 
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II.5.   Biological activity – Results and discussion  
 
The abilities of non fluorinated peptidomimetic 52 and fluorinated compounds to inhibit the three 
catalytic activities of rabbit 20S proteasome were tested using appropriate fluorogenic substrates: 
Suc-LLVY-AMC (Suc, succinyl; AMC, aminomethylcoumaride) for the chymotrypsin-like 
activity (CT-L); Boc-LRR-AMC for the trypsin-like activity (T-L), and Z-LLE-β-NA (Z, 
benzyloxycarbonyl; β-NA, β-naphthylamine) for the post acidic activity (PA) (Figure 20).69, 72 
The aldehyde proteasome inhibitor MG132 (Z-LLL-H) was used as standard.69 
The three peptidases activities were determined by monitoring the hydrolysis of these three 
fluorescent substrates for 45 min (30 min in the case of 52) at 37 °C using a BMG Fluostar 
microplate reader, in the presence of untreated proteasome (control), or proteasome that had been 
incubated with the test compound (0.1-200 µM). The buffers (pH 7.5) were: 20 mM Tris, 1 mM 
DTT, 10% glycerol, 0.02% (w/v) SDS for CT-L and PA activities; 20 mM Tris, 1 mM DTT, 10% 
glycerol for T-L activity. In the case of 52 the buffers for all three activities contained also 3% 
(v/v) DMSO, thus the control experiments were run with the same amount of DMSO solvent. 
The IC50 values (inhibitor concentrations giving 50 % inhibition) were obtained by plotting the 
percent inhibition against inhibitor concentration to equation: % inhibition = 100[I]/(IC50 nH + [I] 
nH), or equation: % inhibition = 100[I] nH /(IC50 nH + [I] nH) where nH  is the Hill number. The Km 
values of the fluorogenic substrates in our experimental conditions were: 30 ± 5 µM (Suc-LLVY-
AMC), 77 ± 4 µM (Z-LLE-β-NA) and 26 ± 6 µM (Boc-LRR-AMC). 
 
 
 
 
 
 
 
 
 
 
Figure 53. Inhibition of CT-L activity of rabbit 20S proteasome by compound 56 at pH 7.5 and 37 °C.  The 
experimental data were fitted to equation % inhibition = 100[56] nH /(IC50 nH + [56] nH) with nH = 4.5. 
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The results show that the non fluorinated compound 52 (Figure 45, see chapter II.2.3 Design, 
page 53) has no inhibitor effect on the three activities of the proteasome at the different doses 
tested, even changing the preincubation time in the first step of the experiment, while several 
fluorinated compounds gave inhibition of these three activities. IC50 values against proteasome 
subsite activities obtained after 45 min of incubation, as mentioned before, are reported in Table 
1. 
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Table 1. IC50 (µM) or % inhibition at 100 µM of  compounds 54-58, 75, 80-83, 86, 92-94 against rabbit 20S 
proteasome at pH 7.5 and 37 °C. x: activation factor. Values are means of three experiments. CT-L: chymotrypsin-
like activity; PA: post-acid activity; T-L: trypsin-like activity.  
 
The data obtained from enzyme inhibition tests underlined that our fluorinated peptidomimetics 
are molecules able to interact with proteasome and could behave as inhibitors (54, 56, 81, 82, 83, 
93, and 94) but also as activators (54, 80, 86, 57, 93, 55, and 58). 
It is known that the protein degradation is predominantly catalyzed by the proteasome, then its 
activation should accelerate the intracellular proteolysis. This is an important effect for example 
in the case of accumulation of oxidized molecules. In fact, the activators of proteasome would 
present an interest in cosmetic against the cutaneous aging. Few natural compounds have been 
identified having proteasome activation properties and among them there are commipheroline 
and megassane, innovative active ingredients of the modern cosmetic industry.103 There are in 
literature some examples of proteasome activators.104-107 
We can observe a protein accumulation also in Alzheimer’s and Parkinson’s diseases. Therefore 
the application of activators for enhancement of the action of the 20S proteasome must be 
considered interesting. 
Multiple non-catalytic sites exist in the 20S proteasome and the binding of hydrophobic peptides 
to these sites stimulates peptide hydrolysis by all three of its active sites. There is  evidence that 
this stimulation occurs by peptide-induced opening of the channel in the α-rings of the 20 S 
proteasome.105 Wilk and coworkers107 synthesized four classes of peptide-based activators and 
described that the efficacy of these compounds is markedly dependent on both hydrophobicity 
and chain length.  
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In the presented work compounds 54, 80, 86, and 57 showed to be activators of the T-L activity 
(with 54> 80> 86 >57) and compounds 58, 93, 55 activators of the CT-L activity (with 58> 93> 
55). However, for now we are unable to explain the origin of this activation effect. 
The inhibitory effect was found with several molecules. 
Two series of molecules were synthesized and tested for their activity on the three catalytic sites 
of 20S proteasome, the first series containing our new trifluoromethyl-β-hydrazino acid scaffold 
in a regular sense 53 and the second one containing the scaffold in an inverse sense 59 (Figure 
49, see chapter II.2.3 Design, page 57). The results of the biological tests are shown in Table 1. 
Only molecules of the first series (regular scaffold) showed interesting inhibitory properties 
against all three active sites (56, 83), two active sites (54, 81), or only one active site (75, 82).  
Effectively, in the case of the inverse scaffold, molecules 58, 93 and 94 showed a very moderate 
inhibition of one activity (PA for 58, 93 and T-L for 94). In other words, these results indicated 
clearly that only the non inverse scaffold induced molecules conformation and interactions 
allowing the molecules to interact with the catalytic sites of the proteasome. 
Probably in the inverse scaffold the second hydrazine group (in blue) induces a too important 
elongation of the backbone thus moving away the groups that have to occupy simultaneously the 
S1 and S3 pockets. 
Compound 54 inhibited the CT-L and PA activities of rabbit 20S proteasome with a IC50 = 85 
and 72 µM respectively (Table 1). Shortening the pseudopeptide by connecting directly the 
phenoxy benzyl moiety on the trifluoromethyl-β-hydrazino acid scaffold and eliminating the 3,4-
dimethoxyphenylalanine totally removed the capacity of molecule 55 to inhibit all three active 
sites (Table1). Also the very weak PA inhibitor effect of compound 75 showed the importance of 
the substitution of the hydrazido group in the activity of the first series of molecules. 
Replacing the 3,4-dimethoxyphenylalanine amino acid by the more hydrophilic lysine amino acid 
could facilitate the interaction of the ε-NH2 group with the aspartic acid residue in the S3 pocket 
of the T-L active site.69,99 It should also increase the solubility of the compound. Indeed, 
molecule 56, where the 3,4-dimethoxyphenylalanine amino acid was replaced by the free lysine 
amino acid, inhibited CT-L (IC50 = 1.6 µM) and PA (IC50 = 2.7 µM) activities and also T-L 
activity (IC50 = 8.4 µM), whereas  protecting the lysine group eliminated inhibitory power (CT-L 
and T-L) or decreased it (PA, factor ≈ 100) (molecule 82). The phenoxysubstituted benzylic N-
terminal group was not essential for inhibition since molecule 83 was a moderate inhibitor 
(compare compound 56). The free N-terminus was favorable (IC50 = 5.9 µM, CT-L) and (IC50 = 
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4.4 µM, T-L), although the εNH2 group was protected (molecule 81 compared to molecule 83). 
Again, a positive charge on the lysine lateral chain or N-terminus stimulated binding to the TL 
active site. Proteasome inhibition was selective. Effectively, neither lysosomal cathepsin B nor 
cytosolic calpain I was inhibited by compounds 56, 81 and 83.108 Using purified enzymes to 
develop new inhibitors is of course the well-known strategy to obtain with security molecules 
acting on the targeted enzyme. It is also important then to test the capacity of the molecules to 
inhibit the enzyme in its cellular or acellular environment. We are performing in Professor M. 
Reboud-Ravaux laboratory such experiments and for now we have shown by using a cell-based 
chemiluminescent assay109 that compound 56 behaved as an inhibitor of the CT-L activity in 
human HeLa cells (20% inhibition at 50 µM after 1h30 incubation). 
 
 
II.6. Present work in the laboratory  
 
Encouraged by these results and in agreement with our previous work, ongoing efforts in the 
laboratory have been made since Octobre 2007 (when I left the laboratory for going to 
Regensburg) more particularly by our colleague Bordessa A. The aim is a better knowledge of 
the Structure-Activity Relationship (SAR) around the fluorinated scaffold, and consequently the 
design and the synthesis of compounds that satisfy specific conformational requirements. In fact, 
the understanding of the mechanism of interaction between these molecules and the different 
active sites of the proteasome is of great importance for the rational design of new inhibitors. 
With the goal of developing a useful tool able to supply some important indications for the 
synthesis of new inhibitors, a docking approach, which allows to evaluate the interactions 
between a ligand and a receptor, has been chosen. 
The work followed the steps below: 
• Identification by means of the literature and crystallographic studies of the essential 
features (occupation of the hydrophobic pockets, hydrogen bonds, etc.) necessary for the 
inhibition of the proteasome from known inhibitors. 
• Docking of known inhibitors to compare our results with the crystallised structures or 
with the reported molecular modelling studies. This allows to define the docking 
parameters and to validate the model. 
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• Docking of the lead compound 83 to formulate a first hypotesis of interaction. 
• Systematic modification of 83 and subsequently docking of the results to address the 
synthetic work. 
• Use of the biological evaluation results of the synthesized molecules to refine the docking 
parameters and to better understand the binding interaction between these molecules and 
the proteasome.  
 
 
The first step was the docking of the known inhibitors. 
 
Autodock4 program was chosen. The first docking experiments was done on the TMC-95 A99 43 
and its biaryl analogues,67, 68 because they are the only non covalent inhibitors co-crystallised 
with the 20S proteasome. The docking results fitted the experimental structure in an excellent 
way, with an RMSD less than 2.0 Å. Some aminostatine based inhibitors synthesised by 
Novartis70, 71 were also docked and the resulting conformations in the CT-L site fitted quite good 
with the molecular modelling studies reported (filling of the S1 and S3 pockets by the same 
groups as described by the authors, and presence of the same principal hydrogen bonds, between 
the main chain of the molecules and the residues 21, 47 and 49 of the proteasome and between 
the methoxy groups of the central 3,4,5-trimethoxyphenylalanine and some serines (in particular 
the residues 118 present at the bottom of the S3 pocket). 
 
 
The second step was the docking of the lead molecule 83 and virtual screening of new 
candidates. 
 
At the begin of Andrea Bordessa’s work, only our molecule 83 was tested and for this reason all 
the efforts to propose a first mechanism of binding were done only on the base of the molecule 
83. Moreover, the biological test was done only on the chymotrypsin-like site, and for this reason 
the first studies were done in the CT-L site. Because the pseudo amino acid 72 was obtained as 
racemic, it was necessary to perform two different calculations, respectively with the S and R 
configuration of the chiral centre bearing the CF3. Unexpected to our preliminary design, the 
docking result for 83 suggested that the Boc group was inserted in the S1 pocket and the 
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phenylalanine in the S3, whereas the free amino group of the lateral chain of the lysine was 
involved in an hydrogen bond with the residue T21 (in Figure 54 is represented the result for the 
S configuration, in green dashed the intermolecular hydrogen bonds). Deeply analysing this 
result, it was possible to see as the Boc group is inserted in the S1 pocket, with a distance 
between the tert-butyl group and the T1 of 3.1 Å, which indicates a good filling of this pocket. 
The phenylalanine is inserted in the S3 pocket and the methoxy group could form an additional 
hydrogen bond with the serine 118, which is at the bottom of the S3 pocket. This hydrogen bond, 
also if is not on of fundamental for the interaction with the proteasome, is also reported by 
Novartis71 as useful to stabilise the complex. In the region between the two hydrophobic pockets, 
the ligand formed hydrogen bonds with the residues G47 and A49 respectively with the oxygen 
and the nitrogen of the urethane moiety, and with T21 with the free amino group on the lateral 
chain of the lysine and with the hydrazine moiety. It was also present a strong interaction 
between the trifluoromethyl group and the residue D114. Moreover, the binding energy 
calculated by Autodock was excellent, with a value of -9.20 Kcal/mol. In addition, the other 
clusters generated by the program, presented an higher binding energy (more than -6.0 Kcal/mol) 
suggesting as this is the most probable conformation. Thus, we could conclude that in this active 
molecule it was possible to find all the features common to the other proteasome inhibitors. Less 
clear was the result obtained for the molecule with the R configuration of the carbonyl bearing 
the CF3. In every case, when the cluster at minor binding energy did not present a good 
conformation, the second better cluster presented a result quite similar to that obtained for the S 
diastereomer, with the Boc group in the S1 pocket and the phenylalanine in the S3. The Boc 
group was less inserted in the S1 pocket (the distance with the T1 was of 4.8 Å), when the 
phenylalanine had a good filling of the S3 pocket (also in this case it was observed the hydrogen 
bond with the S118). Less intermolecular hydrogen bonds could be found (only with T21 and 
D114) and this fact was reflected in an higher binding energy (-6.30 Kcal/mol).  
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Figure 54. Molecule 83 in the CT-L site of the proteasome. 
 
Based on this first model, it was decided to perform pharmacomodulation on the lead molecule 
83 to evaluate the influence of each part of the molecule to try to establish structure-activity 
relationship and to try to obtain better proteasome inhibitors. It was decided to substitute the Boc 
group with other groups adapted to fill better the S1 pocket, the phenylalanine with groups able to 
fill the S3, the lysine with other amino acids and we also tried to see the influence of the 
substitution the central core of the molecules (in Figure 55 the groups tested  and, with a red bar, 
the rejected). 
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Figure 55.  Several substitutions of the molecule 83 on the basis of the previous results.  
 
It was envisaged to substitute the Boc group with a dimethoxy-phenylacetic acid group and the 
docking result showed that a methoxyl group in position 2 of the ring was the most favorable to 
have a good interaction with the T1. The lysine was substituted by different amino acids and the 
docking results showed that the most favorable amino acids were asparagine and glutamine, 
whereas tryptophan and the unnatural 3,4-dimethoxyphenylalanine have the tendency to fill the 
S3 pocket without leaving enough space for a good filling of the S1 pocket by the part 1. For the 
part 3 other peptidomimetics used as β-sheet mimetics and non fluorinated analogues of the same 
peptidomimetic have been evaluated. In particular, this is interesting to prove the role of the 
fluorine to reinforce the hydrogen bond of the adjacent groups. In the part 4 it was decided to 
substitute the phenylalanine with a 3,4,5-trimethoxybenzylamine, which is particularly able to 
form hydrogen bonds with the serines present at the bottom of the S3 pocket of the CT-L site, as 
proved by Novartis.71 
From the already synthesised molecules, some have been already tested on 20S rabbit proteasome 
and the results are shown in Figure 56 and Table 2. 
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Figure 56. New molecules synthesised and tested on rabbit 20S proteasome. 
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Molecule 
 
            CT-L 
 
               PA 
 
            T-L 
95 ni ni ni 
96 30% 54 x1.6 
97 8.6±0.3 i i 
98 30% 77 x2.7 
99 ni ni ni 
100 18.2±0.4 i i 
101 48.5±2.4 i i 
102 10.1±0.4 i i 
103 ni ni x1.8 
 
Table 2. IC50 (µM) or % inhibition at 100 µM of  compounds 95-103 against rabbit 20S proteasome at pH 7.5 and 37 
°C. x: activation factor; i = inhibition at 50, 100 and 200 µM; ni = no inhibition.  
Values are means of three experiments. CT-L: chymotrypsin-like activity; PA: post-acid activity; T-L: trypsin-like 
activity.  
 
From these new biological results and from the biological results of my previous molecules 
(Table 1, page 51) we can establish some preliminary structure-activity relationship that will have 
to be confirmed in the future with the synthesis and the Docking of a large number of analogues : 
 • The presence of a free amino group is often decisive for the activity. In fact, all the 
compounds presenting a free amino group (83, 81, 56, 102, 97 and 100) are active, while the 
protected precursors are or inactive (80, 82, 103) or less active (96, 101).  
 • Concerning the part 1 of the molecules : the 2,5-dimethoxyphenyl acetic group is 
comparable (97 versus 83 and 56) or slightly superior (96 versus 80 and 82) to a Boc group or to 
the 3-phenoxyphenylacetic acid. 
 • Concerning the part 2 of the molecules, a Lysine residue is favorable, specially a free 
Lysine residue which is superior to the 3,4-dimethoxyphenylalanine residue (compare 56 and 54) 
specially on the T-L activity. Moreover a protected or a free Lysine residue is slightly superior to 
the asparagine residue (compare 96 to 99, 97 to 99 and 98 to 83). 
 • Concerning the part 3 of the molecules, non fluorinated scaffold do not seem to decrease 
the activity. For now, only few non fluorinated analogues have been synthesised and tested, so it 
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is a little bit early to do some consideration. However, we could observe that the molecule 100, 
which is the analogue of the fluorinated 81, shows an inhibitory effect of all the active sites of the 
proteasome. The IC50 of molecule 100 was calculated only for the chymotrypsin-like active site, 
but also if this molecule resulted slightly less active of the molecule 81, it was in the same order 
of magnitude (18.2 µM for 100 and 5.9 µM for 81). We can also observe the apparition of a PA 
inhibition with the non-fluorinated molecule 100. A greater difference was found between the 
behaviour of molecule 80, which is not active, and its non fluorinated analogue 101, which have 
an inhibitory activity in all the three active sites. Also if they are just preliminary results and a 
larger series of non fluorinated compounds is necessary to have a good comparison, it seems that 
the presence of the trifluoromethyl group does not greatly improve the activity of our inhibitors. 
In fact, we generally observed for the non fluorinated compounds an improvement of the 
solubility, which can also play an important role in the difference of reactivity observed between 
the molecules 81 and 100. Moreover, as observed previously, the presence of a free amine is 
often very important for the activity. Thus, in the non fluorinated compounds the behaviour of the 
nitrogen of the hydrazine group is more similar to that of a free amine, due to the lack of the 
effect of the vicinal trifluoromethyl group. However, diastereoisomeric fluorinated compound 
must be separated and biologically evaluated individually as we really observe a big influence of 
the chiral center stereochemistry on the Docking analysis. 
 • Concerning the part 4 of the molecules, the phenylalanine residue is comparable to the 
3,4,5-trimethoxybenzylamine (compare 102 and 81). Even then an inhibitory activity on the PA 
site is observed with 102 while no inhibitory activity was shown on this site with 81. This result 
would be very interesting if it is confirmed because in this case we suppressed the peptide 
character of the C-terminal part of our pseudo-peptides. 
 
The docking of the active and non active molecules was done in the 3 active sites (CT-L, PA and 
T-L) in parallel to the synthesis and to the biological results, to establish if we could trust our 
model. In particular, the first thing was to recognize the conformations able to fill both the S1 and 
the S3 pockets of the proteasome. Whereas this research was quite simple for the active 
molecules, in the case of the inactive compounds it was often not possible to find conformations 
with these characteristics. The second step was the research of the intermolecular hydrogen bonds 
between the ligand and the receptor, in particular with the residues T21, G23, G47, A49 and 
D114 (this last residue not present in the caspase) and with D120 (in the T-L site), which are, as 
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illustrated above, the most important for the interaction with the active site of the proteasome. 
When possible, additionally hydrogen bonds were identified. The last element analyzed was the 
distance between the ligand and the T1, which can give us additional information about the filling 
of the S1 pocket. All these analysis have been repeated twice for all the molecules, one for the S 
configuration of the carbon bearing the trifluoromethyl, and one for the R configuration. Often, 
one diastereomer was fitting well in the active sites while the other was not. Almost all the 
docking results were in accordance with the biological results.  
As an exemple of the mode of binding in the CT-L site, we show in Figure 57 the molecule 56 (S 
configuration of the carbon bearing the trifluoro methyl group). The biphenyl group is inserted in 
the S3 pocket (in red color) and the phenylalanine fills the S1 pocket (in blue color). 
 
 
 
Figure 57. Molecule 56 (S configuration) bounds to the CT-L active site into the proteasome. The pockets S1 and S3 
are showed in blue and red respectively. 
 
From these recent results, we demonstrated that the docking can be a useful tool for a better 
understanding of the binding mechanism of small molecules and 20S proteasome and a useful 
tool to support and to drive the synthesis of new candidates for the inhibition of the 20S 
proteasome. In particular, it is possible to explain the differences in the activity between sets of 
similar molecules which bind the receptor in a similar manner. The limits in our methodology are 
particularly relied to the high number of torsions of the inhibitor candidates, which does not 
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allow to obtain a good clustering . Moreover, the structural diversity of the molecules synthesised 
joined with their high flexibility, makes plausible that it does not exist just one mechanism of 
binding interaction common to all the molecules, in particular we could not observe for all the 
active molecules the same way of fitting the two pockets S1 and S3. This fact makes more 
complicated the establishment of a structure-activity relationship.  
 
 
II.7. Conclusion 
 
Given that proteasome inhibition is currently being evaluated for a variety of therapeutic 
purposes, as mentioned before, the need for potent and selective small molecule proteasome 
inhibitors is well recognized. In the presented work, we have designed, synthesized, and defined 
the biological profile of a new series of fluorinated pseudopeptides that incorporate a 
trifluoromethyl-β-hydrazino acid scaffold, as a new class of non covalent proteasome inhibitors.  
These new fluorinated pseudopeptides have also the advantage to be very easy to synthesize.  
A limited SAR around the fluorinated scaffold resulted in the discovery of compounds having 
differential inhibitory capacities for CT-L, PA and T-L in micromolar range without effect on 
challenging proteolytic enzymes such as calpain I and cathepsin B. Part of this work have been 
recently accepted for publication in Bioorg. Med. Chem. Lett.110 
These encouraging results have led us to further optimize the lead compounds 56, 83 and 81 
using molecular modelling and continuing biological evaluation.  
In the series of compounds bearing our inverse scaffold 59 we did two changes: the inversion of 
the scaffold and the addition of another hydrazine group. In perspective we will check if the 
effect that molecules of this series presented no inhibitory effect or very modest effect is due only 
to the inversion or to the length of this scaffold. We envisaged for example to insert an amine 
group in the place of the hydrazine group. 
The objective of my thesis project was to detect in a first step some biological activity in the new 
designed molecules. However, we worked with diastereoisomeric mixtures. In consequence, the 
priority for the next future will be to separate the diastereoisomeric fluorinated compounds to 
evaluate the influence of the chiral centre on the inhibitory activity. That way, we could maybe 
obtain with one isolated diastereoisomer some submicromolar inhibitory activity.  
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In the future other molecules will be designed with the help of molecular modelling (docking), 
synthesized and evaluated to try to obtain even more efficient proteasome inhibitors.  
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III NEW δ-AMINO ACIDS TOWARDS NEW 
FOLDAMERS 
This work has been realized in collaboration with Guitot Karine, PhD student. 
III.1.   INTRODUCTION 
 
 
The folding of polypeptide chains into secondary and eventually into a bewildering array of 
tertiary structures results in protein molecules that are responsible for most of the biological 
interactions and functions found in nature. Therefore, peptides and proteins are attractive targets 
for drug design. Poor bioavailability and metabolic stability of peptidic drugs, however, have 
resulted in significant limitations. A logical next step is to mimic nature and create 
nonbiologically derived molecules that either fold into well-defined secondary structures, or 
assemble into larger architectures. The pioneering studies of Gellman and Seebach on β-peptides, 
a class of unnatural peptidomimetic folding oligomers, have demonstrated the feasibility of 
folding unnatural oligomers into well-defined conformations. Extending the concept of β-
peptides has led to other peptidomimetic foldamers such γ-peptides1,2 and δ-peptides.3 
In the presented work we are interested in δ-amino acids towards new foldamers. 
As mentioned in the chapter I, δ-amino acid residues 104 are isosteres of dipeptide elements in α-
peptides 105 (Figure 58). 
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Figure 58.  Comparison of δ-amino acid residues 104 with α-dipeptide elements 105. φ, ψ, θ, ζ, ρ, ω are the 
backbone torsion angles. 
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Therefore, δ-amino acids are potential surrogates for α-dipetides and can be useful to improve 
the resistance of natural peptide chains toward degradation by proteases. 
There are some examples of the incorporation of a single δ-amino acid into  longer natural amino 
acid sequences,4-6 but most of the cases deal with sequences based on repeating δ-amino acid 
units, particularly on sugar amino acids derived from furanose7 and pyranose.8 In fact, homo-
oligomers of sugar amino acids have been extensively studied and provide many examples of 
foldamers.8-11 
Oligomers of different types of amino acids are also important in conformational design and can 
be potentially useful to obtain new foldamers. Our approach presented in this chapter is based on 
the synthesis of peptides containing α- and δ-amino acids with different chain length and α-amino 
acid composition. 
 
 
III.2.   Model peptides containing δ-amino acid units 
 
III.2.1.   Previous work in the laboratory 
 
The application of unnatural building blocks to induce a predictable conformation requires the 
investigation of their conformational preferences. 
In our group we investigated the conformational preferences of peptide mimics containing the 
two enantiomers of a novel δ-sugar amino acid 106 and 107 (Figure 59). The synthesis of both 
enantiomers was previously developed by M. Haque in our group.12  
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NHBoc
COOH
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Figure 59. (S,S)-106 and (R,R)-107 enantiomers of a novel δ-sugar amino acid. 
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The key intermediate 109 was obtained starting from inexpensive furan-2-carboxylic methyl ester 
108 in four steps by using a procedure that has been previously developed in our group.13 
Treatment of γ-butyrolactonaldehyde 109 with 4-methoxybenzylamine to form the corresponding 
imine, followed by reduction with NaBH4 provided the amine 11014 in 76% yield. N-Boc 
protection afforded the protected amine 111,15 in which the PMB group was removed with CAN 
to give the carbamate 11216 in 79% yield. Finally, ruthenium catalyzed oxidative cleavage of the 
allylic double bond with NaIO4 gave the δ-amino acid enantiomers 106 and 10717 in 86% yield 
(Scheme 8).  
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Scheme 8. Synthesis of compounds 106 and 107. Reagents and conditions: 
a) (i) Na2SO4, 4-methoxybenzylamine (1.1 equiv), CH2Cl2, 3 h; (ii) NaBH4 (2equiv), MeOH, H2O, 0 °C, 30 min, 76%;
b) (Boc)2O, dioxane-1M K2CO3 (1:1.2), r.t., overnight, 74%; c) CAN (4 equiv), CH3CN-H2O (1:3), 0 °C, 1 h and 
r.t., 2 h, 79%; d) RuCl3. 3 H20 (6 mol%), NaIO4 (4.0 equiv), CCl4-CH3CN-H2O (1:1:2), 0 °C, 1 h and r.t., 2 h, 86%.
 
Delatouche and Bordessa synthesized two α-δ pentapeptides 113 and 114 (Figure 60) using the 
scaffolds 106 and 107, respectively, which were alternated with the natural amino acid 
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phenylalanine. In addition, Bordessa synthesized heptapeptide 115 using the R,R enantiomer and 
phenylalanine (Figure 60). 
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Figure 60. Pentapeptides containing α-δ amino acids 113 and 114 and heptapeptide 115. 
 
The aim of our work has been to investigate the conformational analyses of the two pentapeptides 
113 and 114, and of the heptapeptide 115, in order to determine their secondary structure 
preferences. 
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III.2.2.   Conformational investigations  
 
The conformation of peptides depends principally on their amino acidic composition and on the 
sequence of these amino acids. As the physical and biological properties of peptides are 
determined by their structure, the knowledge of the latter is essential to understand these 
properties. There are many techniques to investigate the three dimensional structure of peptides. 
FT-IR and CD spectroscopy are important tools to indicate the presence or absence of secondary 
structure elements, while NMR spectroscopy and X-ray crystallography allow a detailed 
description of the localization and spatial arrangement of such elements within the amino acid 
sequence. However, for the X-ray crystallography single crystals are needed, and there always 
exists the possibility of a difference in the conformation between the solid state and the one seen 
in solution. In the present work we employed NMR, CD, FT-IR spectroscopy, and molecular 
modelling to characterize the peptides synthesized.  
 
 
NMR investigation 
 
The most common and useful tool to investigate the secondary and tertiary structure of peptides 
and proteins in solution is the Nuclear Magnetic Resonance (NMR) spectroscopy.18NMR 
spectroscopy allows an investigation of the structure of biopolymers on an atomic level in 
solution. Moreover, NMR investigations can highlight the presence of conformational equilibria 
and the dynamics of the folding. Important structural information can be obtained from both 
mono- and bidimensional NMR spectra. 
 
 
Information from 1D-proton NMR spectra 
 
Even though the NMR-spectra of biopolymers are derived from the nuclear spins of the 
monomers thea are build up from, there is no straightforward correlation between the NMR 
spectra of the low molecular weight components and the three-dimensional strucutre of the whole 
polymer.18 A dispersion of nucleus’s chemical shift values is the first indication of the presence 
of spatial folding in a peptide chain. When a peptide has a defined conformation in solution, a 
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proton in the sequence will have a different microenvironment compared to those in a random 
coil structure. It will also be different from the same proton contained in an identical residue type 
at a different point in the sequence. This fact leads to different specific chemical shift values 
compared to those for an unfolded structure and to a good dispersion of the signals. 
The presence of a secondary structure in solution can lead to a slower exchange rate for labile 
protons, which can be measured by time dependent NMR-spectroscopy, while in small molecules 
proton exchange is too fast to be observed. Moreover the slower diffusional motions of the 
macromolecul in solution can substantially affect the spin relaxation and the Nuclear Overhauser 
Enhancement (NOE).18 The presence of hydrogen bonds can be detected from onedimensional 
NMR spectra. These techniques are based on the assumption that the NHs involved in a H-bond 
are less sensitive to perturbations such as changing of temperature, concentration or solvent, than 
the NHs that are exposed to the solvent. The determination of the temperature coefficients 
(∆δ/∆T) for the amide protons is based on the observation that, upon warming, NHs involved in 
hydrogen bonds display shifts at a smaller extent than the NHs that are exposed to the solvent. 
Generally, values of -∆δ/∆T > 3 ppb/K indicate amide protons in an equilibrium between a 
hydrogen-bonded and a non-hydrogen-bonded state, while values of -∆δ/∆T < 2.6 ppb/K are 
considered an indication of hydrogen-bonded NH protons or of NH protons locked in a 
hydrogen-bonded conformation.19  
The secondary structures of peptides are characterized by distinct torsion angles along the 
backbone. Since the size of the spin-spin coupling constant 3JHN-Hα depends on the torsion angle 
NH-CHα, on the basis of Karplus relationship, the measurement of 3JHN-Hα is useful for secondary 
structure determination, as it can be directly related to the backbone dihedral angle φ.18, 20 
Generally, 3JHN-Hα values < 6 Hz indicate turn or helical conformations, whereas values higher 
than 6 Hz are referred to unordered structure or an extended conformation (Figure 61). 
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Figure 61: Table of the 3JHN-Hα values in regular secondary structures18 (left side). Torsion angles φ and ψ present 
along the backbone of a α-peptide (right side).  
Secondary structure φ 3JHNα (Hz) 
        α-helix -57°    3.9 
        310-helix -60°    4.2 
antiparallel β-sheet -139°    8.9 
    parallel β-sheet -119°    9.7 
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Information from 2D-proton NMR spectra 
 
The most useful data relating to a peptide conformation is gained from 2D-NMR investigation. 
Of particular interest are the correlation spectroscopy (COSY), total correlation spectroscopy 
(TOCSY) and NOE spectroscopy/rotational frame NOE (NOESY/ROESY) experiments.  
The cross peaks observed in the COSY spectrum correspond to proton-proton correlations due to 
scalar (through-bond) couplings, though the respective protons may only be separated by a 
maximum of three covalent bonds. The TOCSY spectrum contains all correlations between 
protons of one spin system and in the case of peptides each amino acid has a particular spin-
system pattern that allows the identification of every residue type in the sequence. With the help 
of these two experiments, it is possible to assign completely all the chemical shifts of the protons 
in a peptide. Further, NOESY experiment displays cross peaks due to dipolar coupling resulting 
from through space interactions. NOESY cross peaks depend on the distance between two 
protons and occur between two nuclei that are close in the space up to 5 Å. A NOE cross peak 
indicates that two non-covalently bonded nuclei are close enough to interact or to exchange. NOE 
cross peaks are usually defined as sequential distances when they are between backbone protons, 
or between a backbone proton and a β proton of residues that are nearest neighbours in the 
sequence. Medium-range distances are all non-sequential signals between residues within a 
segment of five consecutive residues. Long-range distances are between the backbone protons of 
the residues that are at least six positions away in the sequence.18 Depending on the torsion angles 
that characterize the secondary structure of a peptide, sequential and medium-range proton-
proton distances will have different values. For instance the sequential NH-NH and CHα-NH 
contacts for a regular α-helix are about 2.8 and 3.5 Å, respectively. The CHβ-NH contacts, since 
they depend also on the torsion angle on the side chain χi, vary between 2.5 and 4.1 Å for a α-
helix.18 Medium-range contacts in helices are usually i,i+2, i,i+3, and i,i+4. In particular i,i+4 
contacts are especially useful since they are present in a regular α-helix and not in a 310-helix. 
Tight turns have close i,i+2 values. In the case of β-structure short medium-range distances are 
not observed, since the polypeptide segments are almost fully extended.18 Table 3 lists short 
sequential and medium-range distances that are found in known α-peptide conformations. 
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Table 3. Short sequential and medium-range 1H-1H distances in some common secondary structures in α-peptides.18 
 
 
Circular dichroism 
 
Circular Dichroism (CD) spectroscopy is an important technique to investigate the secondary 
structure of proteins and peptides. It is based on the differential absorption of left and right 
circularly polarized light. To deliver a CD signal, a compound has to possess a chromophore, 
which is either inherent chiral or surrounded by a chiral environment and absorbs in the observed 
wavelength range. These prerequisites are met by the amide bond in peptides and proteins, 
rendering the CD spectroscopy a suitable methodology for the elucidation of their structural 
preferences. The observed bands in the CD spectra of peptides and proteins stem from the n → π*  
and the π → π*
 
transitions of the amide bonds.
 
Every secondary structure gives rise to a specific 
CD spectrum that represents a survey upon the averaged overall structure of a peptide or protein, 
while it is impossible to assign structural preferences to an individual residue (Figure 62). 
However, algorithms based on protein and peptide reference data sets enable the calculation of 
the secondary structure elements composition of a peptide/protein from its CD spectrum.  
In addition to the far-UV region over the range 190-250 nm, also the near-UV region from 250 to 
320 nm can deliver useful information, as it shows the contribution of aromatic residues like 
tyrosine or tryptophan.21, 22
  
 
Distance α-helix 310-helix      β-sheet 
dαN 3.5 3.4           2.2 
dαN(i,i+2) 4.4 3.8  
dαN(i,i+3) 3.4 3.3  
dαN(i,i+4) 4.2   
dNN 2.8 2.6  4.2-4.3 
dNN(i,i+2) 4.2 4.1  
dβN 2.5-4.1 2.9-4.4  3.2-4.7 
dαβ(i,i+3) 2.5-4.4 3.1-5.1  
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Figure 62: CD spectra characteristic for common secondary structure elements (adapted from Greenfield).23 
 
 
The molar ellipticity [Θ]
λ 
at the wavelength λ is defined as follows (Equation 1):  
 
Θ Deg . cm2
   dmol
 100 . Ψ
  l . c
=λ
      Equation 1      
 
where Ψ is the deviance of left- and right-circularly polarized light in degree, l the cell length in 
cm and c the peptide concentration in M. To compare peptides with different chain lengths, the 
molar ellipticity per residue is used, which is obtained by dividing [Θ]
λ 
by the number of amino 
acids. The CD bands characteristic for helical peptides at 190, 208 and 222 nm stem from the π 
→ π* 
 
transition (190 nm and 208 nm are the components perpendicular and parallel to the helix 
axis, respectively) and n → π* transition (222 nm), with the latter being sensitive to hydrogen 
bond formation.24
 
The ratio R between the two minima at 222 and 208 nm can be used as an 
indicator for the presence of interacting helices, as the band at 208 nm, corresponding to the 
parallel component of the π → π*  transition, changes its energy upon an interhelical interaction. 
Ratios larger than 1 are commonly regarded as the result of interacting helices, as found in coiled 
coil structures, while ratios lower than 1 indicate the presence of non-interacting helices.25
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Conformational analysis  
 
As mentioned before (see chapter II.2.2.  Molecular Modelling: tool for the conception, page 47), 
the use of theoretic methods to obtain models that allow predicting structures, properties and 
molecular interactions is known as “Molecular Modelling”. 
Molecular Modelling provides information that is not available directly from conventional 
experiments, thus it has a complementary role in the field of the experimental chemistry. 
There are several simulation technique methods: quantum chemistry, molecular mechanics, 
molecular dynamics (MD).  
It is known that the structures with lower energy states are more stable and take a part in 
chemical and biological processes. Molecular dynamics simulation offers an effective tool to 
detect the energetically most favored 3D structure of a system. 
In our work simulations incorporating NOE derived distance constraints as well as “free” 
dynamics were investigated in vacuum (gas-phase simulations). MD calculations were performed 
using Sybyl program (version 7.0) with MMFF94 force field. The temperature was increased 
progressively from 300 to 700 K and the time period of each simulation was 222 ps, where a 
molecule was extracted every 500 steps. Among the resulting structures those energetically 
favored were then minimized and analyzed. 
 
 
FT-IR spectroscopy 
 
Infrared light is energetic enough to excite molecular vibrations to higher energy levels. The main 
characteristic bands of the peptide group are called amide A, amide I and amide II. Evidence 
exists that the position of these bands is related to the conformation of the peptide.26 The amide A 
band is mainly due to the N−H stretching vibration. It is very sensitive to the strength of a 
hydrogen bond, thus providing an opportunity to gain information about any intra- or 
intermolecular hydrogen bond. Usually, in a non polar solvent, non hydrogen-bonded NHs adsorb 
above 3400 cm-1, while NHs that are involved in hydrogen-bonds absorb below 3400 cm-1.27 The 
amide I and II bands are related to the backbone conformation. The amide I is associated with the 
C=O stretching vibration, while the amide II results from the N–H bending and from C–N 
stretching vibrations. 
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Table 4. Frequencies (cm-1) of the amide I and amide II bands found for different α-peptide conformations. 
 
 
III.2.3.   Results on alternated α/δ amino acids  
 
The pentamer containing alternated (S,S)-δ-amino acid and phenylalanine was analyzed by NMR 
in both CDCl3 and methanol-d3 solvents. Comparing both analyses at different temperatures, the 
spectrum in CDCl3 seemed to be less comprehensible than the spectrum in methanol-d3, showing 
a lower dispersion of the NH signals, and higher temperature coefficients (-∆δ/∆T > 10ppb/K). 
We therefore present here only the analyses performed in methanol-d3. This choice was also 
supported by the CD experiment, where the CD curve appeared to be much more defined in 
methanol than in TFE. Thus, the synthesized α/δ-peptide 113 (Figure 60) was dissolved in 
methanol-d3 and studied by NMR spectroscopy. 1D experiments were first acquired at five 
different temperatures (273, 278, 283, 293 and 303 K), and the one that gave the better resolved 
spectrum (283 K) was chosen to record the 2D experiments. The complete 1H-NMR resonance 
and sequence assignments were done by using the COSY, TOCSY and ROESY spectra. 
Sequential and interresidue NOE cross-peak intensities were classified as strong (1.8-2.7 Å), 
medium (1.8-3.3 Å) and weak (1.8-5 Å) based on the number of contours in the contour plot of 
the ROESY spectrum. The NOE contacts observed for this peptide are shown in Figure 63.  
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Figure 63.  Summary of the interresidue NOE contacts observed for the peptide 113 in methanol-d3 at 283 K (pink 
arrows: strong NOEs; green arrows: medium NOEs; blue arrows: weak NOEs). 
 
The values of the 3JHN-Hα coupling constants were estimated in the 1D 1H-NMR spectrum and 
these vicinal coupling constants showed always values bigger than 6 Hz (Figure 64).  
Amide protons showed high temperature coefficients (Figure 64), suggesting a non-hydrogen-
bonded state. However, studies of deuterium exchange in methanol-d4 showed a slow 
disappearance of one or both amide protons of the lactone residues. The presence of the hydrogen 
bond possibility in this molecule was confirmed by IR experiments in CH2Cl2, which showed two 
bands in the amide region: a broad and intense band at 3311 cm-1 in the H-bonded region, and a 
weaker one at 3420 cm-1.  
 
 
 
 
Figure 64: Variable temperature studies in methanol-d3 of peptide 113. 
 
 
-∆δ (ppb)/ 
∆T(K) 
3
JHN-Hα (Hz) 
 
NHF1 10.3 7.2 
NHX2 7.1   
NHF3 8.3 6.9 
NHX4 7.1   
NHF5 8.1 8.2 
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Molecular modelling was performed using molecular dynamics experiments in vacuum. 
Introduction of four of the NOE contacts found in the ROESY spectrum as constraints in this 
experiment gave the structure shown in Figure 65 as the conformational energetic minimum, 
which is characterized by a large loop locked at the extremities by two hydrogen bonds. 
 
 
 
 
Figure 65: Structure of low-energy conformer calculated for peptide 113. Hydrogen bonds are indicated with dashed 
lines and all hydrogen atoms have been omitted for clarity. 
 
The CD spectrum in methanol at 0.1 mM showed two maxima at 200 and 219 nm that were not 
comparable with any data in the literature (Figure 66). 
 
Figure 66: CD spectrum of the pentapeptide 113 in methanol. 
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The pentamer containing alternated (R,R)-δ-amino acid and phenylalanine 114 (Figure 60) was 
analyzed by NMR in both CDCl3 and methanol-d3 solvents. Due to  low solubility and low 
dispersion of the signals in methanol, we used only the analyses in CDCl3. The synthesized α/δ-
peptide 114 was thus dissolved in CDCl3 and studied by NMR spectroscopy. 1D experiments 
were first acquired at five different temperatures (278, 283, 288, 293, 298 and 303 K), and the 
one that gave the better resolved spectrum (288 K) was chosen to record the 2D experiments. The 
detected NOE contacts are shown in Figure 67. 
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Figure 67: Summary of the interresidue NOE contacts observed for the peptide 114 in methanol-d3 at 288 K (pink 
arrows: strong NOEs; green arrows: medium NOEs; blue arrows: weak NOEs). 
 
In comparison with the pentamer containing the (S,S)-δ-amino acid, this oligomer had a better 
dispersion of the signals in the 1H spectrum with no overlapping of the NH amides, and the 
ROESY spectrum allowed us to find numerous NOE contacts that are reported in Figure 67. In 
counterpart, we could see the presence of more than one conformer. We focused our study on the 
major conformer. NMR analyses showed amide protons at high ppm values (between 7.4 and 8.4 
ppm), which is characteristic of protons involved in hydrogen bonding. However, -∆δ/∆T were 
quite high, ranging between 6 and 10.4 ppb/K, and also the 3J coupling constants were higher 
than 6Hz (Figure 68). 
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Figure 68: Variable temperature studies in methanol-d3 of peptide 114. 
 
 
The CD spectrum was recorded in TFE (0.3 mM) and gave two maxima at 203 and 218 nm 
(Figure 69). 
 
 
Figure 69: CD spectrum of the pentapeptide 114 in TFE. 
 
Finally, molecular dynamics experiments, taking into account eleven NOE contacts, afforded the 
structure shown in Figure 70 corresponding to the energetic minimum. 
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3JHN-Hα (Hz) 
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Figure 70: Structure of the low-energy conformer calculated for peptide 114. For clarity hydrogen bonds are omitted. 
 
The heptamer containing alternated (R,R)-δ-amino acid and phenylalanine was analyzed by 2D 
NMR only in CDCl3, since it was insoluble in methanol. In this solvent it showed a high 
dispersion of the signals, as well as numerous NOE contacts, among them long range NOE 
contacts were also detected. We can remark that the major part of the contacts were found in the 
N-terminal part of the molecule (Figure 71): in particular, we detected contacts between two non 
neighbouring lactones, which gave indication about an eventual organisation of this part of the 
molecule. However, we could not see any repetitive contacts that would have been an evidence 
for the presence of a periodic structure.  
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Figure 71: Summary of the interresidue NOE contacts observed for the peptide 115 in CDCl3 at 292 K (green 
arrows: medium NOEs; blue arrows: weak NOEs). 
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Here again -∆δ/∆T coefficients adopt quite high absolute values between 7 and 8 ppb/K, excepted 
for the third lactone and the Boc terminal phenylalanine, and 3J coupling constants were also 
quite high, excepted for F5 that showed a 3J of 4.8 Hz (Figure 72).  
 
 
 
Figure 72: Variable temperature studies in CDCl3 of peptide 115. 
 
IR in solution was performed in CH2Cl2 at low concentration showing in this case again two 
bands, a weak one at 3420 cm-1 representing the non hydrogen-bonded amide, and an intense 
band at 3300 cm-1, reflecting the presence of amide protons involved in hydrogen bonds. To gain 
further information about the amide protons involved in hydrogen bonding, we tried for the 
penta- and heptapeptides containing the (R,R)-δ-amino acid to perform solvent competition 
experiments, by progressive addition of DMSO in the NMR tube and controlling the changing in 
the chemical shifts. Unfortunately, this experiment failed due to the fact that by adding DMSO 
we were not able anymore to assign the amide protons. Deuterium exchange experiments 
revealed to be unrealisable, since our compounds were precipitating upon addition of minimum 
amounts of methanol-d4. Molecular dynamics was performed including seventeen constraints 
taken from NOE contacts. Two pictures of the energetic minimum are represented below 
showing in the first segment, containing Boc-Phe-Lac-Phe-Lac-Phe, a folded part that describes a 
first loop of helix, while the folding in the C-terminal part seems to be disrupted from the last 
lactone. One reason for the loss of the folding properties in C-terminal part of the peptide could 
be the high spatial freedom of the benzyl ester group that directs the C-head of the peptide in 
 
 
 
-∆δ(ppm)/ 
∆T(K) 
 
3
JHN-Hα (Hz) 
NHF1       0.7        9.6 
NHX2       7.8   
NHF3       7.7        8.4 
NHX4       7.3   
NHF5       7.8        4.8 
NHX6       3.9   
NHF7       7.2        7.2 
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another direction. This is particularly evident in the second view of the structure, in which we can 
see the compact helical structure imposed by the two first lactones X2 and X4, followed by a 
reversal of the structure in the C-terminal part (Figure 73). 
 
 
 
 
 
 
Figure 73: Two views of the structure of low-energy conformer calculated for peptide 115. For clarity hydrogen 
bonds are omitted. 
 
 
In contrast to the CD spectra of the pentamers, the CD spectrum of the heptamer in TFE at 0.5 
mM showed only the maximum at 218 nm, whereas the second maximum near 200 nm found for 
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the pentamers disappeared (Figure 74). This might be indicative of the presence of an ordered 
structure stabilized by the longer peptide chain.  
 
 
 
Figure74: CD spectrum of the heptapeptide 115 in TFE. 
 
The results presented above on the conformational analysis of three peptidomimetics containing  
aromatic α-amino acids alternated with polar δ-amino acids suggest that these δ-amino acids have 
the potential to induce structural motifs, which, however, differ from those typically adopted by 
α-peptides. Interestingly, peptides containing the (S,S)-δ-amino acid showed major solubility in 
methanol, also showing better folding properties in polar solvents. In contrast, peptides 
containing the (R,R)-δ-amino acid showed better folding properties in non polar solvents. 
According to the numerous NOE contacts found in the analysis of pentamer and heptamer 
containing the (R,R)-δ-amino acid, this enantiomer is likely to have better folding properties than 
the S,S enantiomer. Finally, increase in the length of the peptide sequence led to a stabilization of 
the secondary structure. 
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III.3.  New peptides containing δ-amino acids: Objectives and design  
 
After the results obtained with peptides 113, 114, 115 (Figure 60), we decided to synthesize 
further α/δ-peptides containing a variety of -amino acids ranging from apolar to charged residues. 
This should avoid the overlapping of the signals in NMR spectra  and lead to peptides with 
different properties. In the case of 116 (Figure 75), we modified the sequence by increasing the 
number of positively charged residues. Thus, two lysines and one glutamine were alternated with 
δ-units. To investigate the effect of our scaffold on the secondary structure of longer peptides, we 
carried out the synthesis of peptides 117 and 118 (Figure 75), which contain both apolar and 
polar α-amino acids. The synthesis and the results of the 2D-NMR, CD, FT-IR measurements 
and of the molecular modelling will be shown and discussed in the following paragraphs.  
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Figure 75. Lactone containing peptides 116, 117 and 118 that have been synthesized and investigated in this work. 
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III.4.   Synthesis of peptides 116-118 
 
The model peptides containing the enantiomers (S,S) or (R,R) of our lactone-scaffold that were 
synthesized and investigated in the course of this study are shown in Figure 75.          
The synthesis of the building block, being suitably functionalized to be introduced in peptides, 
has been carried out as developed in our group from γ-butyrolactonaldehyde 109 in 
enantiomerically pure form (S,S)12-119 and (R,R)-120 (Figure 76).  
 
O
CHO
O
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NHFmoc
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(R,R) enantiomer
 
 
Figure 76. Pentalactone building blocks 119 and 120 for peptide synthesis. 
 
 
Synthesis of Fmoc protected δ-amino acid (R,R) 120. 
 
The synthesis of the Fmoc protected δ-amino acid (R,R)-120 is described in Scheme 9. 120 was 
synthesized starting from (R,R) lactone 107 (Figure 59), by cleavage of the Boc protecting group 
with TFA in dry CH2Cl2. The resulted product 121 was treated with Fmoc-OSu in dioxane-1 M 
K2CO3 to afford the desired compound in  moderate yield (60%). 
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Scheme 9.  Synthesis of  the Fmoc protected δ-amino acid 120. Reagents: 
a) TFA, dry CH2Cl2, 100%; b) FmocOSu, dioxane-1M K2CO3 (1:2), 60%.
 
 
 
Synthesis of alternated α/δ-unit peptides 
 
The peptides 116-118 were synthesized, as shown in Schemes 10 and 11, using a solid phase 
protocol. The solid phase synthesis can be commonly performed by using two alternative 
protecting groups, tert-butyloxycarbonyl (Boc)28 and fluorenyl-9-methoxycarbonyl (Fmoc),29, 30 
to mask the α-amino group of the amino acid only temporarily to allow further chain elongation. 
Generally, the Fmoc strategy is more suitable for solid phase synthesis, as the Fmoc group is a 
base-labile protecting group which can be removed using secondary amines like piperidine and 
the cleavage of the peptide from the resin occurs under mild acidic conditions. Another very 
important advantage of the Fmoc group is its stability upon different conditions used to remove 
side-chain protecting groups, including strong acidic or reductive conditions. 
The products presented in this work were synthesized by manual coupling using Fmoc chemistry 
on Rink amide MBHA resin 122 (loading 0.6 mmol g-1) (Figure 77). The resin was in the Fmoc-
protected form and, for this reason, to obtain N-free linker, the resin was treated with piperidine 
in DMF/NMP (80:20 v/v).  
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Figure 77. Rink amide MBHA resin 122.  
 
In the case of peptide 116 the synthesis is outlined in Scheme 78, and was performed with (S,S)-
δ-amino acid. The first amino acid (4 equiv.), lysine, was coupled activating in situ the carboxylic 
function with HBTU (3.9 equiv.), HOBt (4 equiv.) in DMF/NMP (80:20 v/v), in the presence of 
DIPEA (8 equiv.). Fmoc cleavage was accomplished by treating the peptidyl-resin with 20% 
piperidine in DMF/NMP (80:20 v/v). For the coupling of the second amino acid, Fmoc-δ-amino 
acid, 2.5 equiv. excess were used, together with HBTU (2.4 equiv.), HOBt (2.5 equiv.) in 
DMF/NMP (80:20 v/v), and DIPEA (5 equiv.). The following steps, the Fmoc deprotection and 
the coupling of glutamine, were done with the same conditions used for lysine. To monitor the 
progress of the synthesis, small scale cleavage was performed and the resulting sample was 
analyzed by MALDI-ToF-MS. To avoid a potential lactone ring opening, we decided to use 
milder conditions for the Fmoc deprotection (only 15% of piperidine in CH2Cl2 for 3 min. instead 
of 20% for 5 min. in DMF/NMP) and to change the coupling conditions for the second Fmoc-δ-
amino acid: DIC (2.5 equiv.) and HOBt (2.5 equiv.) in CH2Cl2 without base. After the coupling 
of the second lysine and the Fmoc deprotection, the last step was the N-terminal acetylation using 
acetic anhydride (5 equiv.) and DIPEA (2.5 equiv.). Final cleavage of the peptide from the resin 
and simultaneous side-chain deprotection was achieved by treatment with a TFA/water/TIS 
mixture (90:5:5) for 2.5 hours. The peptide was then precipitated from ice-cold diethyl ether, 
 115 
centrifuged and subjected to three ether-washing/centrifugation cycles to remove the scavengers. 
The characterization was performed by HPLC and MALDI-ToF-MS.  
 
Fmoc-NH
NH2
Fmoc-Lys(Boc)
linker
Fmoc-Lys(Boc)-OH
HBTU, HOBt, DIPEA in DMF/NMP 8:2  
1) 20% piperidine in DMF/NMP 8:2
2) Fmoc-δ-amino acid-OH
    HBTU, HOBt, DIPEA in DMF/NMP 8:2
Fmoc-δ-amino acid-Lys(Boc)
1) 20% piperidine in DMF/NMP 8:2
2) Fmoc-Gln(Trt)-OH
    HBTU, HOBt, DIPEA in DMF/NMP 8:2
1) 15% piperidine in CH2Cl2
2) Fmoc-δ-amino acid-OH
    DIC, HOBt in CH2Cl2
Fmoc-Gln(Trt)-δ-amino acid-Lys(Boc)
Fmoc-δ-amino acid-Gln(Trt)-δ-amino acid-Lys(Boc)
1) 15% piperidine in CH2Cl2
2) Fmoc-Lys(Boc)-OH
    HBTU, HOBt, DIPEA in DMF/NMP 8:2
1) 15% piperidine in CH2Cl2
2) Ac2O, DIPEA
Ac-Lys-δ-amino acid-Gln-δ-amino acid-Lys-CONH2
TFA:H2O:TIS 90:5:5
Fmoc-Lys(Boc)-δ-amino acid-Gln(Trt)-δ-amino acid-Lys(Boc)
Ac-Lys(Boc)-δ-amino acid-Gln(Trt)-δ-amino acid-Lys(Boc)
20% piperidine in DMF/NMP 8:2
linker
linker
linker
linker
linker
linker
linker
 
Scheme 10. Solid phase synthesis of 116 using the Fmoc chemistry. 
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In the case of peptides 117 and 118 containing (R,R)-δ-amino acid, the solid phase protocol used 
was the same as the one just described for 116, but this time only DMF was used as the reaction 
solvent. A different number of equivalents of the amino acids (Xaa 5 equiv.), coupling reagents 
(HOBt 5 equiv./HBTU 4.8 equiv./DIPEA 10 equiv.) and acetic anhydride/DIPEA (8 equiv./ 
7equiv.) were also used (Scheme 11). 
 
   
Fmoc-NH
NH2
linker
Fmoc-Xaa-OH
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Ac-δ-amino acid-Lys-δ-amino acid-Ala-δ-amino acid-Tyr-CONH2
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Ac-Leu-δ-amino acid-Lys-δ-amino acid-Ala-δ-amino acid-Tyr-CONH2
 Fmoc-Tyr(tBu)-OH
 Fmoc-Ala-OH
 Fmoc-Lys(Boc)-OH  for hexapeptide
 Fmoc-Leu-OH          for heptapeptide
Xaa =
 
 
Scheme 11.  Solid phase synthesis of 117 and 118 using the Fmoc chemistry.  
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III.5.   Results and discussion 
 
III.5.1.   Alternated α/(S,S)-δ-unit peptide 
 
The synthesized α/δ-pentapetide 116 was dissolved in methanol-d3 and studied by NMR 
spectroscopy. 1D experiments were first acquired at five different temperatures (283, 288, 293, 
298 and 303 K), and the one that gave the better resolved spectrum (303 K) was chosen to record 
the 2D experiments. The complete 1H-NMR resonance and sequence assignments were done by 
using the COSY, TOCSY and ROESY spectra. Unfortunately only, medium and weak contacts 
were found and only between one residue and its neighbour, or intralactone in one case (Figure 
78). 
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Figure 78. Summary of the interresidue ROE constraints observed for the peptide 116 in methanol-d3 at 303 
K (green arrows: medium ROEs; blue arrows: weak ROEs). 
 
The values of the 3JHN-Hα coupling constants were estimated by using the amide region in the 1D-
NMR spectrum and the vicinal coupling constant value is always bigger than 6 Hz. No estimation 
was possible in the case of the two lactones. These values are typical of an extended or unordered 
structure (Figure 79). 
The temperature coefficients (∆δ/∆T) for the pentapeptide 116 were also measured, which were 
in the range of -6.6/-8.0 ppb/K (Figure 79). 
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Figure 79. Temperature coefficients for the NHs and vicinal coupling constants for HN-Hα in methanol-d3 for 116. 
 
We used molecular modelling to investigate the possible structures that the peptide could adopt. 
After the construction of the molecule in silico the observed NMR contacts were introduced as 
constraints before carrying out an energy minimization and Molecular Dynamics. In our analysis 
we excluded the molecules in which there were violations of the NMR-derived constraints and 
we considered only the structures energetically favored. The lowest energy conformer of this set 
of molecules is shown in Figure 80. Clearly, the peptide forms a large loop, in which the two 
lactones are located opposite to each other, with the central residue glutamine acting as a pivot.  
 
 
 
Figure 80. Structure of low-energy conformer calculated for compound 116. Hydrogen atoms are omitted for clarity. 
  
 
 
 
 
 
-∆δ(ppm)/ 
∆T(K) 
 
 
 
 
 
 
 
3JHN-Hα (Hz) 
 
NHQ3 7.4 7.0 
NHX4 7.4   
NHX2 7.2   
NHK5 6.6 7.6 
NHK1 8.0 7.2 
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The CD investigation was performed in methanol (5 mM) and the peptide 116 displayed only one 
negative band at 230 nm (Figure 81). Unfortunately, no similar spectra have been reported either 
in the literature or in our previous work. 
 
 
. 
Figure 81. CD spectra of compound 116 (5 mM in methanol). The data are normalized for peptide concentration and 
number of residues. 
 
 
III.5.2.   Alternated α/(R,R)-δ-unit peptides 
 
Two further peptides containing the (R,R)-δ-unit alternated with α-amino acids like lysine, 
alanine, tyrosine and leucine were prepared by solid phase methodology.The 1H NMR spectra of 
hexapeptide 117 were recorded at five different temperatures (280, 287, 296, 303 and 310 K), and 
the one at which the dispersion of the signals was reasonable (280 K) was chosen to record the 
2D experiments. Nevertheless, NMR characterization was complicated from the significant signal 
overlap in the spectrum. The ROESY spectrum in connection with COSY and TOCSY spectra 
revealed several contacts, including those between neighbour amino acids (Figure 82). The 
central part of the peptide seemed to be more structured and the temperature coefficient of 
lactone X5 was relatively small (Figure 83).  
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Figure 82. Summary of the interresidue NOE constraints observed for the peptide 117 in methanol-d3 at 280 K (pink 
arrows: strong NOEs; green arrows: medium NOEs; blue arrows: weak NOEs). 
 
 
 
 
 
 
 
 
Figure 83. Temperature coefficients for the NHs and vicinal coupling constants for HN-Hα in methanol-d3 for 117. 
 
Using several NOE contacts as constraints, MD simulations were carried out, but we could not 
see a periodic structure (Figure 84). 
  
  
 
 
 
 
-∆δ(ppm)/ 
∆T(K) 
 
 
 
 
 
 
3JHN-Hα (Hz) 
 
NHA4 7.6 6.4 
NHX5 4.0  
NHK2        7.9 
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Figure 84. Structure of low-energy conformer calculated for compound 117. Hydrogen atoms are omitted for clarity. 
 
We recorded the circular dichroism spectrum in methanol at concentration of 2 mM (Figure 85), 
which exhibited a strong positive band at 238 nm. 
 
 
 
 
 
Figure 85. CD spectra of compound 117 (2 mM in methanol). The data are normalized for peptide concentration and 
number of residues. 
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The heptapeptide 118 was obtained from 117 after elongation with an additional α-amino acid, 
leucine. The 2D NMR analyses at 303 K revealed only few and non-relevant NOE contacts 
(Figure 86).  
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Figure 86. Summary of the interresidue NOE constraints observed for the peptide 118 in methanol-d3 at 303 K (pink 
arrows: strong NOEs; green arrows: medium NOEs; blue arrows: weak NOEs). 
 
 
The temperature coefficients and coupling constants of 118 are reported in Figure 87. It can be 
noted that the amide protons of the alanine-δ-lactone motif in 117 and 118 show comparable 
temperature coefficients.  
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Figure 87. Temperature coefficient for the NHs and vicinal coupling constants for HN-Hα in methanol-d3 for 118. 
 
The CD spectrum of 118 at 2 mM in methanol was characterized by a weak positive band at 200 
nm, followed by a broad positive band at 230 nm (Figure 88). 
 
 
Figure 88. CD spectra of compound 118 (2 mM in methanol). The data are normalized for peptide concentration and 
number of residues. 
 
 
 
 
 -∆δ(ppm)/ 
∆T(K) 
3JHN-Hα 
(Hz) 
NHL1    
NHX2 6.6   
NHK3 4.0  
NHX4   
NHA5 8.0 6.6 
NHX6 3.7  
NHY7 7.4 8.4 
 124 
III.6.   Monomer studies 
 
III.6.1.   Previous work on the δ-butyrolactone amino acid  
 
In a previous work carried out by  M. Haque12 in our laboratory in Regensburg, the tetramer 123 
consisting of four (S,S)-δ-amino acid units was synthesized (Figure 89). The NMR investigation 
was not possible due to signal overlapping especially in the NH region.  
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Figure 89. Tetramer 123. 
 
Therefore CD analyses in different solvents were performed (Figure 90). The CD spectra were 
recorded in the far UV region, at the concentration of 5 mM in TFE, methanol and 
methanol/water 60:40. In TFE the CD spectrum was characterised by a positive band at 191 nm, 
and by a broad negative band centred at 214 nm, with a crossover at 204 nm. Changing TFE with 
methanol doubled the intensity of the negative band, while the shape and the bands position 
remained the same. The intensity of the negative band further increased in the mixture 
methanol/water, becoming more than two times higher than in methanol and more than four times 
higher than in TFE. Again, the shape of the band remained more or less constant, but a better-
defined minimum was present at 214 nm. The fact that the CD spectra were solvent dependent 
indicates that the conformational properties of the peptide are influenced by the environment. An 
increase in the intensity of CD bands suggests an improved structural stability. For the δ-
oligopeptide a stabilisation effect was observed in methanol rather than in TFE, and in the 
presence also of water rather than in 100% methanol. This behaviour is quite unusual, as the 
conformation of peptide mimics is normally destabilized by addition of water that is a strong 
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donor and acceptor of H-bonds. In contrast, TFE is a well-known secondary structure stabilizer, 
being a strong H-bond donor but a weak H-bond acceptor.  
 
 
 
Figure 90. Left: CD spectra in TFE (green), methanol (red) and water/methanol mixture (blue). Right: Hofmann’s 
calculations: a) in gas-phase, helix-like structure; b) in water, turn-like structure. 
 
To reinforce and illustrate these results, molecular modelling experiments were performed at the 
University of Leipzig by the Hofmann’s group and the results showed two families of structures. 
The first family in gas-phase had a helical tendency (Figure 90 a), whereas the second one in 
water showed a succession of turn-like structures (Figure 90 b). In both cases, the secondary 
structures seemed to be stabilized by H-bonds formed between the carbonyl and the NH of the 
same lactone residue (8-membered hydrogen-bonded ring). Another feature distinguishing both 
Hofmann’s structures is the conformation of the lactone. In the case of the calculations in gas-
phase both substituents on the cycle are occupying an axial position, whereas the calculations in 
water show the two “arms” of the lactone in an equatorial position. It was not possible to confirm 
by NMR and X-ray any of the information obtained from the computational and CD data. 
 
 
Gas phase, 
helix-like 
structure 
Water phase, 
Turn-like 
structure 
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III.6.2.   New analyses on the monomer 
 
In order to gain further information about such structures in solutions, we decided to perform 
conformational studies on the monomer. First we wanted to control its ability to form an internal 
H-bond (8-membered H-bonded ring) that would confirm the possible stabilization of the 
structures described by Hofmann’s calculations and, secondly, we wanted to study the lactone 
ring conformation as it could play a crucial role in the structural behaviour of further lactone-
containing peptidomimetics. 
 
 
Design and synthesis 
 
This kind of conformational studies based on monomeric structures have been previously 
reported by Gellman and co-workers31 in their attempt to evaluate folding properties of β- and γ-
aminoacids. To study the particular H-bond preferred conformation of our lactone we needed two 
types of compounds. In the first one, only one hydrogen bond would be possible, and in the 
second one the monomer could adopt two hydrogen bond patterns. Thus, we synthesised 
compounds 125 and 126 as described in Scheme 12. In the first step the Boc-protected lactone 
derivative 106 was coupled to a mono or dialkylated amine. The resulting compound 124 was 
Boc deprotected by treating it with TFA in dry CH2Cl2, and finally the amino group was 
acetylated to afford our model compounds 125 and 126. 
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Scheme 12.  Synthesis of compounds 125 and 126. Reagents:  
a) NHEtR, EDC, HOBt, DMF, 42% when R=H and 65% when R=Et; b) (i) TFA, dry CH2Cl2 ; (ii) Ac2O, THF, 65% when R=H and 60% when R=Et.
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Conformational analyses 
 
We studied both compounds first by NMR and, secondly, by IR in CH2Cl2 at low concentration 
(3 mM) and room temperature (Figure 91).  
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Figure 91. a) IR studies of 125; b) IR studies of 126. The possible hydrogen bonds are shown in magenta.  
 
 
In the IR spectra it is possible to observe two N−H stretch bands for amide protons: the highest 
one about 3400 cm-1 indicates an amide in a non-hydrogen-bonded state, whereas the lowest one 
appearing near 3300 cm-1 corresponds to an amide in hydrogen-bonded state.  
The disubstituted amide in 125 presented two IR bands at 3347 and 3312 cm-1 with similar 
intensity (Figure 91 a), whereas the monosubstituted compound 126 showed an intense band in 
the non-hydrogen-bonded NH region at 3441 cm-1 and a weaker band in the region of H-bonded 
amides at 3331 cm-1 (Figure 91 b). These data suggest that the intraresidue H-bond is favoured in 
the monomer 125 comporting only one H-bond possibility, whereas in the monosubstituted 
derivative 126 with more possible combinations, the non-H-bonded state is preferred. These 
analyses confirm that an intraresidue H-bond is possible in our structure, supporting indeed the 
H-bond pattern described in Hofmann’s structures. 
In NMR investigations two parameters were considered. On the one hand, variable temperature 
studies gave the temperature coefficients that in some cases can be correlated with the H-bonding 
state of amide protons. On the other hand, NOESY experiments gave insight about the distance 
between two protons in the space.  
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In variable temperature studies the NH(7) of the disubstituted lactone 125 showed a high 
temperature coefficient (-9.2 ppb/K), typical value for non-hydrogen-bonded state, and NOESY 
spectra performed at room temperature did not show any intra-strand NOE contacts. In contrast, 
the monosubstituted lactone 126 appeared to adopt two distinct behaviours depending on the 
temperature in which it was studied, at room temperature and at 225 K. The temperature 
coefficient for the NH(7) (-8.9 ppb/K) was similar to the one in the disubstituted lactone, whereas 
the NH(12) showed a lower value of ∆δ/∆T = -6 ppb/K. For this compound NOESY experiments 
were performed at room temperature and at 225 K, and an intra-strand NOE cross peak was 
found at low temperature between CH3(9) and NH(12). These two parameters, NOE contacts and 
temperature coefficient, found for NH(12) suggest a preferred H-bonding pattern involving 
NH(12) and CO(8) of 126 at low temperature. 
 
 
Investigations on the ring conformation 
 
The γ-butyrolactone system possesses great importance in the chemistry of natural products.32, 33 
Therefore, considerable interest is given at the synthesis and structural characterization of 
substituted γ-butyrolactones.  
One advantage of using γ-butyrolactone as synthetic intermediate is the low conformational 
flexibility: indeed, one needs to consider only the interconversion between two envelope forms A 
and B, in which α  = β = H34 (Figure 92). In this case the interconversion barrier is quite low and 
the lactone adopts both shapes in solution. However, when substituents are introduced on such a 
small ring, both the ring structure and the equilibrium between the A and B forms are greatly 
affected, and the analysis in NMR spectra of ring protons turns into a complicated task.  
 
Figure 92. Interconversion of γ-lactone A in B. 
1.16 Kcal/mol 
A B 
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To evaluate the substituted γ-lactone conformer distribution in solution several methods have 
been developed based on experimental vicinal and geminal coupling constants combined with 
conformational studies by molecular mechanics.34-36 In our case, experimental data gave a really 
large value of J3-4 for both disubstituted 125 and monosubstituted 126 monomers, which was 12.3 
and 13.1 Hz, respectively. Such large coupling constants are in agreement with trans protons 3 
and 4 occupying both a diaxial position on the lactone ring. We then compared these values with 
the one of the coupling constant from the dimethylated lactone 127 (Figure 93), which was 
previously synthesized by Delatouche in our group. In this case the coupling constant value 
between H3 and H4 was 9.8 Hz. It has been earlier demonstrated on 2,4 disubstituted lactones that 
1-3 diaxial strains are quite disfavouring in term of energy in γ-butyrolactones.34 Thus, in our 
dimethylated compound 127 the conformer A that shows a 1-3 diaxial strain between the methyl 
group in position 2 and the lactone arm in position 4 should be unstable, while the predominant 
conformation in solution should be the conformation B, in which H4 and one methyl group in 
position 2 are diaxial (Figure 93). 
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Figure 93. Interconversion between the two envelope conformations A and B of 127. 
 
 
The results suggested by the coupling constants were then supported by molecular mechanics 
calculations using MMFF force field in the program Spartan,37 which gave the conformation with 
the two arms in an equatorial position as energetic minimum for both lactones 125 and 126 
(Figure 94).  
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Figure 94. Energy minimum of 125 and 127 based on a molecular mechanics study with the force field MMFF of 
the Spartan program.   
 
Finally, analysis of the crystal structure data12 obtained by Haque gave further evidence of the 
equatorial distribution of the two lactone arms (Figure 95). 
 
 
 
Figure 95.  X-ray structure of compound 106. 
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               125 
E=-57,62Kcal/mol 
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III.7.   Influence of the (R,R)-δ-lactone amino acid on the α-helix 
stability 
 
III.7.1.   Aim of the study 
 
As it as been described before, on the one hand, this cyclic scaffold 107 can be described as δ-
amino acid bearing a lactone ring at β- and γ-positions (Figure 96). On the other hand, it mimics 
a glycyl-glycyl dipeptide unit 128, in which the amide bond is replaced by a lactone ring. We 
have investigated the folding properties of these building blocks in homo-δ-oligomers12 as well as 
in hetero-α,δ-oligomers. We have previously shown that the δ-lactone amino acid unit possesses 
a tendency to build loop- or turn-like elements.  
 
 
 
Figure 96.  Structure of pentalactone-compound 107 and of glycyl-glycine 128. 
 
The aim of the experiment described in the following paragraphs was to evaluate the influence of 
this δ-amino acid on the helical structure of α-amino acid sequences. To carry out this study we 
used as peptide reference the peptide 129, that was designed by Serrano’s group38 in 1995 and 
adopts an α-helical structure (Figure 97). This peptide is composed of eighteen amino acids and 
shows in the N-terminal part two crucial motifs for the helix initiation: the hydrophobic staple 
and the capping box. The hydrophobic staple consists of residues Phe-2 and Leu-7. A second 
helix inducer effect comes from the presence of the capping box consisting of Ser-3 and Glu-6.39 
NMR analysis of this peptide in aqueous solutions have shown that the helical part of the peptide 
starts at Lys-4 and stops around Arg-15. 
 
107 128 
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Figure 97. Peptide reference 129 used in our studies. 
 
This peptide 129 was analysed using CD spectroscopy and led to a CD spectrum with a 
maximum at 195 nm and two minima at 208 and 222 nm (Figure 98 b). Replacement of Phe-2 by 
Ala (peptide 130, Figure 98 a) led to a destabilization of the helix, as indicated by the reduced 
intensity of the CD spectrum of 130 (Figure 98 b).  
 
 
 
 
 
 
 
 
 
 
a                                                                                 b 
 
Figure 98. a) Peptide references used in our studies; b) CD spectra of 129 and 130 and other analogs, as reported by 
Serrano and co-workers.38 (Reproduction by courtesy of  Dr. Serrano). 
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Thus, we chosed these two peptides as references to carry out our studies. The reference called 
“positive” 129 included Phe-2, whereas the reference called “negative” included Ala-2 (Figure 98 
a). 
 
 
III.7.2.   Design of the modified peptides 
 
In order to check the compatibility of our amino acid with the helical structure of an α-peptide, 
we decided to introduce the lactone unit in the C-terminal part of the helix of the reference 
peptide 130 (from Lys-9 to Arg-14), by substituting either the two residues Arg-11 and Ala-12 
(peptide 131) or Ala-10 and Arg-11 (peptide 132, Figure 99).  
 
 
Figure 99. Peptide mimics 131 and 132 containing the lactone unit in the helical part. 
 
Moreover, we  introduced one lactone unit in the N-terminal part of the peptide: indeed, we 
substituted Ser3 and Lys-4, thus introducing the lactone between the two residues that should 
build the hydrophobic staple (peptide 133, Figure 100). As a final test, we designed an analog of 
the latter peptide 133 that contains the substitution Phe-2/Ala, thus replacing one of the two 
partners of the hydrophobic staple (peptide 134, Figure 100). The goal of this last test was to see 
if our lactone would be able to restore the hydrophobic staple properties and to induce the helix.  
 
 
 
Figure 100. Peptide mimics 133 and 134 containing the lactone unit in the N-terminal part of the helix. 
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III.8.   Synthesis of peptides 129-134 
 
The synthesis of peptides 129-134 was performed on solid phase using Fmoc-chemistry on Rink 
amide MBHA resin (loading 0.6 mmol g -1) (Scheme 13). The seven first amino acids were 
introduced using a single coupling procedure (75 min), whereas the following amino acids were 
introduced by a double coupling procedure (2 x 45 min). We used Fmoc-amino 
acid/HOBt/HBTU/DIPEA (5:5:5:10 equiv.) in DMF/NMP (80:20, v/v), followed by Fmoc 
removal with 25% piperidine in DMF/NMP (80:20, v/v) (2 x 15 min). To monitor the progress of 
the synthesis, test cleavages using small amounts of resin were conducted and the resulting 
samples were analyzed by MALDI-ToF-MS and analytical HPLC. The last step was the N-
terminal acetylation using acetic anhydride (8 equiv.) and DIPEA (7 equiv.). Final cleavage of 
the peptide from the resin and simultaneous side-chain deprotection was achieved by treatment 
with a TFA/water/TIS mixture (90:5:5) for 2.5 hours. The peptide was then precipitated from ice-
cold diethyl ether, centrifuged and subjected to three ether-washing/centrifugation cycles to 
remove the scavengers. 
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Scheme 13. Synthetic procedure for the six peptides 129-134. 
 
Each peptide was then purified by preparative HPLC. Each pure peptide was obtained in mg 
scale and submitted to circular dichroism analyses. The circular dichroism was recorded at 5 °C 
in phosphate buffer at pH 7.0 as it was described by Serrano and co-workers.38 
 
 
III.9.   Results and discussion 
 
The CD spectra of the synthesized peptides are shown in Figure 101. It can be noted, that 
introduction of the lactone led to the loss of the α-helical structure in any case. Indeed, the 
minimum at 222 nm characteristic for α-helices was replaced by a weak shoulder, while the 
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minimum near 208 nm decreased intensity and was slightly blue-shifted to 205 nm.  Such CD 
curves are similar to the one reported in the literature for the 310 helix.40  
 
 
 
Figure 101. CD spectra recorded at 5 °C in phosphate buffer pH=7 and at 0.5 mM. The concentration of the peptides 
was controlled previously by UV measurement.  
 
 
As described before, the α-helix is the most common regular secondary structure of peptides and 
proteins. However, 310 helices are also observed in nature. The latter are more tightly bond and 
more elongated than the α-helix. The set of φ and ψ torsion angles of the α- and 310-helices does 
not differ much, falling within the same region of the Ramachandran map (Table 5). 
 
 
Parameter                   α-Helix                  310-Helix 
       
       Φ (°)                       -63                        -57 
 
     Ψ  (°)                       -42                        -30 
 
Table 5.  Average torsion angles for α- and 310-helices based on α-amino acids. 
 
G F S K A E L A K A Lac A K R G G Y 
                             131 
G F S K A E L A K Lac A A K R G G Y 
                             132 
G F Lac A E L A K A R A A K R G G Y 
                             133 
G A Lac A E L A K A R A A K R G G Y 
                              134 
G F S K A E L A K A R A A K R G G Y 
Ref positive          129 
G A S K A E L A K A R A A K R G G Y 
Ref negative         130 
 137 
However, their intramolecular C=O… H-N H-bonding schemes are remarkably distinct, being of 
the 1←4 type (sub-type III or helical β-turn41) in the 310-helix, and of the 1←5 type (helical α-
bend42) in the α-helix43 (Figure 102). 
 
 
 
 
Figure 102. a) The α-helix and its building block, the helical α-turn (or C13-conformation); b) The 310-helix and its 
building block, the helical (type III) β-turn (or C10-conformation). From Toniolo et al.43 
(Reproduction by courtesy of  Prof. Toniolo). 
 
 
 
Theoretical calculations have predicted a very low conformational energy barrier separating these 
two secondary structures.44 It has been shown that factors influencing the folding through one or 
the other conformation are: the solvent properties, the length of the peptide, the temperature, and, 
of course, changes in the amino acid composition.  
Recently, Toniolo and co-workers45 reported an example of homooligomer made of α,α-amino 
acids able to fold either in α-helix or in 310-helix depending on the solvent. As an example,45 the 
Ac-[L-(αMe)Val]7-NHiPr showed two different folding properties in MeOH, in which it adopts a 
310-helix structure, and in the acidic alcohol HFIP, where it adopts an α-helical structure (Figure 
103). 
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Figure 103.  CD spectra of Ac-[L-(αMe)Val]7-NHiPr in methanol and HFIP solutions. Reported from Toniolo and 
co-workers.45 (Reproduction by courtesy of  Prof. Toniolo). 
 
According to the analysis of Toniolo’s group that demonstrated the different peptide folding 
behaviour depending on the solvent, we performed further CD analyses of peptides 129-134 in 
TFE that is know to be a secondary structure stabilizer, as it is a strong H-bond donor and a weak 
H-bond acceptor, and, consequently, it interacts with carbonyl groups of peptides which are able 
to build bifurcated H-bonds without the necessity of breaking the intramolecular H-bond.  
In our CD analyses in TFE, we can see differences in the structural behaviour of our modified 
peptides. While 131, 133 and 134 showed α-helix-like CD profiles, 132 seemed to maintain the 
structure it already adopted in water (Figure 102), showing the typical CD profile for a 310-helix 
(Figure 104). 
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Figure 104. CD spectra recorded at 5 °C in TFE and at 0.3 mM. The concentration of the peptides was controlled 
previously by UV measurement. 
 
We can conclude from these last experiments, that the introduction of the lactone in already 
existing α-helical peptides has an influence on their secondary structure preferences. In water, a 
non-stabilizing solvent, the presence of one lactone unit in the proximity of the N-end or C-end of 
a α-amino acid sequence with strong α-helix propensity seems to favour the building of the 310-
helix at the expense of the α-helix. In contrast, in the structure-stabilizing solvent TFE, the 
presence of the lactone unit does not prevent the formation of the α-helix, as indicated by the fact 
that the CD spectra of the lactone-containing peptides 131, 133 and 134 are superimposable with 
the CD spectrum of the “negative” reference peptide 130. The striking behaviour of peptide 132, 
whose structure preference seems to be less solvent-dependent, might be due to the fact that the 
shift of the lactone position toward the central part of an α-amino acid sequence prevented the 
formation of a single α-helix segment, while favouring the formation of short 310-helical 
structures of α-amino acids.  
 
 
 
 
G F S K A E L A K A Lac A K R G G Y 
                             131 
G F S K A E L A K Lac A A K R G G Y 
                             132 
G F Lac A E L A K A R A A K R G G Y 
                             133 
G A Lac A E L A K A R A A K R G G Y 
                              134 
G F S K A E L A K A R A A K R G G Y 
Ref positive          129 
G A S K A E L A K A R A A K R G G Y 
Ref negative         130 
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III.10. Conclusion 
 
The synthetic studies performed on oligomers containing the butyrolactone δ-amino acids have 
shown that these interesting new scaffolds are compatible with the solid-phase methodology, 
which allows for a comfortable and efficient preparation of a large number of compounds. 
Moreover, the structural analyses of the synthesized peptide mimics have given insights in the 
conformational properties of peptide backbones based on alternated α/δ-units. In fact, the 
presence of the δ-residue seems to favour the formation of loops or isolated turn-like elements, 
whereas no periodic structures were observed. However, conformational analyses of δ-
homooligomers support the presence of ordered structures, like turn-like repeats stabilized by 
intra-residue CO-NH H-bonds. Moreover, introduction of a δ-amino acid unit in proximity of the 
N- or C-end of a α-helical peptide chain seems to destabilize the α-helix in water, but not to 
prevent its formation in a structure-stabilizing solvent. In contrast, the δ-amino acid unit can act 
as a helix breaker when introduced into a α-helical segment, thus favouring the 310-helix over the 
α-helix.  
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IV.   EXPERIMENTAL PART 
 
IV.1.   Experimental part chapter II 
 
General chemical techniques: 
 
Usual solvents were purchased from commercial sources. DMF was distilled on CaSO4, THF was 
distilled on sodium/benzophenone, ACN was distilled on CaCl2, CH2Cl2 was distilled from calcium 
hydride. Pure products were obtained after liquid chromatography using Merck silica gel 60 (40-63 
µm). TLC analyses were performed with 0.25 mm 60 F254 silica plates (Merck). The plates were 
visualized with UV light (254 nm) or with a solution of vanillin in ethanol or with a solution of 
ninhydrin in ethanol. Element analyses (C, H, N) were performed on a Perkin-Elmer CHN Analyser 
2400, by the microanalyses Service of the Faculty of Pharmacy in Châtenay-Malabry (France) or by 
microanalyses Service at I.C.S.N-C.N.R.S. 91198 Gif sur Yvette Cedex. Mass spectra were 
obtained using a Bruker Esquire electrospray ionization apparatus. IR spectra were recorded on a 
Bruker Vector 22 FT-IR spectrometer. Melting points were determined on a Kofler melting point 
apparatus. NMR spectra were recorded on a Bruker AMX 200, (1H, 200 MHz, 19F: 188 MHz 13C, 
50 MHz) or a Ultrafield AVANCE 300 (1H, 300 MHz, 13C, 75 MHz) or a Bruker AVANCE 400 
(1H, 400 MHz, 13C, 100 MHz). Chemical shift δ are in ppm and the following abbreviations are 
used: singlet (s), broad singlet (br s), doublet (d), doublet of doublet (dd), triplet (t), multiplet or 
more overlapping signals (m). 
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SYNTHESIS OF NON FLUORINATED MOLECULE  52     
 
2-Methoxy-5-nitrobenzoic acid 61.         
 
O2N
OCH3
OH
O
1
2
3
4
5
6
7
 
 
To an ice-cold suspension of 60 (5.0 g, 32.86 mmol) in concentrated aqueous H2SO4 (60 mL) was 
added dropwise NH4NO3 (2.89 g, 36.15 mmol, 1.1 eq). The reaction mixture was stirred at 0°C for 
30 min, then at room temperature for 3h and finally was added in water (100 mL). The resulting 
precipitate was filtered and the pale solid was washed with water (150 mL) and dried (over P2O5 in 
a desiccator) to give 61 as a white solid (5.2 g, 80%). 
 
1H NMR (300 MHz, CDCl3) δ ppm 9.01 (d, J = 2.9 Hz, 1H, H6), 8.46 (dd, J = 9.2 and 2.9 Hz, 1H, 
H4), 7.18 (d, J = 9.2 Hz, 1H, H3), 4.17 (s, 3H, OCH3). 
13C NMR (75 MHz, CD3OD) δ ppm 165.9 (C7), 163.6 (C2), 140.3 (C5), 129.4 (C4), 126.7 (C6), 
122.8 (C1), 112.4 (C3), 55.9 (OCH3). 
Rf: 0.1 (EtOAc/ cyclohexane: 80/20)  
mp: 148-150 °C     litt. data:1 161-162 °C      
 IR (cm -1): 3258 (NH), 1725 (C=O), 1342 (N–O) 
Elemental Anal. 
 
 
 
 
 
 
 
 
 
 
% Calcul Found 
C 48.74 48.53 
H   3.58   3.49 
N   7.10   7.05 
C8H7NO5 
M = 197.14 g/mol 
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N'-(2-Methoxy-5-nitrobenzoyl)hydrazinecarboxylic acid tert-butyl ester 63.   
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To a solution of 61 (2.0 g, 10.15 mmol) in dry CH2Cl2 (30 mL) was added tert-Butyl carbazate 
(1.48 g, 11.17 mmol, 1.1 eq), DIPEA (5.3 mL, 30.45 mmol, 3 eq), HOBt (1.5 g, 11.17 mmol, 1.1 
eq) and EDCI (2.14 g, 11.17 mmol, 1.1 eq). The reaction mixture was stirred under argon for 6 h. 
The solvent was evaporated under reduced pressure and the residue was dissolved in EtOAc (150 
mL). The organic phase was  washed with 10% aqueous citric acid  (100 mL), water (100 mL), 10% 
aqueous  K2CO3  (100 mL), and brine (100 mL). The organic phase was dried over Na2SO4, filtered 
and concentrated under reduced pressure. The resulting crude was purified by chromatography on 
silica gel and eluted with EtOAc/cyclohexane (30/70). The product was obtained as a white powder 
(4.1 g, 85%). A purification by chromatography on silica gel, eluting with EtOAc/cyclohexane 
(5/5), afforded 2.7 g (86%) of 63 as a white powder. 
 
1H NMR (300 MHz, CDCl3) δ ppm 9.40 (br s, 1H, H8), 9.07 (d, J = 2.9 Hz, 1H, H6), 8.35 (dd, J = 
9.1 and 2.9 Hz, 1H, H4), 7.10 (d, J = 9.2 Hz, 1H, H3), 7.00 (br s, 1H, H9), 4.12 (s, 3H, OCH3), 1.51 
(s, 9H, CH3Boc). 
13C NMR (50 MHz, CDCl3) δ ppm 162.0 (C7), 161.7 (C2), 155.1 (C10), 141.9 (C5), 128.7 (C4), 
128.5 (C6), 120.3 (C1), 111.9 (C3), 82.0 (CBoc), 57.3 (OCH3), 28.2 (CH3Boc). 
Rf: 0.3 (EtOAc/ cyclohexane: 60/40)  
mp: 148-150 °C (crude) 
IR (cm -1): 3410 (NH), 1741(C=O), 1678 (C=O). 
 
 
 
 
 
 
 
 
C13H17N3O6 
M = 311.29 g/mol 
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N'-(5-Amino-2-methoxybenzoyl)hydrazinecarboxylic acid tert-butyl ester 64.     
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To a solution of 63 (1.5 g, 4.8 mmol) in MeOH (100 mL) at room temperature was added Pd/C 10 
% (150 mg). The mixture was hydrogenated at athmospheric pressure overnight and filtered through 
a pad of Celite. The filtrate was concentrated to give 1.30 g (96%) of 64 as a beige foam. 
 
1H NMR (300 MHz, CD3OD) δ ppm 7.31 (br s, 1H, H6), 6.92-6.84 (m, 2H, H3, H4), 3.84 (br s, 3H, 
OCH3), 1.45 (s, 9H, CH3Boc). 
13C NMR (75 MHz, CD3OD) δ ppm 168.2 (C7), 157.8 (C10), 152.2 (C2), 142.7 (C5), 122.5 (C1), 
122.2 (C4), 119.5 (C6), 114.7 (C3), 81.9 (CBoc), 57.1 (OCH3), 29.1 (CH3Boc). 
Rf: 0.3 (EtOAc/ cyclohexane: 80/20) 
IR (cm -1): 3290 (NH), 1734 (C=O), 1657 (C=O) 
 
 
N'-(5-Acetylamino-2-methoxybenzoyl)hydrazinecarboxylic acid tert-butyl ester 65.  
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A solution of 64 (1.22 g, 4.3 mmol) in dry THF (17 mL) was heated at 70 °C and acetic anhydride 
(2.4 mL, 24.0 mmol, 5 eq) was added dropwise to this solution. The reaction mixture was stirred for 
1 hour at 70 °C. The solvent of reaction was evaporated under reduced pressure to yield 65 as a 
white powder (1.4 g, quantative yield). This crude product was used without any further purification 
in the course of the synthesis.   
 
1H NMR (300 MHz, DMSO-d6) δ ppm 9.92 (s, 1H, H9), 9.60 (s, 1H, H8), 8.90 (s, 1H, H11), 7.90 
(s, 1H, H6), 7.80 (m, 1H, H4), 7.07 (d, J = 9.0 Hz, 1H, H3), 3.83 (s, 3H, OCH3), 2.02 (s, 3H, H13), 
1.42 (s, 9H, CH3Boc). 
C13H19N3O4 
M = 281.31 g/mol 
C15H21N3O5 
M = 323.34 g/mol 
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13C NMR (75 MHz, DMSO-d6) δ ppm 167.9 (C12), 164.9 (C7), 155.1 (C10), 152.6 (C2), 132.4 (C5), 
123.1 (C4), 121.2 (C6), 112.2 (C3), 79.0 (CBoc), 55.9 (OCH3), 28.0 (CH3Boc),  23.7 (C13).  
Rf: 0.2 (EtOAc/cyclohexane: 80/20)  
mp: 209-211 °C     
IR (cm -1):  3275 (NH), 1712 (C=O), 1665 (C=O). 
Elemental. Anal. 
 
  
 
 
 
N-(3-Hydrazinocarbonyl-4-methoxyphenyl)acetamide, trifluoroacetic acid salt 66.   
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Compound 65 (1.4 g, 4.3 mmol) was suspended in CH2Cl2 (72 mL) and trifluoroacetic acid (3.2 
mL, 189.5 mmol, 55 eq) was then added dropwise at room temperature. The reaction mixture was 
stirred at room temperature for 5 h. Solvent was evaporated under reduced pressure to yield a light 
brown solid 66 (2.6 g, quantitative yield). This crude product was used without any further 
purification in the course of the synthesis. 
1H NMR (300 MHz, DMSO-d6) δ ppm 10.84 (br s, 3H, H9), 10.71 (s, 1H, H8), 10.01 (s, 1H, H10), 
8.06 (d, J = 2.7 Hz, 1H, H6), 7.77 (dd, J = 9.0 and 2.8 Hz, 1H, H4), 7.16 (d, J = 9.0 Hz, 1H, H3), 
3.88 (s, 3H, OCH3), 2.03 (s, 3H, H13). 
13C NMR (75 MHz, CD3OD) δ ppm 171.7 (C11), 166.0 (C7), 161.1 (CF3COOH), 155.8 (C2), 133.7 
(C5), 127.1 (C4), 124.3 (C6), 119.4 (C1), 115.4 (CF3COOH), 113.5 (C3), 56.9 (OCH3), 23.6 (C12).  
Rf: 0.5 (EtOAc/MeOH/NH4OH: 79/20/1)  
     
 
 
 
 
% Calcul Found 
C 55.72 55.53 
H 6.55 6.46 
N 13.00 12.89 
C11H13N3O3.CF3COOH 
M = 337.25 g/mol 
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[2-[N'-(5-Acetylamino-2-methoxybenzoyl)hydrazino]-1-(3,4-dimethoxy-benzyl)-2-
oxoethyl]carbamic acid 9H-fluoren-9-ylmethyl ester 68.    
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To a solution of 66 (200 mg, 0.60 mmol) and Fmoc-L-3,4-dimethoxyphenylalanine (266 mg, 0.60 
mmol, 1.0 eq) in dry DMF (14 mL) was added, after stirring for 5 min at room temperature, 2,4,6-
collidine (350 µL, 2.63 mmol, 5.0 eq), HOBt (88.5 mg, 0.70 mmol, 1.1 eq) and HBTU (248 mg, 
0.70 mmol, 1.1 eq). The mixture was stirred at room temperature under argon atmosphere for 6 h. 
After removal of the solvent under reduced pressure, the residue was dissolved in EtOAc (30 mL). 
The organic phase was washed with 10% aqueous citric acid (20 mL), water (20 mL), 10% aqueous 
Na2CO3 (20 mL) and brine (20 mL). The organic layer was dried over Na2SO4, filtered and 
concentrated. A purification by trituration in EtOAc afforded 194 mg (50%) of 68 as a white solid. 
 
1H NMR (300 MHz, DMSO-d6) δ ppm 10.58 (m, 1H, H11), 10.10 (br s, 1H, H12), 10.04 (m, 1H, 
H7), 7.98-6.81 (m, 14 H, H3, H4, H6, H17, H20, H21, H27, H28, H29, H30, H33, H34, H35, H36), 4.35 (m, 
1H, H14 ), 4.17-4.10 (m, 3H, H24, H25), 3.87 (s, 3H, OCH3), 3.73 (s, 3H, OCH3), 3.68 (s, 3H, OCH3), 
3.03 (m, 1H, H15a), 2.80 (m, 1H, H15b), 2.02 (s, 3H, H9). 
13C NMR (75 MHz, DMSO-d6) δ ppm 170.1 (C13), 168.1 (C8), 163.1 (C10), 155.8 (C23), 152.6 
(C2), 148.3, 147.3 (C18, C19), 143.8, 140.6 (C26, C37, C31, C32), 132.7 (C5), 130.4 (C16), 127.6, 127.0, 
125.3, 123.4, 121.2, 120.1, 113.2, 112.4, 111.5 (C3, C4, C6, C17,  C20, C21, C27, C28, C29, C30, C31, C33, 
C34, C35, C36), 120.1 (C1), 65.7 (C24), 56.2 (OCH3), 55.3 (2 OCH3), 55.1 (C14), 46.5 (C25), 37.3 
(C15), 23.4 (C9). 
Rf: 0.7 (EtOAc/MeOH : 85/15) 
mp: 208-210 °C (crude) 
IR (cm-1 ): 3480 (NH), 1742 (C=O), 1644 (C=O) 
HRMS (EI) m/e: [M+Na]+  calcd 675.2431, found 675.2408  
C36H36N4O8 
M = 652.25 g/mol 
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Elemental Anal. 
 
 
 
 
 
N-(3-{N'-[2-Amino-3-(3,4-dimethoxyphenyl)propionyl]hydrazinocarbonyl}-4-
methoxyphenyl)acetamide 69.   
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To compound 68 (159 mg, 0.24 mmol) was added a solution of piperidine in DMF (10% v/v, 2.4 
mL). The mixture was stirred at room temperature for 4.0 h. The organic phase was evaporated. The 
crude product 69, 115 mg of a light yellow solid (quantitative yield), was used without any further 
purification in the course of the synthesis. 
 
1H NMR (300 MHz, DMSO-d6) δ ppm 10.10 (br s, 1H, H12), 7.95 (d, J = 2.6 Hz, 1H, H6), 7.76 
(dd,  J = 9.0 and 2.7 Hz, 1H, H4), 7.10 (d, J = 9.0 Hz, 1H, H3), 6.86-6.71 (m, 3H, H17, H20, H21), 3.84 
(s, 3H, OCH3), 3.70 (s, 3H, OCH3), 3.68 (s, 3H, OCH3), 3.49 (m, 1H, H14), 2.89 (dd, J = 13.3 and 
4.8 Hz, 1H, H15a), 2.56 (m, 1H, H15b), 2.00 (s, 3H, H9). 
13C NMR (75 MHz, DMSO-d6) δ ppm 172.2 (C13), 168.0 (C8), 162.0 (C10), 152.0 (C2),  148.5, 
147.3 (C18, C19), 132.8 (C5), 130.9 (C16), 120.0 (C1), 123.4, 121.3, 113.2, 112.4, 111.7 (C3, C4, C6, 
C17, C20, C21), 56.2 (OCH3), 55.5 (OCH3), 55.4 (OCH3), 54.9 (C14), 40.9 (C15), 23.8 (C9). 
Rf: 0.2 (EtOAc/MeOH : 85/15)  
IR (cm-1 ): 3230 (NH), 1656 (C=O) 
MS (ESI Positive) m/z: 453 [M+Na]+   
 
 
        % Calcul(+1.5H2O) Found 
C 54.87 54.87 
H   6.57 5.81 
N 9.70           9.41 
 
C21H26N4O6 
M = 430.19 g/mol 
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N-[2-[N'-(5-Acetylamino-2-methoxybenzoyl)hydrazino]-1-(3,4-dimethoxybenzyl)-2-oxoethyl]-
2-(3-phenoxyphenyl)acetamide 52.     
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To a solution of 69 (79 mg, 0.18 mmol) and 3-phenoxyphenylacetic acid (45 mg, 0.20 mmol, 1.1 
eq) in dry DMF (7 mL) was added, after stirring for 5 min at room temperature, 2,4,6-collidine (50 
µL, 0.36 mmol, 2.0 eq), HOBt (27 mg, 0.20 mmol, 1.1 eq) and HBTU (75 mg, 0.20 mmol, 1.1 eq). 
The mixture was stirred at room temperature under argon atmosphere for 20 h. After removal of the 
solvent under reduced pressure, the residue was dissolved in EtOAc (20 mL). The organic phase 
was successively washed with 10% aqueous citric acid (15 mL), water (15 mL), 10% aqueous 
K2CO3 (15 mL) and brine (15 mL). The organic layer was concentrated. A purification by 
chromatography on silica gel, eluting with EtOAc/MeOH (8/2), afforded 87 mg (75%) of  52 as a 
white powder. 
 
1H NMR (300 MHz, DMSO-d6) δ ppm 10.50 (br s, 1H, H11), 10.10 (br s, 1H, H12), 10.00 (s, 1H, 
H7), 8.32 (d, J = 7.5 Hz, 1H, H22), 7.95 (d, J = 2.6 Hz, 1H, H6), 7.76 (dd, J = 8.9 and 2.6 Hz, 1H, 
H4), 7.10 (d, J = 9.0 Hz, 1H, H3), 7.39-6.72 (m, 13H, H3, H17, H20, H21, H26, H29, H30, H31, H32, H33, 
H34, H35, H36), 4.62 (m, 1H,  H14), 3.86 (s, 3H, OCH3), 3.68 (s, 6H, 2 OCH3), 3.40 (d, J = 6.9 Hz, 
2H, H24), 3.01 (m, 1H, H15a), 2.75 (m, 1H, H15b), 2.01 (s, 3H, H9). 
13C NMR (75 MHz, CDCl3) δ ppm 169.0 (C23), 168.2 (C8), 164.0 (C10), 157.0, 155.6 
(C27, C28), 152.0 (C2), 147.5, 147.0 (C18, C19), 134.8 (C25), 133.0 (C5), 129.3, 128.9, 124.0, 122.9, 
122.7, 121.4, 120.9, 118.4, 118.2, 116.6, 111.7, 111.0, 109.7 (C3, C4, C6, C17, C20, C21, C26, C29, C30, 
C31, C32, C33, C34, C35, C36), 127.3 (C16), 116.5 (C1), 55.6 (OCH3), 54.6 (OCH3), 54.5 (OCH3), 51.5 
(C14), 42.51 (C24), 39.6 (C15), 22.8 (C9). 
Rf: 0.5 (EtOAc/MeOH : 90/10)  
C35H36N4O8 
M = 640.25 g/mol 
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mp: 108 - 110 °C (crude) 
IR (cm-1 ): 3273 (NH), 1649 (C=O) 
MS (ESI Positive) m/z: 663 [M+Na]+   
Elemental Anal. 
 
 
 
 
 
 
 
SYNTHESIS OF FLUORINATED MOLECULE  54     
 
3-(N’-tert-Butoxycarbonylhydrazino)-4,4,4-trifluorobutyric acid ethyl ester 72. 
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To a solution of 71 (2.00 g, 11.9 mmol) in MeOH (5 mL) was added tert-Butyl carbazate (4.72 g, 
23.8 mmol, 3 eq). The mixture was stirred for 3 days at 70 °C in a sealed tube. After concentration 
in vacuo, the purification by chromatography on silica gel (EtOAc/cycloexane 5/5)
 
gave 3.37 g 
(94%) of 72 as a colorless oil. 
  
1H NMR (200 MHz, CDCl3) δ ppm 6.48 (br s, 1 H, H8), 4.80 (br s, 1 H, H7), 4.46 (q, J = 7.2 Hz, 
2H, H2), 4.16 (m, 1H, H5 ), 2.90 (m, 2H, H4), 1.71 (s, 9H, CH3Boc), 1.53 (t, J = 7.2 Hz, 3H, H1).  
 
13C NMR (75 MHz, CDCl3) δ ppm  169.8 (C3), 125.3 (q, J = 279.8 Hz, C6), 81.3 (CBoc), 61.3 
(C2), 58.5 (q, J = 27.8 Hz, C5), 32.1 (C4), 28.2 (CH3Boc), 14.0 (C1). 
19F (188 MHz, CDCl3) δ ppm  -75.3 (d, J = 5.6 Hz). 
Rf: 0.3 (EtOAc/cyclohexane : 20/80) 
IR (cm-1 ):  3193 (NH), 1715 (C=O), 1157 (C-O), 1121 (C-O), 774 (CF3) 
MS (ESI Positive) m/z: 323 [M+Na]+ 
        % Calcul(+3.5H2O) Found 
C 59.73 59.50 
H   6.17  5.32 
N   7.96            7.62 
C11H19F3N2O4 
M = 300.13 g/mol 
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Elemental Anal. 
 
 
 
 
 
 
 
3-(N’-tert-Butoxycarbonylhydrazino)-4,4,4-trifluorobutyric acid 73. 
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To a solution of 72 (500 mg, 1.67 mmol) in THF/MeOH (2,5 mL / 2,5 mL) was added a 2N 
aqueous NaOH (917 µl, 1.84 mmol, 1.1 eq). The mixture was stirred for 2 h at room temperature. 
After concentration in vacuo, the residue was diluted with  water (5 mL). Then EtOAc (6 mL) and 
1N aqueous HCl (2 mL) were added. The separated organic phase was dried (Na2SO4), filtered and 
concentrated to yield 444 mg (98%) of  73 as a white solid. 
 
1H NMR (300 MHz, DMSO-d6) δ ppm 12.54 (br s, 1H, COOH), 8.39 (br s, 1H, H6), 3.82 (m, 1H, 
H3), 2.61 (dd, J = 16.6 and 5.4 Hz, 1H, H2a), 2.44 (dd, J  = 16.6 and 6.8Hz, 1H, H2b), 1.38 (s, 9H, 
CH3Boc). 
13C NMR (75 MHz, DMSO-d6) δ ppm 170.8 (C1), 156.4 (C7), 125.9 (q, J = 280.5 Hz, C4), 78.9 
(CBoc), 57.4 (C3), 32.4 (C2), 28.0 (CH3Boc).   
 
19F (188 MHz, DMSO-d6) δ ppm  -74.1 (d, J = 6.8 Hz). 
Rf: 0.3 (EtOAc/cyclohexane: 70/30) 
mp: 138-140 °C (crude) 
IR (cm-1 ): 3325 (NH), 3100 (OH), 1732 (C=O), 1687 (C=O), 1122 (C-O), 760 (CF3) 
MS (ESI Negative) m/z: 271 [M-H]- 
Elemental Anal. 
 
 
 
 
 
 
% Calcul Found 
C 44.00 43.72 
H   6.38   6.16 
N   9.33   9.69 
% Calcul Found 
C 39.71 39.83 
H   5.55   5.50 
N 10.29 10.29 
 
 
C9H15F3N2O4 
M = 272.10 g/mol 
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2-[3-(N’-tert-Butoxycarbonylhydrazino)-4,4,4-trifluorobutyrylamino]-3-phenyl-propionic acid 
methyl ester 75.                                                                                         
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To a solution of 73 (100 mg, 0.37 mmol) and phenylalanine methyl ester hydrochloride (88 mg, 
0.41 mmol, 1.1 eq) in dry CH2Cl2 (3 mL) and dry DMF (1 mL) was added DIPEA (135 µL, 0.82 
mmol, 2.0 eq), HOBt (55 mg, 0.41 mmol, 1.1 eq) and HBTU (155 mg, 0.41 mmol, 1.1 eq). The 
mixture was stirred at room temperature under argon atmosphere for 23 h. After removal of the 
solvent under reduced pressure, the residue was dissolved in EtOAc (10 mL). The organic solution  
was successively washed with 10% aqueous citric acid (10 mL), water (10 mL), 10% aqueous 
K2CO3 (10 mL), brine (10 mL) and dried over Na2SO4. The organic layer was evaporated and the 
residue was triturated with petroleum ether to yield 146 mg (91%) of 75 as a white solid. 
 
1H NMR (400 MHz, DMSO-d6) δ ppm 8.56;8.58 (2 d, J = 6.3;6.4 Hz, 1H, H8, 2 dia), 8.36 (m, 1H, 
H6), 7.27-7.17 (m, 5H, Har), 4.98;5.02 (2 br s, 1H, H5, 2 dia), 4.46 (m, 1H, H9), 3.73 (m, 1H, H3), 
3.56;3.57 (2s, 3H, OCH3, 2 dia), 3.00 (dd, J = 13.6 and 5.8 Hz, 1H, H10a), 2.89 (m, 1H, H10b), 2.38-
2.48 (m, 2H, H2), 1.36;1.37 (s, 9H, CH3Boc, 2 dia). 
13C NMR (100 MHz, DMSO-d6) δ ppm 172.2;172.1 (C17, 2 dia), 168.7 (C1), 156.7 (C7), 
137.5;137.4 (C11, 2 dia), 129.4;129.3 (C13, C15, 2 dia), 128.7 (C12, C16), 127.0 (C14), 126.3 (q, J = 
278.0 Hz, C4), 79.3 (CBoc), 58.3;58.0 (2 m, C3, 2 dia), 54.1;54.0 (C9, 2 dia), 52.1;52.2 (OCH3, 2 dia), 
37.2;37.1 (C10, 2 dia), 33.4 (C2), 28.5 (CH3Boc). 
19F (188 MHz, DMSO-d6) δ ppm  (-73.6) − (-73.8) (m).     
Rf: 0.7 (EtOAc/cyclohexane: 70/30) 
mp: 94-96 °C (crude) 
IR (cm-1 ): 3351 (NH), 3288 (NH), 1739 (C=O), 1709 (C=O), 1683 (C=O), 1164 (C-O), 1124 (C-
O), 698 (CF3) 
MS (ESI Positive) m/z: 456 [M+Na]+              
    C19H26F3N3O6 
M = 433.18 g/mol 
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Elemental Anal. 
 
 
 
 
 
 
 
3-Phenyl-2-(4,4,4-trifluoro-3-hydrazinobutyrylamino)propionic acid methyl ester, trifluoro-
acetic acid salt 76. 
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Compound 75 (134 mg, 0.31 mmol) was dissolved in CH2Cl2 (7 mL) and trifluoroacetic acid (1.4 
mL, 18.6 mmol, 60.0 eq) was added dropwise at room temperature. The reaction mixture was 
stirred for 2 h. Solvent was evaporated under reduced pressure to yield an orange solid oil 76 (159 
mg, with excess of TFA). Azeotropic removal of excess TFA with toluene gave a crude product 
used without further purification in the course of the synthesis.  
 
1H NMR (300 MHz, CDCl3) δ ppm 8.11 (bs, 3H, H6), 7.27-7.13 (m, 5H, Har), 4.41 (br s, 1H, H8 ), 
3.78 (m, 1H, H3), 3.71 (s, 3H, OCH3), 3.33 (m, 2H, H9), 3.11 (m, 1H, H2a), 2.59 (m, 1H, H2b). 
 
13C NMR (100 MHz, CDCl3) δ ppm 169.4 (C16), 158.9 (q, J = 31.0 Hz, CF3COOH), 133.2 (C10), 
129.4, 129.1 (C11, C15, C12, C14), 128.0 (C13), 114.8 (q, J = 284.2 Hz, CF3COOH), 54.6 (C8), 53.3 
(OCH3), 52.8 (C3), 36.0 (C9), 30.8;30.4 (C2, 2 dia). 
19F (188 MHz, DMSO-d6) δ ppm  -76.4 (CF3COOH), -78.0 (d, J = 5.6 Hz). 
 Rf: 0.7 (EtOAc/MeOH/NH4OH: 79/20/1) 
 
 
 
 
       
 % 
 
Calcul 
 
Found 
C 52.65 52.15 
H  6.05  6.07 
N  9.69  9.37 
 
C14H18F3N3O3.CF3COOH 
M = 447.15 
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2-(3-{N’-[3-(3,4-Dimethoxyphenyl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)propionyl] 
hydrazino}-4,4,4-trifluorobutyrylamino)-3-phenylpropionic acid methyl ester 77. 
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To a solution of 76 (300 mg, 0.67 mmol) and Fmoc-L-3,4-dimethoxyphenylalanine (300 mg, 0.67 
mmol, 1.0 eq) in dry DMF (14 mL) was added, after stirring for 5 min at room temperature,  2,4,6-
collidine (357 µL, 2.68 mmol, 4.0 eq), HOBt (99 mg, 0.74 mmol, 1.1 eq) and HBTU (279 mg, 0.74 
mmol, 1.1 eq). The mixture was stirred at room temperature under argon atmosphere for 21 h. After 
removal of the solvent under reduced pressure, the residue was dissolved in EtOAc (14 mL). The 
organic phase was washed with 10% aqueous citric acid (14 mL), water (14 mL), 10% aqueous 
K2CO3 (14 mL) and brine (14 mL). The organic layer was dried over Na2SO4, filtered and 
concentrated. A purification by chromatography on silica gel, eluting with EtOAc/cyclohexane 
(5/5), afforded 112 mg (22%) of 77 as a white powder. 
   
1H NMR (400 MHz, DMSO-d6) δ ppm  9.63 (br s, 1H, H6), 8.61 (d, J = 7.4 Hz, 1H, H7), 7.87 (d, J 
= 7.5 Hz, 2H, H34, H37), 7.66-7.61 (m, 3H, H31, H40, H26), 7.40 (m, 2H, H33, H38), 7.32-7.20 (m, 7H, 
H11, H12, H13, H14,  H15, H32, H39), 6.94 (d, J = 11.8 Hz, 1H, H24), 6.79 (m, 2H, H21, H25), 5.48 (m, 1H, 
H5), 4.50 (m, 1H, H8), 4.16-4.14 (m, 4H, H18, H28, H29), 3.80 (m, 1H, H3), 3.71 (s, 3H, OCH3), 3.67 
(s, 3H, OCH3), 3.57 (s, 3H, OCH3), 3.02 (dd, J = 13.8 and 5.9 Hz, 1H, H9a), 2.92 (m, 1H, H9b), 2.84 
(m, 1H, H19a), 2.70 (m, 1H, H19b), 2.50 (m, 2H, H2).  
 
13C NMR (100 MHz, DMSO-d6) δ ppm 171.8 (C17), 171.4;171.2 (C16, 2 dia), 168.2 (C1), 155.7 
(C27), 148.4 (C23), 147.4 (C22), 143.9;143.7 (C30, C41), 140.6 (C35, C36), 137.0;136.9 (C10, 2 dia), 
130.0 (C20), 129.0 (C11, C15), 128.2 (C12, C14), 127.6 (C33, C38), 127.0 (C32, C39), 126.5 (C13), 125.3 
(C31, C40), 121.2 (C25), 120.1 (C34, C37), 113.1 (C24), 111.6 (C21), 65.7 (C28), 55.3 (2 OCH3), 55.0 
(C29), 53.7;53.6 (C8, 2 dia), 51.8 (OCH3), 46.5 (C18), 37.1 (C19), 36.7 (C9), 32.9 (C2).  
C40H41F3N4O8 
M = 762.29 g/mol 
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19F (188 MHz, DMSO-d6) δ ppm (-73.8) − (-73.9) (m). 
Rf: 0.6 (EtOAc/cyclohexane: 70/30) 
mp: 178-180 °C (crude) 
IR (cm-1 ): 3304 (NH), 1738 (C=O), 1686 (C=O), 1667 (C=O), 1170 (C-O), 1121 (C-O), 698 (CF3)  
MS (ESI Positive) m/z: 785 [M+Na]+              
Elemental Anal. 
 
 
 
 
 
2-(3-{N’-[2-Amino-3-(3,4-dimethoxyphenyl)propionyl]hydrazino}-4,4,4-trifluoro-
butyrylamino)-3-phenylpropionic acid methyl ester 78. 
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To compound 77 (115 mg, 0.15 mmol) was added a solution of piperidine in DMF (10% v/v, 4 
mL). The mixture was stirred at room temperature for 1.30 h. The organic phase was evaporated. 
The crude product 78, 70 mg of a white solid (84%), was used without any further purification in 
the course of the synthesis. 
  
1H NMR (300 MHz, CD3OD) δ ppm 7.31-7.21 (m, 5H, H11, H12, H13, H14, H15), 6.86-6.71 (m, 3H, 
H21, H24, H25), 4.94 (m, 1H, H8), 4.71 (m, 1H, H18), 3.80 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 3.68 (s, 
3H, OCH3), 3.49 (m, 1H, H3), 3.12 (m, 2H, H9), 2.91 (dd, J = 13.7 and 7.1 Hz, 1H, H19a), 2.68 (dd, 
J = 13.7 and 7.0 Hz, 1H, H19b), 2.41 (m, 2H, H2). 
13C NMR (75 MHz, CD3OD) δ ppm 176.0, 173.6, 171.3 (C17, C1, C16), 150.5, 149.5 (C22, C23), 
138.2 (C10), 131.3 (C20), 130.3, 129.5 (C11, C12, C14, C15), 127.9 (C13), 122.9 (C25),  114.3, 113.2 (C21, 
C24), 60.0 (q, J = 28.2 Hz, C3), 56.5 (OCH3), 56.4 (OCH3), 55.6 (C8), 52.8 (OCH3), 45.9 (C18), 
41.8 (C19), 38.3 (C9), 34.0 (C2). 
 % Calcul (+ 1 H2O) Found 
C 61.57 61.72 
H   5.57   5.17 
N   7.18   7.15 
 
C25H31F3N4O6 
M = 540.22 g/mol 
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Rf: 0.2 (CH2Cl2/MeOH: 97/3) 
 
 
2-[3-(N’-{3-(3,4-Dimethoxyphenyl)-2-[2-(3-phenoxyphenyl)acetylamino]propionyl}hydrazino)-
4,4,4-trifluorobutyrylamino]-3-phenylpropionic acid methyl ester 54. 
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To a solution of 78 (70 mg, 0.13 mmol) and 3-phenoxyphenylacetic acid (32 mg, 0.14 mmol, 1.1 
eq) in dry DMF (4 mL) was added, after stirring for 5 min at room temperature, DIPEA (66 µL, 
0.45  mmol, 3.0 eq), HOBt (19 mg, 0.14 mmol, 1.1 eq) and HBTU (53 mg, 0.14 mmol, 1.1 eq). The 
mixture was stirred at room temperature under argon atmosphere for 24 h. After removal of the 
solvent under reduced pressure, the residue was dissolved in EtOAc (12 mL). The organic solution 
was washed with 10% aqueous citric acid (12 mL), water (12 mL), 10% aqueous K2CO3 solution 
(12 mL) and brine (12 mL). The organic layer was dried over Na2SO4, filtered and concentrated. A 
purification by chromatography on silica gel, eluting with EtOAc/cyclohexane (6/4), afforded 40 mg 
(41%) of 54 as a white powder. 
 
1H NMR (300 MHz, DMSO-d6) δ ppm  9.62 (d, J = 4.9 Hz, 1H, H6), 8.60 (d, J = 7.6 Hz, 1H, H7), 
8.33, 8.30 (2d,  J = 8.7 and 9.0 Hz, 1H, H26, 2 dia), 7.40-6.70 (m, 17H, H11, H12, H13, H14, H15, H21, 
H24, H25, H30, H33, H34, H35, H36, H37, H38, H39, H40), 5.47 (m, 1H, H5), 5.0 (m, 1H, H18), 4.54-4.39 
(m, 1H, H8), 3.83-3.67 (m, 7H, H3, 2 OCH3), 3.57;3.54 (2s, 3H, OCH3, 2 dia), 3.38 (m, 2H, H28), 
3.05-2.82 (m, 4H, H19, H9), 2.68 (m, 1H, H2a), 2.45 (m, 1H, H2b).  
13C NMR (100 MHz, DMSO-d6) δ ppm 171.7 (C16), 170.9 (C17), 169.5 (C27), 168.2 (C1), 
156.6,156.3 (C31, C32), 148.0, 147.3 (C22, C23), 138.3 (C29), 136.9 (C10), 129.9, 129.4, 129.0, 128.9, 
128.2, 126.5,  123.9, 123.3, 121.1, 119.3, 118.5, 116.3 , 112.9, 111.5 (C11, C12, C13, C14, C15, C21, 
C24, C25, C30, C33, C34, C35, C36, C37, C38, C39, C40), 55.3 (OCH3), 55.2 (OCH3), 53.7;53.6 (C8, 2 
dia), 52.7 (C3), 51.8 (OCH3), 47.1 (C18), 41.7(C28), 37.4 (C19), 36.7 (C9), 32.9 (C2).  
C39H41F3N4O8 
M = 750.29 g/mol 
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19F (188 MHz, CDCl3) δ ppm   -74.9 (d, J = 7.0 Hz), -75.0 (d, J = 6.9 Hz), ratio between the two 
diastereomers is 40-60% respectively.  
Rf: 0.5 (EtOAc/cyclohexane: 70/30) 
mp: 138-140 °C (crude) 
IR (cm-1 ): 3277 (NH), 1741 (C=O), 1634 (C=O), 1161 (C-O), 1118 (C-O), 696 (CF3)  
MS (ESI Positive) m/z: 751 [M+H]+ 
Elemental Anal. 
 
 
 
 
 
 
SYNTHESIS OF FLUORINATED MOLECULE  55      
 
3-Phenyl-2-(4,4,4-trifluoro-3-{N’-[2-(3-   
phenoxyphenyl)acetyl]hydrazino}butyrylamino)propionic acid methyl ester 55. 
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To a solution of the 76 (309 mg, 0.69 mmol) and 3-phenoxyphenylacetic acid (174 mg, 0.76 mmol, 
1.1 eq) in dry DMF (16 mL) was added, after stirring for 5 min at room temperature, 2,4,6-collidine 
(368 µL, 2.76 mmol, 4.0 eq), HOBt (103 mg, 0.76 mmol, 1.1 eq), and HBTU (288 mg, 0.76 mmol, 
1.1 eq). The mixture was stirred at room temperature under argon atmosphere for 24 h. After 
removal of the solvent under reduced pressure, the residue was dissolved in EtOAc (13 mL). The 
% Calcul (+ 0.75 H2O) Found 
C 61.32 61.37 
H   5.62   5.61 
N   7.34   7.31 
 
C28H28F3N3O5 
M = 543.20 g/mol 
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organic phase was successively washed with 10% aqueous citric acid (13 mL), water (13 mL), 10% 
aqueous K2CO3 (13 mL) and brine (13 mL). The organic layer was dried over Na2SO4, filtered and 
concentrated.  Purification by chromatography on silica gel, using EtOAc/cyclohexane (6/4) as 
eluent, 
 
afforded 159 mg (42%) of 55 as a white powder. 
  
1H NMR (400 MHz, DMSO-d6) δ ppm 9.64 (s, 1H, H6), 8.60;8.59 (2d, J = 7.7 and 7.6 Hz, 1H, H7, 
2 dia), 7.40-7.11 (m, 9H, H11, H12, H13, H14, H15, H21, H26, H27, H28), 7.02-6.84 (m, 5H, H22, H30, H25, 
H29, H20), 5.44 (br s, 1H, H5), 4.48 (m, 1H, H8), 3.72 (m, 1H, H3), 3.57 (s, 3H, OCH3), 3.38 (m, 2H, 
H18), 3.01 (dd, J = 13.8 and 5.8 Hz, 1H, H9a), 2.90 (m, 1H, H9b), 2.49 (m, 1H, H2a), 2.44 (dd, J = 
12.8 and 6.1 Hz, 1H, H2b). 
13C NMR (100 MHz, DMSO-d6) δ ppm 171.8-171.7 (C16, 2 dia), 169.6;169.5 (C17, 2 dia), 168.1 
(C1), 156.5 (C23, C24), 137.9 (C19), 137.0;136.9 (C10, 2 dia), 130.0 (C26, C28), 129.7 (C21), 129.0 (C12, 
C14), 128.2 (C11, C15), 126.5 (C13), 124.1 (C20), 123.4 (C27), 119.1 (C30), 118.6 (C25, C29), 116.7 
(C22), 57.5 (q, J = 26.0, C3), 53.70;53.60 (C8, 2 dia), 51.8 (OCH3), 40.1 (C18), 36.7 (C9), 33.0 (C2).     
19F (188 MHz, DMSO-d6) δ ppm -74.9 (d, J = 7.1 Hz), -75.2 (d, J = 6.8 Hz).  
Rf: 0.6 (EtOAc/cyclohexane: 60/40) 
mp: 82-84 °C (crude) 
IR (cm-1 ): 3285 (NH), 1737 (C=O), 1637 (C=O), 1164 (C-O), 1118 (C-O), 693 (CF3) 
MS (ESI Positive) m/z: 566 [M+Na]+ 
Elemental Anal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 % Calcul Found 
C 61.87 61.61 
H   5.19   5.34 
N   7.73   7.53 
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SYNTHESIS OF FLUORINATED MOLECULE   56    
 
2-{3-[N’-(2-Benzyloxycarbonylamino-6-tert-butoxycarbonylaminohexanoyl)hydrazino]-4,4,4-
trifluorobutyrylamino} -3-phenylpropionic acid methyl ester 80. 
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To a solution of 76 (1.22 g, 2.73 mmol) and Nα-BOC-Nε-Z-L-lysine (1.52 g, 4.00 mmol, 1.5 eq) in 
dry DMF (20 mL) was added, after stirring for 5 min at room temperature, DIPEA (2.7 mL, 16.33 
mmol, 6.0 eq), HOBt (540 mg, 4.00 mmol, 1.5 eq) and HBTU (1.52 g, 4.00 mmol, 1.5 eq). The 
mixture was stirred at room temperature under argon atmosphere for 68 h. After removal of the 
solvent under reduced pressure, the residue was dissolved in EtOAc (15 mL). The organic phase 
was washed with 10% aqueous citric acid (15 mL), water (15 mL), 10% aqueous K2CO3 (15 mL) 
and brine (15 mL). The organic layer was dried over Na2SO4, filtered and concentrated. A 
purification by chromatography on silica gel, eluting with EtOAc/cyclohexane (4/6)
 
and
 
a trituration 
in petroleum ether afforded 1.09 g (57%) of 80 as a white solid. 
 
 1H NMR (400 MHz, DMSO-d6) δ ppm 9.42 (m, 1H, H6), 8.61 (d, J = 7.6 Hz, 1H, H7), 7.40-7.19 
(m, 11 H, H11, H12, H13, H14, H15, H23, H27, H28, H29, H30, H31), 6.81 (m, 1H, H32), 5.40 (bs, 1H, H5), 
5.00 (s, 2H, H25), 4.49 (m, 1H, H8), 3.83 (m, 1H, H18 ), 3.74 (m, 1H, H3), 3.58 (s, 3H, OCH3), 3.05-
2.89 (m, 4H, H9, H22), 2.46 (m, 2H, H2), 1.46 (m, 2H, H19), 1.40-1.28 (m, 11H, H21, CH3Boc), 1.26 
(m, 2H, H20). 
C33H44F3N5O8 
M = 695.31 g/mol 
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13C NMR (100 MHz, DMSO-d6) δ ppm 171.8 (C16), 168.1 (C1), 156.1 (C24), 155.2 (C33), 137.3 
(C26), 137.0 (C10), 129.0, 128.9, 128.3, 128.2, 127.7, 126.5 (C11, C12, C13, C14,  C15, C27, C28, C29, C30, 
C31), 78.0 (CBoc), 65.1 (C25), 57.5 (q, J = 20.9 Hz, C3), 53.6 (C8), 52.8 (C18), 51.8 (OCH3), 39.7 
(C22), 36.7 (C9), 32.8 (C2), 31.3 (C19), 29.0 (C21), 28.1 (CH3Boc), 22.7 (C20).  
19F (188 MHz, DMSO-d6) δ ppm  -76.4 (d, J = 7.4 Hz), -76.5 (d, J = 7.2 Hz).  
Rf: 0.6 (EtOAc/cyclohexane: 70/30) 
mp: 92-94 °C (crude) 
IR (cm-1 ): 3321 (NH), 1741 (C=O), 1686 (C=O), 1634 (C=O), 1161 (C-O), 1127 (C-O), 698 (CF3)  
HRMS (EI) m/e: [M+Na]+  calcd 718.3040, found 718.3019  
Elemental Anal.  
 
 
 
 
 
 
2-{3-[N’-(2-Amino-6-benzyloxycarbonylaminohexanoyl)hydrazino]-4,4,4-trifluoro-
butyrylamino}-3-phenylpropionic acid methyl ester 81. 
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Compound 80 (800 mg, 1.15 mmol) was dissolved in dry CH2Cl2 (10 mL) and trifluoroacetic acid 
(5 mL, 69.00 mmol, 60.0 eq) was added dropwise at room temperature. The reaction mixture was 
stirred at room temperature for 2 h. Solvent was evaporated under reduced pressure to yield a brown 
 % Calcul (+ 1.5 H2O) Found 
C 54.87 54.87 
H   6.57   5.81 
N   9.70   9.41 
 
C28H36F3N5O6.CF3COOH 
M = 709.28 g/mol 
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solid (815 mg). This crude product 81 was used without any further purification in the course of the 
synthesis. 
  
1H NMR (400 MHz, DMSO-d6) δ ppm  9.94 (d, J = 4.2 Hz, 1H, H6), 8.64, 8.61 (2d,  J = 8.4 and 
8.8 Hz, 1H, H7), 8.17 (m, 3H, H32), 7.38-7.12 (m, 11 H, H11, H12, H13, H14, H15, H23, H27, H28, H29, 
H30, H31), 5.70 (m, 1H, H5), 5.00 (s, 2H, H25), 4.50 (m, 1H, H8), 3.80 (m, 1H, H3 ), 3.63 (m, 1H, 
H18), 3.58 (s, 3H, OCH3), 3.02 (m, 1H, H9a), 2.96 (m, 2H, H22), 2.89 (m, 1H, H9b), 2.49 (m, 2H, H2), 
1.66 (m, 2H, H19), 1.39 (m, 2H, H21), 1.26 (m, 2H, H20). 
13C NMR (100 MHz, DMSO-d6) δ ppm 171.8;171.7 (C16, 2 dia), 168.2, 168.1 (C1, C17), 156.1 
(C24), 137.2;137.0 (C26,C10), 129.0, 128.9, 128.3, 128.2, 127.7, 126.6 (C11, C12, C13, C14,  C15, C27, 
C28, C29, C30, C31), 65.1 (C25), 57.5 (q, J = 22.4 Hz, C3), 53.6 (C8), 51.8 (OCH3), 50.9 (C18), 40.1 
(C22), 36.7 (C9), 32.8 (C2), 30.6 (C19), 28.9 (C21), 21.4 (C20).  
19F (188 MHz, DMSO-d6) δ ppm -76.6 (d, J = 7.5 Hz), -76.7 (d, J = 5.6 Hz), -76.4 (CF3COOH). 
Rf: 0.5 (EtOAc/MeOH/NH4OH: 79/20/1) 
mp: 92-94 °C (crude) 
IR (cm-1 ): 3297 (NH), 1666 (C=O), 1172 (C-O), 1130 (C-O), 697 (CF3)  
MS (ESI Negative) m/z: 596 [M+H]+ 
Elemental Anal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
% Calcul (+ 2 H2O) Found 
C 45.12 47.83 
H 
N 
  5.42 
  9.40 
  5.01 
  8.93 
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2-[3-(N’-{6-Benzyloxycarbonylamino-2-[2-(3-phenoxy-phenyl)acetylamino]hexanoyl}-  
hydrazino)-4,4,4-trifluoro-butyrylamino]-3-phenyl-propionic acid methyl ester 82. 
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To a solution of 81 (400 mg, 0.56 mmol) and 3-phenoxyphenylacetic acid (141 mg, 0.62 mmol, 1.1 
eq) in dry DMF (12 mL) was added, after stirring for 5 min at room temperature, DIPEA (370 µL, 
2.24 mmol, 4.0 eq), HOBt (84 mg, 0.62 mmol, 1.1 eq) and HBTU (235 mg, 0.62 mmol, 1.1 eq). 
The mixture was stirred at room temperature under argon atmosphere for 24 h. After removal of the 
solvent under reduced pressure, the residue was dissolved in EtOAc (15 mL). The organic phase 
was successively washed with 10% aqueous citric acid (15 mL), water (15 mL), 10% aqueous 
K2CO3 (15 mL) and brine (15 mL). The organic layer was dried over Na2SO4, filtered and 
concentrated. A purification by chromatography on silica gel, eluting with EtOAc/cyclohexane 
(6/4), afforded 322 mg (71%) of 82 as a white powder. 
 
1H NMR (400 MHz, DMSO-d6) δ ppm 9.57 (br s, 1H, H6), 8.61 (m, 1H, H7), 8.23, 8.21 (2d, J = 
7.8 Hz, 1H, H32, 2dia), 7.40-7.11 (m, 15 H, H11, H12, H13, H14, H15, H23, H27, H28, H29, H30, H31, H40, 
H41, H42, H45), 7.02-6.98 (m, 3H, H39, H43, H46), 6.92 (s, 1H, H36), 6.83 (d, J = 8.0 Hz, 1H, H44), 5.43 
(br s, 1H, H5), 5.00 (s, 2H, H25), 4.47 (m, 1H, H8), 4.16 (m, 1H, H18 ), 3.74 (m, 1H, H3), 3.57 (s, 3H, 
OCH3), 3.40 (d, J = 15 Hz, 1H, H34a), 3.48 (d, J = 15 Hz, 1H, H34b), 3.01 (dd, J = 13.8 and 5.6 Hz, 
1H, H9a), 2.93-2.88 (m, 3H, H9b, H22), 2.46 (m, 2H, H2), 1.53 (m, 2H, H19), 1.36 (m, 2H, H21), 1.20 
(m, 2H, H20).  
 
 
C42H46F3N5O8 
M = 805.33 g/mol 
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13C NMR (100 MHz, CD3OD) δ ppm 173.6 (C16, C17), 171.2;171.1 (C1), 158.9 (C24), 158.6 (C33), 
138.8 (C35), 138.4 (C26), 138.0 (C10), 130.9, 130.8, 130.2, 129.5, 128.9, 128.8, 127.9, 125.1, 124.4, 
120.5, 119.9, 118.2 (C11, C12, C13, C14,  C15, C27, C28, C29, C30, C31, C36, C39, C40, C41, C42,  C43, C44, C45 
,C46), 67.3 (C25), 59.5 (q, J = 27.6 Hz, C3), 55.5;55.4 (C8, 2 dia), 53.3;53.2 (OCH3, 2 dia), 52.8;52.7 
(C18, 2 dia), 43.3 (C34), 41.4 (C22), 38.4;38.3 (C9, 2 dia), 34.1 (C2), 32.7;32.6 (C19, 2 dia), 30.4 (C21), 
23.9 (C20).  
19F (188 MHz, DMSO-d6) δ ppm  -76.4 (d, J = 7.3 Hz). 
Rf: 0.4 (EtOAc/cyclohexane: 70/30) 
mp: 130-132 °C (crude) 
IR (cm-1 ): 3386 (NH), 1739 (C=O), 1687 (C=O), 1634 (C=O), 1166 (C-O), 1122 (C-O), 697 (CF3)  
MS (ESI Positive) m/z: 806 [M+H]+ 
Elemental Anal. 
 
 
 
 
 
2-[3-(N’-{6-Amino-2-[2-(3-phenoxyphenyl)acetylamino]hexanoyl}hydrazino)-4,4,4-trifluoro-
butyrylamino]-3-phenyl-propionic acid methyl ester, trifluoro-acetic acid salt 56. 
 
 
 
To a solution of 82 (264 mg, 0.33 mmol) in MeOH (20 mL) at room temperature was added Pd/C 
20% (53 mg). The mixture was hydrogenated at athmospheric pressure overnight and filtered 
through a pad of Celite. Before the total evaporation under reduced pressure, trifluoro acetic acid 
(245 µL, 3.3, 10 eq) was added to give 56 as a beige hygroscopic solid (259 mg) without any 
further purification. 
 
% Calcul (+ 0.75 H2O) Found 
C 61.60 61.65 
H 
N 
  5.86 
  8.55 
  5.67 
  8.45 
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C34H40F3N5O6.CF3COOH 
M = 785.31 
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1H NMR (400 MHz, DMSO-d6) δ ppm 9.60 (br s, 1H, H6), 8.62, 8.60 (2d, J = 5.8 and 6.9 Hz, 1H, 
H7, 2dia), 8.25, 8.23 (2d, J = 8.2 and 8.3 Hz, 1H, H32, 2dia), 7.73 (br s, 3H, H23), 7.41-6.83 (m, 14 
H, H11, H12, H13, H14, H15, H36, H39, H40, H41, H42, H43, H44, H45, H46), 5.43 (br s, 1H, H5), 4.47 (m, 
1H, H8), 4.18 (br s, 1H, H18), 3.75 (br s, 1H, H3), 3.58 (1s, 3H, OCH3), 3.46 (m, 2H, H34), 3.01 (m, 
1H, H9a), 2.92 (m, 1H, H9b), 2.70 (br s, 2H, H22), 2.43 (m, 2H, H2), 1.58-1.48 (m, 4H, H19, H21), 
1.24 (m, 2H, H20).  
13C NMR (100 MHz, DMSO-d6) δ ppm 171.8;171.7 (C16, 2dia), 171.0 (C17), 169.7 (C33), 
168.2;168.1 (C1, 2dia), 157.9 (q, J = 31.0 Hz, CF3COOH) 156.6,156.5 (C37, C38), 138.5 (C35), 
137.0;136.9 (C10, 2dia), 130.0, 129.6, 129.0, 128.6, 128.2, 126.6, 124.2, 123.4, 119.2, 118.6, 116.5 
(C11, C12, C13, C14, C15, C36, C39, C40, C41, C42, C43, C44, C45,C46), 117.3 (q, J = 299.0 Hz, 
CF3COOH), 57.5 (q, J = 23.5 Hz, C3), 53.7;53.6 (C8, 2 dia), 51.8 (OCH3), 50.8;50.7 (C18, 2 dia), 
41.8 (C34), 38.6 (C22), 36.7 (C9), 33.0 (C2), 31.5 (C19), 26.5 (C21), 22.1(C20). 
19F (188 MHz, CD3OD) δ ppm (-78.0) − (-78.1) (m), -78.8 (CF3COOH). 
mp: 90-92 °C (crude) 
IR (cm-1 ): 3266 (NH), 1730 (C=O), 1655 (C=O), 1177 (C-O), 1128 (C-O), 695 (CF3)  
MS (ESI Positive) m/z: 672 [M+H]+ 
Elemental Anal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
% Calcul (+ 3 H2O) Found 
C 51.51 51.37 
H 
N 
  5.66 
  8.35 
  5.11 
  7.91 
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2-{3-[N’-(6-Amino-2-tert-butoxycarbonylaminohexanoyl)hydrazino]-4,4,4-
trifluorobutyrylamino}-3-phenylpropionic acid methyl ester, citric acid salt 83. 
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To a solution of 80 (100 mg, 0.14 mmol) in MeOH (10 mL) at room temperature was added Pd/C 
20% (20 mg). The mixture was hydrogenated at atmospheric pressure overnight and filtered through 
a pad of Celite. Before the total evaporation under reduced pressure, citric acid monohydrate (10 
mg, 0.05 mmol, 0.35 eq) was added. After washing with several organic solvents we obtained 55 
mg of 83 (51%)  as a white powder. 
 
1H NMR (300 MHz, CD3OD) δ ppm 7.30-7.20 (m, 5 H, H11, H12, H13, H14, H15), 4.70 (m, 1H, H8), 
4.0 (m, 1H, H18), 3.78 (m, 1H, H3), 3.69,3.68 (2s, 3H, OCH3, 2dia), 3.20-2.70 (m, 8H, H9, H22, 2 
CH2 citric acid), 2.53 (m, 2H, H2), 1.78-1.52 (m, 4H, H19, H21), 1.48-1.41 (m, 11H, CH3Boc, H20). 
 
13C NMR (75 MHz, CD3OD) δ ppm  176.8, 175.0 (C=O citric acid), 173.5, 171.2 (C16, C17), 157.0 
(C25), 138.1 (C10), 130.3, 129,5 (C12, C14, C11, C15), 127.9 (C13), 80.7 (CBoc), 60.0 (C–OH citric 
acid), 55.6;55.5 (C8, 2 dia), 54.6 (OCH3), 52.8;52.7 (C18, 2 dia), 41.0 (C22), 38.4 (C9), 34.1 (C2), 
32.8 (C19), 29.8 (C21), 28.7 (CH3Boc),  23.9 (C20).                                   
19F (188 MHz, CD3OD) δ ppm  -78.0  (d, J = 5.8 Hz), -78.1 (d, J = 6.3 Hz). 
mp: 260-262 °C (crude) 
MS (ESI Positive) m/z: 562 [M+H]+ 
Elemental Anal. 
 
 
 
 
 
 
% Calcul (+7 H2O 
and +3 citric acid ) 
Found 
C 39.17 38.81 
H   6.22   4.78 
N   5.32   5.81 
C25H38F3N5O6.HOC(COOH)(CH2COOH)2.H2O 
M = 771,43 g/mol 
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SYNTHESIS OF FLUORINATED MOLECULE  57     
 
N’-(2,2,2-Trifluoro-1-hydrazinocarbonylmethylethyl)hydrazinecarboxylic acid tert-butyl ester 
85. 
NH2
N
H
N
H
N
H
O CF3
O
O
1
2
3
4
5
6
7
8
9
 
 
To a solution of 72 (2.0 g, 6.7 mmol) in ethanol (50 mL) was added hydrazine monohydrate (3.34 g, 
66.7 mmol, 10.0 eq) and the mixture was stirred at room temperature overnight. After removal of 
the solvent under reduced pressure, the product 85 was obtained as 2.11 g of a white solid 
(quantitative yield). 
 
1H NMR (300 MHz, CDCl3) δ ppm 3.60 (m, 1H, H4), 2.32 (m, 2H, H6), 1.32 (s, 9H, CH3Boc). 
13C NMR (75 MHz, CDCl3) δ ppm 173.6 (C7), 129.4 (q, J = 286.3 Hz, C5), 85.0 (CBoc), 62.5 (q, J 
= 27.7 Hz, C4), 35.4 (C6),  32.0 (CH3Boc).  
19F (188 MHz, CD3OD) δ ppm  -75.1 (d, J = 7.1 Hz). 
 
 
N’-(1-{N’-[3-(3,4-Dimethoxyphenyl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)propionyl] 
hydrazinocarbonylmethyl}-2,2,2-trifluoroethyl)hydrazinecarboxylic acid tert-butyl ester 86. 
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To a solution of the 85 (100 mg, 0.35 mmol) and Fmoc-L-3,4-dimethoxyphenylalanine (157 mg, 
0.35 mmol, 1.0 eq) in dry DMF (3 mL) was added, after stirring for 5 min at room temperature, 
C35H40F3N5O8 
M = 715.28 g/mol 
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2,4,6-collidine (140 µL, 1.05 mmol, 3.0 eq), HOBt (53 mg, 0.39 mmol, 1.1 eq) and HBTU (148 mg, 
0.39 mmol, 1.1 eq). The mixture was stirred at room temperature under argon atmosphere for 21 h. 
After removal of the solvent under reduced pressure, the residue was triturated with EtOAc to 
obtain 171 mg (68%) of 86 as a white solid. 
 
1H NMR (400 MHz, DMSO-d6) δ ppm 10.18 (br s, 2H, H8, H9), 8.41 (br s, 1H, H2), 7.81-7.86 (m, 
2H, Har), 7.60 (d, J = 7.2 Hz, 2H, Har), 7.23-7.40 (m, 5H, Har, H19), 6.98 (d, J = 2.8 Hz, 1H, H15), 
6.80 (br s, 2H, H14, H18), 5.13 (br s, 1H, H3), 4.28 (m,1H, H11), 4.10-4.14 (m, 3H, H22, H21), 3.84 (br 
s, 1H, H4), 3.70 (s, 3H, OCH3), 3.66 (s, 3H, OCH3), 2.94 (m, 1H, H12a), 2.72 (m, 1H, H12b), 2.50 (m, 
2H, H6), 1.37 (s, 9H, CH3Boc).  
 
13C NMR (100 MHz, DMSO-d6) δ ppm 170.8;170.7 (C7, 2 dia), 167.4 (C10), 155.7 (C20), 148.9 
(C17), 147.9 (C16), 144.1-144.3 (C23, C34), 141.1 (C28, C29), 130.8 (C13), 128.0, 127.5, 125.7 (C24, 
C25, C26, C31, C32, C33), 121.8 (C14), 120.5 (C27, C30), 113.9 (C18), 112.3 (C15), 79.3 (CBoc), 66.2 
(C21), 55.9-56.0 (2 OCH3),  55.3 (C11), 47.0 (C22), 31.9 (C6), 28.6 (CH3Boc). 
19F (188 MHz, DMSO-d6) δ ppm -73.7. 
Rf: 0.4 (EtOAc/cyclohexane: 70/30) 
mp: 208-210 °C (crude) 
IR (cm-1 ): 3284 (NH), 1696 (C=O), 1159 (C-O), 1124 (C-O), 738 (CF3)  
MS (ESI Positive) m/z: 738 [M+Na]+  
Elemental Anal. 
 
 
 
 
 
 
 
 
 
 
 
 
 % Calcul Found 
C 58.73 58.35 
H   5.63   5.55 
N   9.79   9.76 
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N’-(1-{N’-[2-Amino-3-(3,4-dimethoxyphenyl)propionyl]hydrazinocarbonylmethyl}-2,2,2-
trifluoroethyl)-hydrazinecarboxylic acid tert-butyl ester 87.   
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To compound 86 (382 mg, 0.53 mmol) was added a solution of piperidine in DMF (10% v/v, 5 
mL). The mixture was stirred at room temperature for 1.30 h. The organic phase was evaporated. 
The residue was triturated in Et2O to yield 231 mg (88%) of 87 as a white solid. 
 
1H NMR (300 MHz, DMSO-d6) δ ppm 8.42 (br s, 1H, H2), 6.83 (br s, 1H, H15), 6.81 (br s, 1H, 
H18), 6.72 (m, 1H, H14), 5.14 (bs, 1H, H3), 3.84 (m, 1H, H11), 3.72 (s, 3H, OCH3), 3.70 (s, 3H, 
OCH3), 3.44 (m, 1H, H4), 2.89 (m, 1H, H12a ), 2.84 (m, 1H, H12b), 2.54 (dd, J = 16.8 and 8.2 Hz, 1H, 
H6a), 2.49 (m, 1H, H6b), 1.38 (s, 9H, CH3Boc).  
13C NMR (75 MHz, DMSO-d6) δ ppm 172.7 (C7), 166.7 (C1), 148.4 (C17), 147.2 (C16), 130.7 
(C14), 121.3 (C14), 113.1 (C15), 111.6 (C18), 78.8 (CBoc), 55.4 (OCH3), 55.3 ( OCH3), 54.9 (C11), 
40.8 (C12), 31.4 (C6), 28.1 (CH3Boc).  
19F (188 MHz, DMSO-d6) δ ppm (-73.6) − (- 73.8) (m). 
Rf: 0.1 (CH2Cl2/MeOH: 90/10) 
mp: 146-148 °C (crude) 
IR (cm-1 ): 3270 (NH), 3261 (NH), 1726 (C=O), 1678 (C=O), 1159 (C-O), 1130 (C-O), 688 (CF3) 
MS (ESI Positive) m/z: 516 [M+Na]+ 
Elemental Anal. 
 
 
 
 
 
 
% Calcul(+ 0.5 H2O) Found 
C 47.83          47.86 
H   6.23            6.42 
N 13.95         13.50 
 
C20H30F3N5O6 
M = 493.21 g/mol 
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N-[1-(N-{3-(3,4-Dimethoxyphenyl)-2-[2-(3-phenoxyphenyl)acetylamino]propionyl}-
hydrazinocarbonylmethyl)-2,2,2-trifluoroethyl]hydrazinecarboxylic acid tert-butyl ester 57.   
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To a solution of 87 (76 mg, 0.15 mmol) and 3-phenoxyphenylacetic acid (38 mg, 0.17 mmol, 1.1 
eq) in dry DMF (4 mL) was added, after stirring for 5 min at room temperature, 2,4,6-collidine (60 
µL, 0.45  mmol, 3.0 eq), HOBt (23 mg, 0.17 mmol, 1.1 eq) and HBTU (64 mg, 0.17 mmol, 1.1 eq). 
The mixture was stirred at room temperature under argon atmosphere for 24 h. After removal of the 
solvent under reduced pressure, the residue was triturated in EtOAc (15 mL) to obtain 88 mg (84%) 
of 57 as a white solid.  
 
1H NMR (400 MHz, DMSO-d6) δ ppm 10.20, 10.10 (2s, 2H, H8, H9), 8.41 (s, 1H, H2), 8.30 (m, 
1H, H19), 7.35 (t, J = 7.8 Hz, 2H, H27,H29), 7.20 (t, J = 8.3 Hz, 1H, H32), 7.12 (t, J = 7.8 Hz, 1H, 
H28), 7.00 (d, J = 7.8 Hz, 2H, H26, H30), 6.87-6.69 (m, 6H, H18, H14, H15 H23, H31, H33), 5.13 (s, 1H, 
H3), 4.55 (m, 1H, H11), 3.85 (br s, 1H, H4), 3.67 (s, 6H, 2 OCH3), 3.40 (m, 2H, H21), 2.93 (m, 1H, 
H12a), 2.70 (m, 1H, H12b), 2.49 (m, 2H, H6), 1.38 (s, 9H, CH3Boc). 
13C NMR (100 MHz, DMSO-d6) δ ppm 170.0 (C20), 170.1, 167.4 (C7, C10), 157.1 (C25), 156.8 
(C24), 148.9, 147.9 (C16, C17), 138.8 (C22), 130.4 (C27, C29), 129.9 (C32), 123.8 (C28), 119.0 (C26, C30), 
124.5, 121.7, 119.8, 116.8, 113.7, 112.1 (C18, C14, C15, C23, C31, C33), 79.3 (CBoc), 55.9 (OCH3), 55.8 
(OCH3), 52.9  (C11), 42.2 (C21), 38.0 (C12), 31.9 (C6), 28.6 (CH3Boc).  
19F (188 MHz, DMSO-d6) δ ppm (-73.6) − (- 73.8) (m). 
Rf: 0.4 (EtOAc/cyclohexane: 70/30) 
mp: 184-186 °C (crude) 
IR (cm-1 ): 3216 (NH), 1699 (C=O), 1653 (C=O), 1159 (C-O), 1121 (C-O), 691 (CF3)  
MS (ESI Positive) m/z: 726 [M+Na]+  
 
 
C34H40F3N5O8 
M = 703.28 g/mol 
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Elemental Anal.  
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4,4,4-Trifluoro-3-hydrazinobutyric acid ethyl ester, trifluoroacetic acid salt 90. 
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Compound 72 (200 mg, 0.66 mmol) was dissolved in dry CH2Cl2 (2,5 mL) and trifluoroacetic acid 
(2.5 mL, 33.0 mmol, 50.0 eq) was added dropwise at room temperature. The reaction mixture was 
stirred at room temperature for 2 h. Solvent was evaporated under reduced pressure to yield light 
brown solid oil (228 mg, with excess of TFA). Azeotropic removal of excess TFA with toluene. 
This crude product 90 was used without any further purification in the course of the synthesis.  
 
 
1H NMR (300 MHz, CDCl3) δ ppm 6.76 (br s, 3 H, H8), 4.30-4.19 (m, 3H, H5, H2 ), 2.70 (m, 2H, 
H4), 1.27 (t, J = 6.6 Hz, 3H, H1).  
 
13C NMR (75 MHz, CDCl3) δ ppm 171.2 (C3), 159.4 (q, J =42.0 Hz, CF3COOH), 114.8 (q, J = 
284.0 Hz, CF3COOH), 62.4 (C2,), 32.7 (C4), 13.7 (C1). 
19F (188 MHz, CDCl3) δ ppm  -75.3 (d, J = 6.5 Hz), -75.5 (d, J = 6.5 Hz), -76.3 (CF3COOH). 
Rf: 0.4 (EtOAc/MeOH/NH4OH: 79/20/1) 
 
 
 
 
 
 
 
 
% Calcul Found 
C 58.03 57.01 
H   5.73   5.68 
N   9.95   9.86 
 
C6H11F3N2O2.CF3COOH 
M = 314.18 g/mol 
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3-(N’-Benzyloxycarbonylhydrazino)-4,4,4-trifluorobutyric acid ethyl ester 91. 
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Compound 90 (207 mg, 0.66 mmol) was dissolved in CH2Cl2 (6 mL) and Benzylchloroformiate 
(104 µL, 0.73 mmol, 1.1 eq) was added dropwise at 0 °C. After was added DIPEA (287 µL, 1.65 
mmol, 2.5 eq) and  the reaction mixture was stirred at room temperature for 21 h. After removal of 
the solvent under reduced pressure, the residue was dissolved in EtOAc (9 mL). The organic phase 
was successively washed with 10% aqueous citric acid (9 mL), water (9 mL), 10% aqueous K2CO3 
(9 mL) and brine (9 mL). The organic layer was dried over Na2SO4, filtered and concentrated. A 
purification by chromatography on silica gel, eluting with EtOAc/cyclohexane (5/5), afforded 168 
mg (76%) of 91 as a colorless oil. 
 
1H NMR (200 MHz, CDCl3) δ ppm 7.42-7.28 (m, 5 H, Har), 6.29 (br s, 1 H, H8), 5.11 (s, 2H, H10), 
4.20 (q, J = 7.2 Hz, 2H, H2), 3.89 (m, 1H, H5 ), 2.58 (m, 2H, H4), 1.22 (t, J = 7.1 Hz, 3H, H1). 
 
13C NMR (75 MHz, CDCl3) δ ppm 169.7 (C3), 157.2 (C9), 135.7 (C11), 128.6 (C13, C15), 128.4 
(C14), 128.2 (C12, C16), 125.2 (q, J = 279.8 Hz, C6), 67.5 (C10), 61.5 (C2), 58.2 (q, J = 27.8 Hz, C5), 
32.1 (C4), 14.0 (C1).  
19F (188 MHz, CDCl3) δ ppm -75.5 (d, J = 7.2 Hz). 
Rf: 0.6 (EtOAc/cyclohexane: 40/60) 
IR (cm-1 ):  3336 (NH), 1722 (C=O), 1159 (C-O), 1128 (C-O), 699 (CF3)   
MS (ESI Positive) m/z: 357 [M+Na]+ 
 
Elemental Anal. 
 
 
 
 
 
 
 
 % Calcul (+ 0.5 H2O) Found 
C 49.00 49.05 
H   5.30   4.91 
N   8.17   8.49 
C14H17F3N2O4 
M = 334.11 g/mol 
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N’-(2,2,2-Trifluoro-1-hydrazinocarbonylmethylethyl)hydrazinecarboxylic acid benzyl ester 
92. 
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To a solution of 91 (148 mg, 0.44 mmol) in EtOH (3 mL) was added hydrazine monohydrate (214 
µL, 4.4 mmol, 10.0 eq) and  the reaction mixture was stirred at room temperature for 23 h. After 
removal of the solvent under reduced pressure, the final product 92 was obtained as a white solid 
(140 mg, quantitative yield). 
 
1H NMR (200 MHz, CD3OD) δ ppm 7.33-7.23 (m, 5 H, H12, H13, H14, H15, H16), 5.09 (s, 2H, H10), 
3.80 (m, 1H, H5 ), 2.48 (dd, J = 4.8 and 15.0 Hz, 1H, H4a), 2.39 (m, 1H, H4b). 
 
13C NMR (75 MHz, CD3OD) δ ppm 170.9 (C3), 159.6 (C9), 138.0 (C11), 129.5 (C13, C15), 129.1 
(C12, C16), 129.0 (C14), 123.3 (q, J = 279.8 Hz, C6), 67.9 (C10), 59.5 (q, J = 27.8 Hz, C5), 32.6 (C4).  
19F (188 MHz, CD3OD) δ ppm -76.9 (d, J = 7.3 Hz). 
Rf: 0.2 (EtOAc/cyclohexane: 70/30) 
mp: 146-148 °C (crude) 
IR (cm-1 ):  3307 (NH), 1705 (C=O), 1654 (C=O), 1174 (C-O), 1120 (C-O), 696 (CF3)   
MS (ESI Positive) m/z: 343 [M+Na]+ 
Elemental Anal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 % Calcul (+ 0.4 H2O) Found 
C 44.03 43.93 
H   4.88   4.54 
N 17.12 17.57 
C12H15F3N4O3 
M = 320.11 g/mol 
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N’-(3-{N’-[3-(3,4-Dimethoxyphenyl)-2-(9H-fluoren-9-
ylmethoxycarbonylamino)propionyl]hydrazino}-3-oxo-1-
trifluoromethylpropyl)hydrazinecarboxylic acid benzyl ester 93. 
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To a solution of the 92 (359 mg, 1.12 mmol) and Fmoc-L-3,4-dimethoxyphenylalanine (501 mg, 
1.12 mmol, 1.0 eq) in dry DMF (13 mL) was added, after stirring for 5 min at room temperature, 
2,4,6-collidine (447 µL, 3.36 mmol, 3.0 eq), HOBt (166 mg, 1.23 mmol, 1.1 eq) and HBTU (467 
mg, 1.23 mmol, 1.1 eq). The mixture was stirred at room temperature under argon atmosphere for 
40 h. After removal of the solvent under reduced pressure, the residue was triturated in EtOAc (15 
mL) to obtain 560 mg (67%) of 93 as a white solid.  
 
1H NMR (400 MHz, DMSO-d6) δ ppm 10.23 (br s, 1H, H18), 10.15 (br s, 1H, H17), 8.90 (br s, 1H, 
H8), 7.90 (d, J = 7.4 Hz, 2H, H36, H39), 7.70 (d, J = 7.6 Hz, 1H, H28), 7.43-7.26 (m, 11 H, H12, H13, 
H14, H15, H16,  H33, H34, H35, H40, H41, H42), 7.01 (br s, 1H, H26), 6.89-6.80 (m, 2 H, H23, H27), 5.36 
(br s, 1H, H7), 5.08 (s, 2H, H10), 4.32 (m, 1H, H20), 4.19-4.10 (m, 3H, H30, H31), 3.93 (m, 1H, H5 ), 
3.72 (s, 3H, OCH3), 3.68 (s, 3H, OCH3), 2.99 (m, 1H, H21a), 2.76 (m, 1H, H21b), 2.52 (m, 2H, H4). 
 
13C NMR (100 MHz, DMSO-d6 ) δ ppm 170.6;170.4 (C19, 2 dia), 166.9 (C3), 157.0 (C9), 155.8 
(C29), 148.4, 147.4 (C24, C25), 143.8;143.7 (C32, C43, 2 dia), 140.6 (C37, C38), 136.8 (C11), 130.3 (C22), 
128.4, 127.9, 127.7, 127.6, 127.0, 125.3 (C12, C13, C14,  C15, C16, C33, C34, C35, C40, C41, C42), 120.1 
(C36, C39), 113.2 (C26), 121.2, 111.6 (C23, C27), 65.7;65.6 (C30, 2 dia), 59.7 (C10), 55.4 (OCH3), 55.3 
(OCH3), 54.9 (C20), 46.5 (C31), 37.3 (C21), 31.5 (C4).  
19F (188 MHz, DMSO-d6) δ ppm  (-73.6)−(-73.8) (m). 
Rf: 0.3 (CH2Cl2/MeOH: 90/10) 
mp: 202-204 °C (crude) 
C38H38F3N5O8 
M = 749.27 g/mol 
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IR (cm-1 ): 3284 (NH), 1696 (C=O), 1605 (C=O), 1171 (C-O), 1124 (C-O), 692 (CF3)   
MS (ESI Positive) m/z: 772 [M+Na]+ 
Elemental Anal. 
 
 
 
 
 
 
N’-(3-{N’-[2-Amino-3-(3,4-dimethoxyphenyl)propionyl]hydrazino}-3-oxo-1-trifluoromethyl-
propyl)hydrazinecarboxylic acid benzyl ester 94. 
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To compound 93 (70 mg, 0.10 mmol) was added a solution of piperidine in DMF (10% v/v, 2 mL). 
The mixture was stirred at room temperature for 1.30 h. The organic phase was evaporated. The 
residue was triturated in Et2O to yield 37 mg (78%) of 94 as a white powder. 
 
1H NMR (300 MHz, DMSO-d6) δ ppm 8.87 (br s, 1H, H8), 7.40-7.31 (m, 5 H, H12, H13, H14, H15, 
H16), 6.85-6.70 (m, 3 H, H23, H26, H27), 5.36 (br s, 1H, H7), 5.06 (s, 2H, H10), 3.90 (m, 1H, H20), 3.73 
(s, 3H, OCH3), 3.71 (s, 3H, OCH3), 3.45 (m, 1H, H5), 2.90 (m, 1H, H21a), 2.85 (m, 1H, H21b), 2.50 
(m, 2H, H4).  
 
13C NMR (75 MHz, DMSO-d6 ) δ ppm  172.8 (C19), 166.6 (C3), 156.9 (C9), 148.4, 147.2 (C24, 
C25), 136.7 (C11), 130.7 (C22), 128.3, 127.8, 127.7 (C12, C13, C14,  C15, C16), 113.1 (C26), 121.3, 111.6 
(C23, C27), 65.6 (C10), 55.0 (OCH3), 54.9 (OCH3), 54.3 (C20), 40.8 (C21), 31.4 (C4).  
19F (188 MHz, DMSO-d6) δ ppm -73.7 (d, J = 7.3 Hz). 
Rf: 0.8 (EtOAc/MeOH/NH4OH: 79/20/1) 
mp: 102-104 °C (crude) 
IR (cm-1 ): 3229 (NH), 1709 (C=O), 1602 (C=O), 1158 (C-O), 1118 (C-O), 696 (CF3)   
 % Calcul (+ 0.4 H2O) Found 
C 60.33 60.57 
H   5.18   4.97 
N   9.26   9.01 
C23H28F3N5O6 
M = 527.20 g/mol 
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MS (ESI Positive) m/z: 550 [M+Na]+ 
 
 
N’-[3-(N’-{3-(3,4-Dimethoxyphenyl)-2-[2-(3-
phenoxyphenyl)acetylamino]propionyl}hydrazino)-3-oxo-1-trifluoromethyl-
propyl]hydrazinecarboxylic acid benzyl ester 58. 
 
N
H
O
N
H
CF3
N
H
O
O
N
H
O
N
H
O
O
O
O
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21 22 23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
40
41
42
39
 
 
To a solution of 94 (178 mg, 0.34 mmol) and 3-phenoxyphenylacetic acid (84 mg, 0.37 mmol,  
1.1 eq) in dry DMF (11 mL) was added, after stirring for 5 min at room temperature, DIPEA (112 
µL, 0.68  mmol, 2.0 eq), HOBt (50 mg, 0.37 mmol, 1.1 eq) and HBTU (140 mg, 0.37 mmol, 1.1 
eq). The mixture was stirred at room temperature under argon atmosphere for 38 h. After removal 
of the solvent under reduced pressure, the residue was triturated in EtOAc (20 mL) to obtain 213 
mg (85%) of 58 as a white solid. 
 
1H NMR (400 MHz, DMSO-d6) δ ppm 10.22 (br s, 1H, H18), 10.11 (br s, 1H, H17), 8.85 (br s, 1H, 
H8), 8.33 (m, 1H, H28), 7.40-7.32 (m, 7H, H12, H13, H14, H15, H16, H36, H38), 7.22 (t, J = 8.1 Hz, 1H, 
H41), 7.14 (t, J = 7.1 Hz, 1H, H37), 6.98 (d, J = 7.9 Hz, 2H, H35, H39), 6.90-6.71 (m, 6 H, H23, H26, 
H27, H32, H40, H42), 5.35 (br s, 1H, H7), 5.07 (s, 2H, H10), 4.58 (m, 1H, H20), 3.91 (m, 1H, H5 ), 3.70 
(s, 6H, 2OCH3), 3.40 (m, 2H, H30), 2.96 (m, 1H, H21a), 2.71 (m, 1H, H21b), 2.55 (m, 2H, H4).  
 
13C NMR (100 MHz, DMSO-d6 ) δ ppm  170.2 ;170.0 (C19,  2 dia), 169.5 (C29), 166.9 (C3), 156.9 
(C9), 156.6 (C33), 156.3 (C34), 148.3, 147.4 (C24,C25), 138.4 (C31), 136.8 (C11), 130.0 (C36, C38), 
129.5 (C41), 128.3, 127.9, 127.7 (C12, C13, C14,  C15, C16), 124.0 (C42), 123.3 (C37), 121.2 (C27), 119.4 
(C32), 118.5 (C35,C39), 116.4 (C40), 113.1 (C26), 111.5 (C23), 65.6 (C10), 55.4 (OCH3), 55.3 (OCH3), 
52.5 (C20), 41.7 (C30), 37.6 (C21), 31.49 (C4).  
19F (188 MHz, DMSO-d6) δ ppm -73.7 (d, J = 4.9 Hz). 
Rf : 0.6 (CH2Cl2/MeOH: 90/10) 
C37H38F3N5O8 
M = 737.27 g/mol 
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mp: 178-180 °C (crude) 
IR (cm-1 ):  3271 (NH), 1704 (C=O), 1601 (C=O), 1161 (C-O), 1121 (C-O), 690 (CF3)   
MS (ESI Positive) m/z: 760 [M+Na]+ 
Elemental Anal. 
 
 
 
 
 
 
 
 
 
Reference of Chapter IV 
 
 
1. Nowick, J. S.; Pairish, M.; Lee, I. Q.; Holmes, D. L.; Ziller, J. W., An Extended β-Strand Mimic 
for a Larger Artificial beta -Sheet. J. Am. Chem. Soc. 1997, 119, (23), 5413-5424. 
 
 
 % Calcul (+0.25 H2O) Found 
C 59.91 59.93 
H   5.24   5.32 
N   9.44   9.57 
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IV.2.   Experimental part chapter III 
 
 
General chemical techniques: 
 
The Nα-Fmoc protected amino acids and HBTU were purchased from MultiSynTech (Witten, 
Germany). Peptide-synthesis grade DMF, NMP, piperidine and diethylether, ACN and TFA for 
spectroscopy were purchased from Biosolve (Valkenswaard, The Netherlands). 
HOBt, DIPEA, TFA, DCM, DMSO, and α-cyano-4-hydroxy-cinnamic acid for mass 
spectrometry were bought from Fluka (Taufkirchen, Germany). Methanol was obtained from J.T. 
Baker (Deventer, The Netherlands), TIS from Aldrich (Steinheim, Germany) and TFE from 
Acros (Geel, Belgium). Acetic anhydride, acetic acid, NaH2PO4 and Na2HPO4 were purchased 
from Merck (Darmstadt, Germany). THF was distilled on sodium/benzophenone before use. Pure 
products were obtained after liquid chromatography using Merck silica gel 60 (40-63 µm mesh). 
TLC analyses were performed with 0.25 mm 60 F254 silica plates (Merck). The plates were 
visualized with UV light (254 nm) or with a solution of vanillin in ethanol or with a solution of 
ninhydrin in ethanol. The mass spectra were recorded on Finnigan MAT 95, Varian MAT 311A, 
Finnigan TSQ 7000 and Future GSG spectrometer (Bruchsal, Germany) for MALDI-ToF-MS 
analysis. IR spectra were recorded on a Varian 800 FT-IR spectrometer. Optical rotations were 
measured on a Perkin-Elmer-Polarimeter 241 with sodium lamp at 589 nm in the specified 
solvent. NMR spectra were recorded on a Bruker AVANCE 300 (300.13 MHz) or a Bruker 
AVANCE 400 (400.13 MHz) or a Bruker AVANCE 600 (600.13 MHz). The 2D-NMR standard 
experiments DQF-COSY, 80 ms-TOCSY and 500 ms-ROESY the water resonance was 
suppressed by using the presaturation method. The concentration of the peptide samples prepared 
for CD measurements were determined UV spectrophotometrically on a Cary 100 Conc from 
Varian (Darmstadt, Germany) using 1 cm quartz cuvettes obtained from Hellma (Müllheim, 
Germany). CD spectra were recorded at room temperature or at 5 °C on a JASCO J710 
spectropolarimeter between 300 and 200-180 nm in the specified solvent. The path length of the 
quartz cuvette was 1.0 mm. For each CD spectrum ten scans were accumulated using a step 
resolution of 1 nm, a bandwidth of 1 nm, a response time of 2 s, a scan speed of 20 nm min-1 and 
a sensitivity of 10 mdeg, 20 mdeg, depending on the peptide concentration. The background was 
subtracted to each spectrum. The absorption value is measured as Molar Ellipticity per Residue 
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(deg cm2 dmol-1). The noise reduction was obtained by a Fourier transform filter using the 
program Origin 6.0 (OriginLab Corporation, Northampton, USA). Analytical and preparative 
reverse Phase HPLC was performed on Agilent equipment (Böblingen, Germany) by using the 
columns: Luna C18(2), 3 µm, 4.60 x 150 mm and the Luna C18(2), 90 µm, 21.2 x 250 mm 
(Phenomenex, Aschaffenburg, Germany). The flow rate was 1 mL/min for the analytical HPLC 
runs and 21 mL/min for preparative applications. The binary solvent system (A/B) was: (A) 
0.012% TFA in water (B) 0.01% of TFA in ACN. The absorbance was detected at 220 nm. 
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SYNTHESIS OF MOLECULES  121 AND 120     
 
 
(3-Aminomethyl-5-oxo-tetrahydro-furan-2-yl)acetic acid, trifluoroacetic acid salt 121.
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Compound 107 (100 mg, 0.37 mmol) was dissolved in dry CH2Cl2 (5 mL) and trifluoroacetic 
acid (1.7 mL, 22.0 mmol, 60.0 eq) was added dropwise at room temperature. The reaction 
mixture was stirred for 2 h. Solvent was evaporated under reduced pressure to yield a brown solid 
oil 121 (106 mg). This crude product was used without further purification in the course of the 
synthesis.  
 
1H NMR (300 MHz, CD3OD) δ ppm 4.69 (m, 1H, H4), 3.20 (m, 2H, H8), 2.96-2.71 (m, 4H, H3, 
H6, H 2a), 2.51 (dd, J  = 17.0 and 6.9 Hz, 1H, H2b). 
13C NMR (75 MHz, CD3OD) δ ppm  177.1 (C7), 173.4 (C1), 80.0 (C4), 42.7 (C8), 39.9 (C6), 39.3 
(C2), 33.6 (C3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C7H11NO4.CF3COOH 
M =287.09 g/mol 
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{3-[(9H-Fluoren-9-ylmethoxycarbonylamino)-methyl]-5-oxo-tetrahydro-furan-2-yl}acetic acid 120.
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To a cold (0°C) solution of 121 (106 mg, 0.37 mmol) in dioxane /1M aqueous solution of K2CO3 
(2 ml /4 ml) was added portionwise FmocOSu (187.2 mg, 0.55 mmol, 1.5 eq.). The reaction was 
allowed to come at room temperature and stirred overnight. The mixture was poured in water (7 
mL ) and extracted with EtOAc (3 x 9 mL). 
The combined organic layers were dried over Na2SO4, filtered and evaporated in vacuo to give a 
sticky solid wich was purified by column chromatography (PE:EtOAc 2:1) to obtain 120 (86.9 
mg, 60%) as a sticky, colorless solid. 
 
 
1H NMR (300 MHz, CD3OD) δ ppm  7.80 (d, J = 7.4 Hz, 2H, H17, H20), 7.63 (d, J = 7.2 Hz, 2H, 
H14, H23), 7.40-7.27 (m, 4H, H15, H16, H21, H22), 4.64 (m, 1H, H4), 4.39 (d, J = 6.6 Hz, 2H, H11), 
4.20 (m, 1H, H12), 3.23 (m, 2H, H8), 2.73-2.47 (m, 4H, H3, H6, H2a), 2.35 (dd, J = 17.2 and 7.0 
Hz, 1H, H2b). 
13C NMR (75 MHz, CD3OD) δ ppm  128.8, 128.2, 126.2, 121.0 (C14, C15, C16, C17,C20, C21, C22, 
C23), 81.0 (C4), 68.2 (C11), 48.6 (C12),43.1 (C8), 41.9 (C3), 39.9 (C2), 33.2 (C6). 
 
 
 
 
 
 
 
 
C22H21NO6 
M =395.14 g/mol 
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SYNTHESIS OF MOLECULES  125 AND 126     
 
 
(5-Oxo-tetrahydro-furan-3-ylmethyl)-carbamic acid tert-butyl ester; compound with 
N,N-diethyl-
propionamide 124 a.
 
 
 
N
O
N
H
O
O
OO 1
4
5
11 12 13
2
3
6 7
8 9
10
14
15
 
 
 
To a solution of 106 (142 mg, 0.52 mmol) and diethylamine (41.8 mg, 0.57 mmol, 1.1 eq) in 
DMF (8 mL) was added DIPEA (180 µL, 1.04 mmol, 2.0 eq), HOBt (88 mg, 0.57 mmol, 1.1 eq) 
and HBTU (218 mg, 0.57 mmol, 1.1 eq). The mixture was stirred at room temperature under 
argon atmosphere for 25 h. After removal of the solvent under reduced pressure, the residue was 
dissolved in EtOAc (20 mL). The organic solution  was successively washed with 10% aqueous 
citric acid (20 mL), water (20 mL), 10% aqueous K2CO3 (20 mL), brine (20 mL). The organic 
layer was dried over Na2SO4, filtered and concentrated. A purification by chromatography on 
silica gel, eluting with CH2Cl2/MeOH (9/1), afforded 110 mg (65%) of 124 a as a sticky  light 
yellow solid. 
  
 
1H NMR (300 MHz, CDCl3) δ ppm 5.40 (br s, 1 H, H12), 4.78 (m, 1H, H4), 3.43-3.15 (m, 6H, 
H11, H14, H9), 2.86 (dd, J  = 16.3 and 4.3 Hz, 1H, H6a), 2.73-2.58 (m, 2H, H6b, H2a), 2.52 (m, 1H, 
H3 ), 2.38 (dd, J  = 18.1 and 5.9 Hz, 1H, H2b), 1.43 (s, 9H, CH3Boc), 1.22-1.0 (m, 6H, H10, H15).  
13C NMR (75 MHz, CDCl3) δ ppm  175.5 (C7), 168.1 (C1), 156.3 (C13), 80.0 (CBoc), 79.6 (C4), 
42.1, 41.6 (C9, C14), 40.3 (C3), 37.9 (C11), 32.4 (C6), 28.3 (CH3Boc), 14.2, 13.0 (C10, C15).   
Rf: 0.4 (CH2Cl2/MeOH: 90/10)  
HRMS (EI) m/e: [M]+ calcd 328.1998, found 328.1996 
C16H28N2O5 
M =328.20 g/mol 
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2-[3-(Acetylamino-methyl)-5-oxo-tetrahydro-furan-2-yl]-N,N-diethyl-acetamide 125.
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Compound 124 a (54 mg, 0.18 mmol) was dissolved in dry CH2Cl2 (6 mL) and trifluoroacetic 
acid (3.0 mL, 10.8 mmol, 60.0 eq) was added dropwise at room temperature. The reaction 
mixture was stirred for 2 h. Solvent was evaporated under reduced pressure to afford the 
corresponding TFA salt. 
A solution of this salt in dry THF (5 mL) was heated at 70 °C and acetic anhydride (32 µL, 0.22 
mmol, 1.2 eq) was added dropwise to this solution. The reaction mixture was stirred for 2 hours 
at 70 °C. The solvent of reaction was evaporated under reduced pressure. A purification by 
chromatography on silica gel, eluting with CH2Cl2/MeOH (9/1), afforded 29 mg (60%) of  126 as 
a colorless solid oil. 
 
1H NMR (600 MHz, CD2Cl2) δ ppm 7.1 (br s, 1H, H12), 4.77 (m, 1 H, H4), 3.41-3.21 (m, 6H, H9, 
H14, H11), 2.88 (dd, J  = 16.3 and 4.3 Hz, 1H, H6a), 2.72 (dd, J  = 18.1 and 9.3 Hz, 1H, H2a), 2.66 
(dd, J  = 16.3 and 8.8 Hz, 1H, H6b), 2.49 (m, 1H, H3 ), 2.30 (dd, J  = 18.1 and 5.9 Hz, 1H, H2b), 
1.94 (s, 3H, C16), 1.19 (t, J = 7.3 Hz, 3H, H10), 1.11 (t, J = 7.2 Hz, 3H, H15).  
13C NMR (150 MHz, CD2Cl2) δ ppm 175.6 (C7), 170.7 (C1), 168.8 (C13), 80.3 (C4), 42.4, 42.3 
(C9, C14), 40.7 (C11), 40.6 (C3), 38.3 (C6), 32.4 (C2), 23.1 (C16), 14.2, 13.1 (C10, C15).   
IR in CH2Cl2 (cm-1 ): 3447 (NH), 3312 (NH), 1781 (C=O), 1671 (C=O), 1629 (C=O). 
 
 
 
 
 
C13H22N2O4 
M =270.16 g/mol 
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(2S, 3S)-(2-Ethylcarbamoylmethyl-5-oxo-tetrahydro-furan-3-ylmethyl)-carbamic acid tert-
butyl ester 124 b. 
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To a solution of 106 (71 mg, 0.26 mmol) and ethylamine hydrochloride (23.6 mg, 0.29 mmol, 1.1 
eq) in DMF (4 mL) was added DIPEA (90 µL, 0.52 mmol, 2.0 eq), HOBt (44 mg, 0.29 mmol, 1.1 
eq) and HBTU (109 mg, 0.29 mmol, 1.1 eq). The mixture was stirred at room temperature under 
argon atmosphere for 23 h. After removal of the solvent under reduced pressure, the residue was 
dissolved in EtOAc (10 mL). The organic solution  was successively washed with 10% aqueous 
citric acid (10 mL), water (10 mL), 10% aqueous K2CO3 (10 mL), brine (10 mL). The organic 
layer was dried over Na2SO4, filtered and concentrated. A purification by chromatography on 
silica gel, eluting with CH2Cl2/MeOH (9/1), afforded 33 mg (42%) of 124 b as a sticky, light 
yellow solid. 
 
1H NMR (300 MHz, CDCl3) δ ppm 6.10 (br s, 1 H, H8), 5.22 (m, 1 H, H12), 4.64 (dd, J = 12.6 
and 6.3 Hz, 1H, H4), 3.31-3.22 (m, 4H, H9, H11), 2.65 (dd, J  = 16.6 and 8.3 Hz, 1H, H2a), 2.57 (d, 
J = 6.0 Hz, 2H, H6), 2.52 (m, 1H, H3 ), 2.39 (dd, J  = 16.6 and 7.7 Hz, 1H, H2b), 1.42 (s, 9H, 
CH3Boc), 1.12 (t, J = 7.2 Hz, 3H, H10).  
 
13C NMR (75 MHz, CDCl3) δ ppm  175.8 (C7), 168.8 (C1), 156.4 (C13), 80.0 (CBoc), 79.8 (C4), 
41.6 (C3), 41.2 (C6, C11), 34.5 (C9), 32.4 (C2),  28.3 (CH3Boc), 14.63 (C10). 
Rf: 0.3 (CH2Cl2/MeOH: 90/10)  
IR in CH2Cl2 (cm-1 ): 3443 (NH), 1782 (C=O), 1714 (C=O), 1673 (C=O). 
HRMS (EI) m/e: [M]+ calcd 300.1685, found 300.1685 
[α]25D: -19.3 (c 1.0, CHCl3) 
 
 
 
C14H24N2O5 
M = 300.17 g/mol 
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2-[3-(Acetylamino-methyl)-5-oxo-tetrahydro-furan-2-yl]-N-ethyl-acetamide 126. 
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Compound 124 b (27 mg, 0.09 mmol) was dissolved in dry CH2Cl2 (3 mL) and trifluoroacetic 
acid (1.5 mL, 5.4 mmol, 60.0 eq) was added dropwise at room temperature. The reaction mixture 
was stirred for 2 h. Solvent was evaporated under reduced pressure to afford the corresponding 
TFA salt. 
A solution of this salt in dry THF (3 mL) was heated at 70 °C and acetic anhydride (16 µL, 0.11 
mmol, 1.2 eq) was added dropwise to this solution. The reaction mixture was stirred for 2 hours 
at 70 °C. The solvent of reaction was evaporated under reduced pressure. A purification by 
chromatography on silica gel, eluting with CH2Cl2/MeOH (9/1), afforded 14 mg (65%) of 126 as 
a colorless solid oil. 
  
1H NMR (600 MHz, CD2Cl2) δ ppm 6.67 (br s, 1 H, H12), 6.07 (br s, 1 H, H8), 4.63 (m, 1H, H4), 
3.33 (m, 2H, H11), 3.25 (m, 2H, H9), 2.66 (dd, J = 17.5 and 8.9 Hz, 1H, H2a), 2.58 (d, J = 6.2 Hz 
2H, H6), 2.53 (m, 1H, H3), 2.34 (dd, J  = 17.5 and 7.5 Hz, 1H, H2b), 1.95 (s, 3H, H14), 1.12 (t, J = 
7.3 Hz, 3H, H10).  
13C NMR (150 MHz, CD2Cl2) δ ppm  175.7 (C1), 171.0 (C13), 169.2(C7), 80.3 (C4), 41.3 (C6), 
41.2 (C11), 41.0 (C3), 34.8 (C9), 32.7 (C2), 23.2 (C14), 14.8 (C10). 
Rf: 0.3 (CH2Cl2/MeOH: 90/10)  
IR in CH2Cl2 (cm-1 ): 3441 (NH), 3331 (NH), 1781 (C=O), 1673 (C=O), 1629 (C=O). 
HRMS (EI) m/e: [M]+ calcd 242.1267, found 242.1269 
[α]25D: -17.3 (c 1.0, CHCl3) 
 
 
 
 
C11H18N2O4 
M = 242.13 g/mol 
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METHODS FOR PEPTIDE CHARACTERIZATION  
 
 
Analytical HPLC 
 
For the analytical HPLC measurements a small amount of the peptide was dissolved in methanol 
or in millipore water containing 0.1% TFA The binary elution system consisted of 0.012% (v/v) 
TFA in water (eluent A) and 0.01% (v/v) TFA in ACN (eluent B). The following gradients were 
applied: 15% B for 3 min, 15-70% B over 40 min, 70-95% B over 50 min and 95% B over 55%   
(peptides 113 and 114); 5% B for 5 min, 5-55% B over 45 min, 55-65% B over 50 min and 65-
95% B over 60 min (peptides 117, 118, 129-134). 
 
 
MALDI-ToF-MS 
 
For the mass spectrometry MALDI-ToF measurements a small sample of the peptide was 
dissolved in methanol or in millipore water containing 0.1% TFA and mixed with a solution of α-
cyano-4-hydroxycinnamic acid in MeOH/ACN (1:1, v/v). 
 
 
UV spectroscopy 
 
The concentration of the peptide samples prepared for CD measurements were determined UV 
spectrophotometrically. By measuring the tyrosine absorption at 280 nm the concentration was 
calculated according to the Lambert-Beer law using an extinction coefficient of 1480 M-1 cm-1 
per tyrosine residue. The ratio between the peptide concentration values obtained by UV and by 
weight gave the peptide content. In case of peptides lacking tyrosine or tryptophan residues the 
peptide contents of similar peptides containing these residues were applied to calculate the 
concentration. 
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Boc-F-(S,S)-Lac-F-(S,S)-Lac-F-Bn 113.  
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1H NMR (600 MHz, CD3OH, 283 K) δ ppm 8.51 (d, J = 8.4 Hz, 1H, H26), 8.39 (d, J = 7.2 Hz, 
1H, H14), 8.23 (m, 2H, H18, H6), 7.31-7.11 (m, 20H, Har), 6.89 (d, J = 7.8 Hz, 1H,  H2), 5.46 (s, 
2H, H30), 4.70 ( m, 1H, H26), 4.48 (m, 1H, H14), 4.37 (m, 2H, H6, H18), 4.18 (m, 1H, H2), 3.10-
3.30 (m, 6H, H9, H7a, H19a, H21), 3.10-2.97 (m, 6H, H4a H16a, H28, H7b, H19b), 2.95-2.79 (m, 2H, 
H4b, H16b), 2.65-2.59 (m, 2H, H12a, H24a), 2.47-2.34 (m, 2H, H12b, H24b), 2.31-2.17 (m, 2H, H8, 
H20), 1.43 (s, 9H, CH3Boc). 
IR in CH2Cl2 (cm-1 ): 3420 (NH), 3314 (NH), 1783(C=O), 1731(C=O), 1672(C=O). 
MALDI-ToF-MS: 983 [M+Na]+, 999 [M+K]+        
tR: 36.0 min 
 
 
Boc-F-(R,R)-Lac-F-(R,R)-Lac-F-Bn 114.  
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1H NMR (600 MHz, CDCl3, 288K) δ ppm 8.56 (d, J = 7.8 Hz, 1H, H26), 8.42 (d, J = 7.6 Hz, 
1H, H14), 8.22 (m, 1H, H6), 8.04 (m, 1H, H18), 8.38-7.10 (m, 20H, Har), 6.90 (d, J = 7.8 Hz, 1H, 
M =959.4 g/mol 
M =959.4 g/mol 
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H2), 5.04 (s, 2H, H30), 4.70 (m, 1H, H27), 4.54 (m, 1H, H15), 4.52-4.42 (m, 2H, H11, H23),  4.26-
4.17 (m, 2H, H3, H11), 3.22-3.16 (m, 3H, H7, H19a), 3.16-3.10 (m, 3H, H19b, H28a, H16a), 3.0-2.90 
(m, 2H, H4a, H28b), 2.93-2.81 (m, 2H, H4b, H16b), 2.56-2.44 (m, 6H, H12, H24, H9a, H21a), 2.35-2.25 
(m, 2H, H20, H8), 2.23-2.14 (m, 2H, H9b, H21b), 1.36 (s, 9H, CH3Boc).  
IR in CH2Cl2 (cm-1 ): 3421 (NH), 3314 (NH), 1783(C=O), 1733(C=O), 1669(C=O). 
HRMS (EI) m/e: [M+H]+ calcd 960.4395, found 960.4417  
tR: 37.0 min 
 
 
Boc-F-(R,R)-Lac-F-(R,R)-Lac-F-(R,R)-Lac-F-Bn 115. 
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1H NMR (600 MHz, CDCl3, 292K) δ ppm 8.54 (d, J = 5.8 Hz, 1H, H14), 8.49 (br s, 1H, H26), 
8.34 (d, J = 9.5 Hz, 1H, H18), 8.0 (d, J = 9.5 Hz, 1H, H6), 7.74 (d, J = 6.8 Hz, 1H, H38), 7.52 (d, J 
= 9.1 Hz, 1H, H30), 7.46-7.0 (m, 25H, Har), 5.22 (d, J = 8.5 Hz, 1H, H2), 5.17 (d, JAB = 12.1 Hz, 
1H, H42a), 5.12 (d, JAB = 12.3 Hz, 1H, H42b), 4.81 (m, 1H, H39), 4.73-4.65 (m, 2H, H23, H15), 4.63 
(m, 1H, H35), 4.57 (m, 1H, H11), 4.47 (m, 1H, H3), 4.22 (m, 1H, H27), 3.90-3.80 (m, 2H, H19a, 
H7a), 3.72 (m, 1H, H31a), 3.17-2.80 (m, 15H, H4, H16, H24, H36, H28, H40, H31b, H19b, H7b), 2.80-
2.60 (m, 3H, H9a, H21a, H33a), 2.50 (m, 1H, H8), 2.43-2.10 (m, 5H, H33b, H21b H9b, H20, H32), 1.40 
(s, 9H, CH3Boc).  
IR in CH2Cl2 (cm-1 ): 3420 (NH), 3302 (NH), 1783 (C=O), 1732 (C=O), 1652 (C=O). 
MALDI-ToF-MS: 1284 [M+Na]+, 1300 [M+K]+         
M =1261.6 g/mol 
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Ac-K-(S,S)-Lac-Q-(S,S)-Lac-K-CONH2 116. 
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1H NMR (600 MHz, CD3OH, 303 K) δ ppm 8.36 (d, J = 6.3 Hz, 1H, H19), 8.32 (m, 1H, H26), 
8.27 (m, NH, 1H, H11), 8.22 (d, J = 7.4 Hz, 1H, H34), 8.19 (d, J = 6.3 Hz, 1H,  H3), 7.74 (br s, 
4H, H9,  H40), 7.65-7.45 (m, 2H, H24 or H42), 7. 10-7.0 (m, 1H, H24 or H42), 6.82 (br s, 1H, H24 or 
H42), 4.71-4.63 (m, 2H, H16, H31), 4.39 (m, 1H, H35), 4.26-4.22 (m, 2H, H20, H4), 3.38-3.32 (m, 
2H, H12, H27), 2.99-2.90 (m, 4H, H8, H39), 2.79-2.67 (m, 4H, H14a, H17a, H29a, H32a), 2.64-2.50 (m, 
4H, H13, H17b, H28, H32b), 2.47-2.39 (m, 2H, H14b, H29b), 2.34 (m, 2H, H22), 2.11 (m, 1H, H21a), 
2.0; 1.96 (s, 3H, H1, 2 conf.), 1.95-1.87 (m, 2H, H21b, H36a), 1.82 (m, 1H, H5a), 1.73-1.61 (m, 6H, 
H7, H38, H5b, H36b), 1.57-1.36 (m, 4H, H37, H6).  
MALDI-ToF-MS: 753 [M]+, 776 [M+Na]+, 792 [M+K]+       
 
 
 
 
 
 
 
 
 
 
 
 
M =753.1 g/mol 
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Ac-(R,R)-Lac-K-(R,R)-Lac-A-(R,R)-Lac-Y-CONH2 117. 
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1H NMR (600 MHz, CD3OH, 280 K) δ ppm 9.20 (br s, 1H, H46), 8.51 (d, J = 6.4 Hz, 1H, H27), 
8.34-8.30 (m, 3H, H3, H19, H39), 8.25 (d, J = 7.9 Hz, 1H, H11), 7.90 (m, 1H,  H31), 7.71 (br s, 2H, 
H17), 7.65 (br s, 1H, H50a), 7.22 (br s, 1H, H50b), 7.10 (d, J = 8.6 Hz, 2H, H45, H47), 6.70 (d, J = 
8.4 Hz, 2H, H44, H48), 4.70 (m, 1H, H36), 4.66-4.58 (m, 2H, H8, H24), 4.51 (m, 1H, H40), 4.29 (m, 
1H, H12), 4.22 (m, 1H, H28), 3.45 (m, 2H, H20a), 3.39-3.27 (m, 2H, H4a, H32a), 3.26-3.17 (m, 3H, 
H32b, H20b, H4b), 3.04 (dd, J = 5.3 and J = 14.0 Hz, 1H, H41a), 2.90 (br s, 2H, H16), 2.78 (dd, J = 
9.3 and J = 13.9 Hz, 1H, H41b), 2.75-2.65 (m, 4H, H6a, H9a, H22a, H34a), 2.64-2.51 (m, 7H, H5, H9b, 
H21,H25, H37), 2.47-2.37 (m, 3H, H6b, H22b, H33), 1.94 (s, 3H, H1), 1.78 (m, 1H, H13a), 1.70-1.61 
(m, 2H, H15a, H13b), 1,58 (m, 1H, H15b), 1.41 (m, 2H, H14), 1.33 (d, 3H, J = 7.3 Hz, H29). 
 HRMS (EI) m/e: [M+H]+ calcd 887.4151, found 887.4143 
tR: 11.5 min 
 
 
 
 
 
 
 
 
 
M =886.4 g/mol 
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Ac-L-(R,R)-Lac-K-(R,R)-Lac-A-(R,R)-Lac-Y-CONH2 118. 
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1H NMR (600 MHz, CD3OH, 303 K) δ ppm 9.10 (br s, 1H, H53), 8.37 (d, J = 6.5 Hz, 1H, H34), 
8.25 (m, 1H, H10), 8.19-8.12 (m, 4H, H3, H18, H26, H46), 7.84 (m, 1H,  H38), 7.70 (br s, 2H, H24), 
7.52 (br s, 1H, H57a), 7.10-7.05 (m, 3H, H57b, H54,  H51), 6.7 (d, J = 8.6 Hz, 2H, H55, H50), 4.80-
4.59 (m, 3H, H15, H31, H43), 4.54 (m, 1H, H47), 4.32 (m, 1H, H19), 4.30-4.22 (m, 2H, H35, H4), 
3.48-     3.37 (m, 3H, H11a, H27a, H39a), 3.36-3.22 (m, 3H, H11b, H27b, H39b), 3.05 (dd, J = 5.5 and J 
= 14.0 Hz, 1H, H48a), 2.93 (m, 2H, H23), 2.80 (dd, J = 9.1 and J = 13.9 Hz, 1H, H48b), 2.76-2.63 
(m, 6H, H13a, H16a, H29a, H32a, H41a, H44), 2.63-2.54 (m, 6H, H12, H16b, H28,H32b, H40, H44b), 2.49-
2.35 (m, 3H, H13b, H29b, H41b), 1.98 (s, 3H, H1), 1.82 (m, 1H, H20a), 1.72-1.58 (m, H, H20b, H22, 
H6), 1,58 (m, 2H, H5), 1.43 (m, 2H, H21), 1.34 (d, J = 7.3 Hz, 3H, H36), 0.96 (d, J = 6.7 Hz, 3H, 
H7 or H8), 0.92 (d, J = 6.7 Hz, 3H, H7 or H8). 
MALDI-ToF-MS: 1000 [M]+, 1023 [M+Na]+, 1039 [M+K]+        
tR: 16.3 min 
 
 
 
 
 
 
 
 
M =1000.1 g/mol 
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Ac-G-F-S-K-A-E-L-A-K-A-R-A-A-K-R-G-G-Y-CONH2 129. 
M = 1922.1 
MALDI-ToF-MS: 1923 [M+H]+ 
tR: 20.18 min 
 
Ac-G-A-S-K-A-E-L-A-K-A-R-A-A-K-R-G-G-Y-CONH2 130. 
M = 1845.1 
MALDI-ToF-MS: 1846 [M+H]+ 
tR: 17.51 min 
 
Ac-G-F-S-K-A-E-L-A-K-A-Lac-A-K-R-G-G-Y-CONH2 131. 
M = 1849.0 
MALDI-ToF-MS: 1849  [M]+              
tR: 21.0 min 
 
Ac-G-F-S-K-A-E-L-A-K-Lac-A-A-K-R-G-G-Y-CONH2 132. 
M = 1848.2 
MALDI-ToF-MS: 1849  [M+H]+              
tR: 20.51 min 
 
Ac-G-F-Lac-A-E-L-A-K-A-R-A-A-K-R-G-G-Y-CONH2 133. 
M = 1785.0 
MALDI-ToF-MS: 1785  [M]+              
tR: 18.82 min 
 
Ac-G-A-Lac-A-E-L-A-K-A-R-A-A-K-R-G-G-Y-CONH2 134. 
M = 1861.1 
MALDI-ToF-MS: 1862 [M+H]+           
tR: 21.89 min 
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GENERAL CONCLUSIONS 
 
A first objective of my PhD was the synthesis of molecules able to inhibit the 26S proteasome, a 
multicatalytic protease complex which is responsible for intracellular protein turnover in 
prokaryotes and eukaryotes. The proteins degraded by the 26S proteasome are various regulators of 
crucial processes, like the cell-cycle progression, apoptosis, inflammatory responses, NF-kB 
activation, antigen presentation, and others. Therefore, the proteasome constitutes an interesting 
target for drug discovery. 
In the presented work, we designed, synthesized, and defined the biological profile of a new 
original series of proteasome inhibitors: four lead compounds with micromolar IC50 values. We 
designed our compounds, by the help of molecular modelling, introducing fluorinated 
peptidomimetics to exploit the  properties of this atom. 
In the second part of this project, our attention was turned to the peptidomimetics containing δ-
amino acids with the aim to obtain new oligomers of non-natural amino acids. These oligomers 
form a variety of controlled secondary structures and fall in the domain of “foldamers”. 
We used the solid-phase methodology to synthesized several α-δ peptides and analytical HPLC and 
MALDI-TOF-MS to characterize the products. The following step was the evaluation of the 
properties of these new peptides by using 2D-NMR, FT-IR, circular dicroism, molecular modelling. 
The structural analyses have given insights in the conformational properties of peptide backbones 
based on alternated α-δ-units. 
